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Over the past decades, extensive new knowledge on the cellular and molecular 
mechanisms of vision has been acquired. During the genomic era, numerous genes 
involved in retinal function have been identified, some of which have been causally 
associated with various forms of retinal disorders. Despite this rapid progress in the 
understanding of retinal biology, retinal degeneration, the most common cause of 
blindness in the developed world remains an untreatable condition. A therapeutic 
strategy that has been tested in several animal models of retinal degeneration has been 
to deliver intraocularly a survival factor, ciliary neurotrophic factor (CNTF), in an 
attempt to rescue photoreceptor cells prior to cell death. 
 To begin addressing the question about the mechanism of CNTF-mediated 
neuroprotection, the retinal expression of the specific receptor for CNTF (CNTFRα) 
was characterized. Using different molecular approaches, we found that photoreceptor 
cells from non-rodent mammalian species (including dog and human) express 
CNTFRα. This led to the conclusion that in these species, a CNTF- mediated 
photoreceptor rescue effect would most likely result from the direct activation of a 
pro-survival response in rods and cones.  
The underlying expectation in testing CNTF as a potential treatment for 
retinitis pigmentosa (RP) and allied disorders is that it may provide a means of 
protecting photoreceptor cells regardless of the genetic and/or environmental causes of 
the disease. This hypothesis is based on the evidence that CNTF rescues 
photoreceptors in several non-allelic animal models of RP. One such model has been 
rcd1, a canine form of early-onset and rapidly progressing retinal degeneration caused 
by a mutation in the PDE6B gene. In this work, we evaluated whether CNTF could 
also rescue photoreceptors in XLPRA2, another early-onset canine model of RP caused 
by a mutation in a different gene (RPGR exon ORF15). The characterization of the 
histological stages of the disease, and the examination of the kinetics of cell death 
provided time-points to optimally test CNTF’s neuroprotective effect in this model. 
Intravitreal injections of CNTF in XLPRA2 at these determined ages failed to show 
any significant rescue from cell death, and caused some abnormal peripheral retina 
remodeling that was disease- and age-specific.  
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CHAPTER ONE 
 
INTRODUCTION 
 
Background information 
Retinal degenerations (RD) are the major cause of blindness in the developed 
world. Some forms occur at birth (eg: Leber Congenital amaurosis), during adulthood 
[numerous forms of Retinitis Pigmentosa (RP)], or in the elderly [eg: age-related 
macular degeneration (ARMD)]. Retinitis Pigmentosa is a heterogenous group of 
inherited retinal degenerative diseases, characterized by the progressive death of rod 
and cone photoreceptors. Over the past decades, numerous genes have been identified 
as causing RP, yet, the molecular and cellular mechanisms that lead from a mutation 
in a gene to the death of a photoreceptor cell are still largely unknown. As a 
consequence, no treatments are currently available to treat patients with these 
devastating diseases. 
Animal models of RP have been critical to understand the function of genes in 
the retina, as well as to unveil the cellular and molecular events that occur during the 
disease processes. They have also been used to examine the effects of environmental 
factors (such as diet, light exposure) on the disease, and finally, have provided an 
indispensable tool to develop and evaluate the safety and efficacy of novel therapeutic 
approaches. 
The most common therapeutic strategies that are being evaluated for RP can be 
divided into three groups: 1) approaches aimed at replacing the non-functional 
photoreceptors or retina, such as grafting of retinal sheets or retinal precursor cells, or 
the implantation of artificial retinal prostheses. 2) approaches aimed at curing the 
disease through corrective gene therapy. 3) approaches aimed at delaying the course of 
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the disease and the onset of photoreceptor death through the use of neuroprotective 
agents such as vitamin A, anti-apoptotic agents, calcium channel blockers, and 
survival factors. 
Several survival factors have been tested in animal models of RP. These 
include basic fibroblast growth factor (bFGF), ciliary neurotrophic factor (CNTF), 
brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor 
(GDNF), and pigment epithelium-derived factor (PEDF). Among these, CNTF has 
been the most extensively studied and has been shown to rescue photoreceptors in 
rodent as well as large animal species (dog and cat). Because of the side-effects 
associated with both systemic and intravitreal bolus administration of CNTF, long-
term intraocular drug delivery is necessary and can be achieved through gene therapy, 
as well as by means of an encapsulated cell-based device. This latter technology 
allows the slow and continuous release of small doses of CNTF into the eye, and has 
recently been evaluated in experimental animal models, and in Phase I clinical trial in 
humans. 
The molecular mechanisms of CNTF’s mediated photoreceptor survival are not 
fully elucidated. Yet, CNTF is known to trigger several signaling pathways through 
the binding to CNTFRα, its specific membrane receptor. Determining the mechanism 
of action of CNTF is critical to 1) optimize the neuroprotective property of this agent. 
2) inhibit, or reduce biological properties of this factor that can lead to deleterious 
side-effects. 3) select the forms of RP that would benefit most from this potential 
treatment. 
 
Numerous genes cause retinitis pigmentosa in humans 
 Retinitis pigmentosa is genetically and phenotypically a heterogeneous group 
of diseases that has an estimated prevalence of approximately 1:4,000.1-3 It is 
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classically divided into two clinically distinct group of diseases: rod-cone dystrophies 
(RCD) and cone-rod dystrophies (CRD). 
Most RP diseases are rod-cone dystrophies. They are characterized by an 
initial loss of rods in the peripheral and mid-peripheral retina that progresses towards 
the central retina, and may lead to secondary loss of cones. The most common clinical 
signs are an initial loss of peripheral vision and night blindness. The progressive 
concentric reduction of the peripheral visual fields causes what patients describe as 
“tunnel vision”.4 The progression of the disease to the foveo-macular region of the 
retina leads ultimately to the loss of central vision and complete blindness. Fundus 
examination of patients with RP usually reveals pigmentary deposits (known as bone 
spicule pigments) that are caused by the migration of retinal pigment epithelial (RPE) 
cells into the neurosensory retina.4 Attenuation of the retinal vessels and pallor of the 
optic disc are also commonly observed signs. 
 A smaller group of diseases under the RP rubric are cone-rod dystrophies, in 
which primary degeneration of cones is followed by the loss of rods.5 Cone-rod 
dystrophies are clinically characterized by an early reduction in visual acuity and color 
vision, photophobia, central or paracentral scotomas, and occasionally fine nystagmus. 
Fundus examination reveals an early-onset maculopathy characterized by atrophy and 
pigmentary deposits that occasionally extend to the midperipheral retina at later stages 
of the disease. 
At present, 114 genes responsible for some form of retinal degeneration in man 
have been cloned and 164 mapped. A listing of these genes is available on the Retnet 
web site (http://www.sph.uth.tmc.edu/Retnet/home.htm) (see Figure 1.1). Of these, 36 
genes and 9 loci cause RCD, and 10 genes and 6 loci cause CRD. Both forms of 
dystrophies are inherited as either autosomal recessive, autosomal dominant or X-
linked diseases (Table 1.1). 
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Figure 1.1 Mapped and identified retinal disease genes 1980-2006 as of January 2006 
(from RetNet; http://www.sph.uth.tmc.edu/Retnet/home.htm ). 
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Table 1.1 List of cloned and mapped genes associated with retinitis pigmentosa 
(from RetNet, 01/17/06; http://www.sph.uth.tmc.edu/Retnet/home.htm) 
 
Disease category Mapped loci  
(not identified) 
 
Mapped and 
Identified genes 
 
Retinitis pigmentosa (RCD) 
 autosomal dominant 
 
RP31
 
CA4, CRX, 
FSCN2, 
GUCA1B, 
IMPDH1, NRL, 
PRPF3, PRPF8, 
PRPF31, RDS, 
RHO, ROM1, 
RP1, RP9, 
SEMA4A
 
Retinitis pigmentosa (RCD) 
 autosomal recessive 
 
RP22, RP25, RP28, 
RP29, RP32
 
ABCA4, CERKL, 
CNGA1, 
CNGB1, CRB1, 
LRAT, MERTK, 
NR2E3, NRL, 
PDE6A, PDE6B, 
RGR, RHO, 
RLBP1, RP1, 
RPE65, SAG,  
TULP1, USH2A
 
Retinitis pigmentosa (RCD) 
X-linked 
 
RP6, RP23, RP24
 
RP2, RPGR
 
Retinitis pigmentosa (CRD) 
 autosomal dominant 
  
 
CORD4, RCD1
 
AIPL1, CRX, 
GUCA1A, 
GUCY2D, 
RIMS1, 
SEMA4A, 
UNC119
 
Retinitis pigmentosa (CRD) 
 autosomal recessive 
 
CORD8, CORD9
 
ABCA4, RDH5
 
Retinitis pigmentosa (CRD) 
X-linked 
 
 
COD2, COD4
 
 
RPGR
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Despite the identification of several RP-associated genes that encode for 
proteins involved in the phototransduction pathway, the visual cycle, cell trafficking, 
the spliceosome complex, the structural integrity of photoreceptor outer segments, or 
that are transcription factors,6 little is known about the cascade of molecular events 
that leads from gene mutation to phenotype in a patient. A final common pathway to 
most forms of retinal degeneration appears to be the cell death of photoreceptors 
through apoptosis,7-10 yet, there is mounting evidence coming from the 
neurodegeneration field that several distinct cell death pathways may be activated  at 
the same time and lead to an apoptosis-necrosis cell death continuum.11-14 In such a 
case, this may account for some of the variability in the phenotype of RP diseases, and 
must be taken into account when developing and testing therapeutic strategies in 
patients with different forms of RP. 
 
Animal models are indispensable to understand the pathogenesis of RP and 
develop new therapies. 
Animal models of retinal degeneration have been essential to understand the 
role of numerous genes/proteins in the normal physiology of the retina, to examine the 
molecular and cellular events that take place during the course of the 
disease/degeneration, and to investigate potential therapeutic strategies. 
Rodents, mice in particular, have been critical in understanding the function of 
disease genes in the process of photoreceptor degeneration. Currently, more than 16 
mutant strains of mice with a naturally occurring form of retinal degeneration have 
been identified (http://www.jax.org/mmod/retinal_degen.html). 15 Genetic engineering 
has allowed the generation of over 50 additional models of RD,  through gene 
knockout (KO), gene overexpression, or the introduction of point mutations.16 
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With the exception of the rhodopsin transgenic pig,17,18  large animal models of 
RP occur in the feline19-21 and canine species (see Table 1.2) and are naturally-
occurring disorders. In the absence of a non-human primate model of RP, these large 
animal models offer advantages over rodents such as a higher cone to rod ratio, and an 
eye size that are closer to that of the human.22-25 These anatomical characteristics 
enable the use in the dog of several non-invasive methods of imaging and functional 
assessment of the retina that are commonly applied in humans.26-28 They also allow 
surgical procedures for the intraocular placement of devices,29,30 and delivery of large 
volumes of drugs intravitreally or subretinally.31   Work originating over the past 30 
years, from several research groups, has led to the identification, in the dog, of several 
non-allelic forms of retinal degeneration collectively termed progressive retinal 
atrophies (PRA). These have been traditionally subdivided in forms that occur before 
retinal development is attained (= dysplasia; e.g. rcd1) and forms with an age of onset 
that begins after retinal maturity is achieved (= degeneration; e.g. prcd, XLPRA1). 
While the vast majority of PRA forms in the dog are diseases of rods with later 
involvement of cones, studies also have identified three breeds that are affected by 
non-allelic forms of RD that resemble human cone rod dystrophy. These have been 
named crd1, crd2, and crd3 .32  The six genes (PDE6α, PDE6β, RHO, RPGR, RPE65, 
and CNGB3) that have been identified to this date as causing PRA in the dog are all 
involved in some form of RP in the human. Progressive retinal atrophy in dogs is most 
often inherited in an autosomal recessive manner (e.g. rcd1, prcd), yet -linked PRA 
(XLPRA) has been described in the Siberian Husky and Samoyed,42 and a dominant 
form of PRA caused by a mutation in the rhodopsin gene has been recently reported in   
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 Table 1.2 Canine models of retinitis pigmentosa 
 
Animal model Mutant gene Affected breeds References 
rcd1 PDE6B Irish setter 33, 34, 35, 36 
rcd2 unknown Collies 37, 38 
rcd3 PDE6A Cardigan Welsh corgi 39 
rd unknown Norwegian elkhound 40 
erd unknown Norwegian elkhound 41 
XLPRA2 RPGR mongrel-derived 42 
XLPRA1 RPGR Siberian husky, Samoyed 42, 43 
prcd PRCD American cocker spaniel, 
English cocker spaniel, 
Poodles, 
Labrador retriever, 
Chesapeake bay retriever, 
Portuguese water dogs, 
and others 
 
44, 45, 46 
T4R RHO RHO English mastiff, Bull mastiff 47 
crd1 Unknown American Staffordshire terrier 32 
crd2 Unknown American Bull terrier 32 
crd3 Unknown Glen of Imaal terrier 32 
cd CNGB3 Alaskan Malamute 
German shorthaired pointer 
48 
canine LCA RPE65 Briard 49, 50 
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the English and Bull Mastiff breeds.47  
The typical clinical manifestations of PRA show remarkable similarities with 
human RCD. Loss of vision in dim light or darkness is one of the earliest signs, and is 
progressively followed by visual impairment under bright light conditions. 
Ophthalmoscopically, the earliest alterations are a change in tapetal reflectivity that 
often takes the appearance of a grayish discoloration in the peripheral tapetal fundus. 
Concurrently, mild retinal vascular attenuation may also be observed in that region. 
This progresses to involve the entire tapetal fundus, and is followed at later stages by 
tapetal hyperreflectivity and marked vascular attenuation that causes optic disc pallor. 
In the non tapetal fundus, patches of depigmentation are commonly observed. The 
high genetic and phenotypic homology that exists between canine PRA and human 
RP, argues for the use of the dog as valuable model system to better understand the 
mechanisms of disease, and test the safety and efficacy of new therapeutic modalities. 
 
Therapeutic strategies for retinitis pigmentosa 
The availability of several animal models of RP and the improved 
understanding of the genetic and biochemical mechanisms of these diseases has led to 
the development of therapeutic strategies aimed at either, replacing, curing or 
sustaining the diseased photoreceptors. 
 
1) Retinal transplantation. 
The transplantation into the subretinal space of RPE cells, dissociated retinal 
cells, or full thickness retinal sheets as a way of restoring vision by replacing diseased 
photoreceptors with new functional cells has been investigated for over 20 years (for 
review see 51). Subretinal transplantation of RPE cells or fetal retinal sheets was 
shown in several studies to promote a morphologic rescue of the host’s 
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photoreceptors,52 as well as a delay in the deterioration of visual acuity.53 54 However, 
it is unclear whether this functional rescue is due solely to the release by the 
transplanted cells of trophic/survival factors,55 or to the establishment of synaptic 
connectivity between the transplant and the host.56,57 
Recently, the transplantation of neural or retinal progenitor cells has been 
considered as a novel approach for the replacement of damaged photoreceptors (for 
review see 58,59). Although a number of studies in animal models have shown that 
transplanted progenitor cells are capable of integrating into the recipient retina, and 
expressing retinal cell markers such as opsin, recoverin, PKCα, or calbindin,60,61 it is 
still not known whether they can fully differentiate into functional photoreceptors and 
establish synapses with the host’s cells.  
In an attempt to bypass diseased or degenerated photoreceptors, several groups 
have been developing artificial retinal implants. They are designed to stimulate 
existing neural circuits in diseased retinas to create a visual signal. There are two kinds 
of retinal prostheses that have been tested: subretinal and epiretinal implants (for 
review see 62,63). A subretinal implant is composed of an array of microphotodiodes 
that are connected to microelectrodes. The implant is surgically placed in the 
subretinal space between the RPE and the outer plexiform layer (OPL) of the 
degenerated retina. Light that enters the eye is converted by the microphotodiodes into 
small currents that are released by the microelectrodes and stimulate second order 
neurons (horizontal cells, bipolar cells) in the host retina. The epiretinal implant on the 
other hand is essentially a readout chip that generates electrical impulses and 
stimulates directly the ganglion cells and their axons after receiving information from 
a camera and an image processor that are external to the eye. Surgical implantation 
and long-term biocompatibility of both types of implants have been evaluated in cats 
and dogs 64,65 30,66 before being tested in humans.67,68 Implantation of epiretinal 
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prosthesis in individuals with RP has shown that light perception could be 
obtained.67,68 
Subjective improvement in  visual function that included improved perception of 
brightness, contrast, color, movement, shape, resolution, and visual field size has also 
been observed in RP patients that were implanted with a subretinal prosthesis, yet the 
improvements occurred in visual areas that were distant from the implant.69 It has been 
suggested that mechanical injury of the retina during the surgical procedure as well as 
low-level electrical stimulation by the implant may elicit the release of endogenously 
secreted survival factors that provide a generalized neuroprotective effect to the retina. 
 
2) Corrective gene therapy 
Corrective gene therapy has been considered as a promising approach to cure 
inherited retinal degenerations. The identification of several RP causing genes, and 
relevant animal models, as well as unique features of the eye (contained organ, small 
area to treat, easily accessible for examination, gene delivery and functional 
assessment) have led several groups to develop delivery systems that would allow 
both safe and efficient transduction of the RPE and/or photoreceptor cells. 
Gene therapy can be used in recessive disorders to replace the mutated gene by 
its wild-type version, and correct the loss of function caused by the mutation. The first 
demonstration that gene therapy could rescue photoreceptors in an autosomal 
recessive disorder was conducted ten years ago in the rd mouse (PDE6B mutation) 
using a first generation adenovirus.70 Since then, several studies using different viral 
vectors have shown in the rd,71-73  rds,74-76 rd12,77 , LRAT -/- ,78, and RPGRIP -/- mice,79  
as well as in the RCS rat,80-82 that transduction of the wild-type gene can delay or 
prevent photoreceptor cell death and restore function. The most exciting results have 
come from studies conducted in the RPE65 -/- dog, a model for Leber congenital 
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amaurosis (LCA), in which gene replacement by means of a recombinant adeno-
associated virus (rAAV) provided long-term restoration of vision.27,50 Using a similar 
approach, functional rescue was also obtained in the rd12 mouse, a model of LCA 
caused by a nonsense mutation in the RPE65 gene.77 Biosafety studies in rats, dogs as 
well as in monkeys are currently being carried out, and a Phase I clinical trial in 
human patients with RPE65 LCA is expected to begin in 2006.83 
In autosomal dominant diseases in which a mutation causes a toxic gain of 
function, the purpose of gene therapy is to inhibit the translation of the gene 
responsible for the deleterious effects. Gene silencing can be achieved through the use 
of single-strand antisense oligonucleotides, ribozymes, and more recently by RNA 
interference. These knock down strategies can be allele-specific (i.e. directed against 
the mutant gene only) or non-allelic (i.e. directed against both the mutant and wild 
type gene). Because allele-specificity is often difficult to attain, non-allelic silencing 
has to be complemented with gene replacement. A hardened target (i.e. wild type copy 
of the gene that has been modified to be resistant to the silencing) needs to be 
provided in parallel.  To this date, only ribozyme technology has been used to knock 
down genes involved in retinal degeneration (for review see 84). This was conducted in 
a transgenic rat model of autosomal dominant retinitis pigmentosa, the rhodopsin 
P23H rat, and shown to delay the course of photoreceptor death and the loss of retinal 
function.85 The ribozyme rescue was shown to persist for over 6 months, and be 
equally effective when the gene transfer was done at a late-stage of disease than earlier 
on.86 The use of RNA interference technology has not been yet reported in any animal 
model of RP, yet, it was recently shown to be effective in inhibiting vascular 
endothelial growth factor (VEGF) expression, and reduce choroidal 
neovascularization, in a rodent model for age-related macular degeneration 
(ARMD).87 
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3) Photoreceptor neuroprotection 
Although corrective gene therapy offers the potential for curing retinal 
degeneration, it is a therapeutic approach that is gene-specific. Even with a gene 
knockdown strategy that would allow inhibition in an allele-independent manner of 
both the wild type and all mutant forms of a gene, followed by replacement with a 
resistant wild-type cDNA,88 identification of the deleterious gene is a pre-requisite. An 
approach that would circumvent this inherent limitation of corrective gene therapy is 
the use of neuroprotective agents that could be applicable to a wide range of forms of 
RP, whether or not the disease-causing mutation is known. Since the gene defect is not 
corrected, this strategy does not “cure” per se, but intends to slow down the 
progression of the disease. Numerous agents that include nutrients, ionic channel 
blockers, anti-apoptotic genes, and neurotrophic factors, have been evaluated over the 
past decades for their photoreceptor rescue properties. 
Vitamin A supplementation (15,000 IU/day) was shown in a randomized, 
controlled, double-masked clinical trial to slow the rate of decline in ERG amplitudes 
in patients with RP.89 Recently, two more studies have shown that supplementation 
with docosahexaenoic acid (DHA) shortens the time for vitamin A to have a positive 
effect, only in those patients that were newly started on Vitamin A.90,91 Although the 
mechanism by which vitamin A preserves retinal function is unknown, dietary 
recommendations for RP patients have been made that include the intake of vitamin A 
palmitate (15,000 IU/day), the supplementation with DHA capsules (600 mg 
twice/day for 2 years) (if no prior intake of vitamin A), and the consumption of omega 
3-rich fish at least once a week.91 
The beneficial effect of calcium channel blockers as a potential treatment for 
retinal degenerations has been a matter of debate since the first report that D-cis-
diltiazem (a blocker of L-type calcium channels and cGMP-gated channels) rescued 
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rod photoreceptors in the rd mouse.92 Indeed, while these results were further 
confirmed by the same group,93, as well as in a light-induced model of RD,94 others 
failed to demonstrate a similar rescue effect in the rd mouse,95 RCS rat,96 P23H 
rhodopsin mutant rat,97, and rcd1 dog.98 Among the other calcium channel blockers 
tested, a positive photoreceptor rescue effect was observed with nilvadipine in both the 
rd mouse, 99, RCS rat,96, and a rat model of cancer-associated retinopathy.100 These 
conflicting results about the neuroprotective effect of calcium channel blockers on 
photoreceptor cells are most likely explained by differences in experimental 
conditions such as mouse strains, animal model studied, or type of calcium channel 
blocker used. 
Since numerous forms of RD appear to share a common final pathway of cell 
death via apoptosis, several groups have investigated whether the overexpression of 
anti-apoptotic genes of the Bcl-2 family can rescue photoreceptor cells. When 
transgenic mice overexpressing Bcl-2 in their photoreceptors were crossed to four 
murine models of RD (PDEγ knockout, rd, S334ter rhodopsin mutant, and normal 
albino mice exposed to bright light that causes retinal damage), a limited and transient 
(2-3 weeks) survival effect was attained.101,102 A longer suppression of cell death was 
obtained, in the S334ter mouse when the Bcl-2 transgene was co-expressed with BAG-
1,103 or when transgenic Bcl-2 mice were crossed with rds mice that exhibit a slower 
form of retinal degeneration.104 By means of an adenoviral vector, somatic delivery of 
the Bcl-2 gene to photoreceptors of the rd mouse also provided a transient delay in rod 
cell death.105 
Over the past decade, extensive research using different rodent models has 
shown that various survival factors can slow the course of RD. Work conducted in the 
early nineties by LaVail’s group on bFGF launched the concept of using growth 
factors/neurotrophic factors as a potential strategy for treating RD.106 Basic FGF was 
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shown to protect rat photoreceptors from degeneration in inherited,106 light-
induced,107,108 and age-related109 models of RD after intravitreal or subretinal 
injection. Because an increased incidence of cataracts, retinal macrophages, and retinal 
neovascularization was observed following intraocular injections of bFGF,106,107,110,111 
the light-damage model was used to screen various growth factors and cytokines with 
the expectation that novel neuroprotective factors causing minimal side-effects could 
be identified.112 Among these agents, CNTF and BDNF were shown to provide 
structural112-115 and functional114 rescue of photoreceptors both in vivo in rat and 
mouse models of RD, as well as in retinal explants.116,117 Other agents, e.g. GDNF118-
120, PEDF,121-123 as well as the cytokines IL-1beta,124 and cardiotrophin-1 (CT-1),125 
have been shown to have a survival-promoting activity in rodents. Rod photoreceptor 
cells are critical in providing structural and trophic support to cones. Studies 
conducted in Sahel’s group have shown that  diffusible factors released by rods 
promote cone rescue in the retina of the rd mouse.126 Recently, characterization and 
identification of one of these factors, termed rod-derived cone viability factor 
(RdCVF), has been reported.127 
 
CNTF: a promising agent for photoreceptor neuroprotection? 
Ciliary neurotrophic factor was first purified in 1984 from chick eyes and 
identified as a 20.4 kDa polypeptide that promotes the survival of dissociated 8-day 
chick embryo ciliary ganglionic (parasympathetic) neurons.128 Soon after, it was 
purified in the rat129 and rabbit130, and its gene cloned for these species as well as for 
human.131,132 The human CNTF gene encodes a protein of 200 amino acids, and shares 
83% and 87 % identity with, respectively, the rat and rabbit amino acid sequences.131 
BLAST analysis of the human amino acid sequence of CNTF against the canine 
genome, revealed a 89% homology with the putative canine CNTF protein. 
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  Following the identification of the biological activity of CNTF on chick 
parasympathetic ciliary neurons, numerous in vitro and in vivo studies demonstrated 
that CNTF also promotes the survival of sensory,133,134 sympathetic,135,136 and motor 
neurons.137,138 This led to the testing of CNTF as a potential therapy for amyotrophic 
lateral sclerosis (ALS) in both  animal models139,140  and human patients141-145 affected 
with this disease. Because of the limited number of individuals that were included in 
the two Phase I clinical trials that evaluated the safety of intrathecal long-term delivery 
of CNTF, no claims were made about its effect on motor neuron loss. Intracerebral 
long-term delivery of CNTF has also be shown to protect striatal neurons from 
excitotoxic damage following quinolinic acid intrastriatal injection in a rodent model 
of Huntington’s disease (HD).146-148 In a primate model of HD, CNTF not only 
protected neurons from degeneration,149 but it also restored motor and cognitive 
function.150 
  The intraocular delivery of CNTF as an approach to treating retinitis 
pigmentosa has been investigated for the past 14 years since the first report that it 
rescued rat photoreceptors from cell death in a light-damage model of RD.112 
Numerous studies conducted in transgenic, experimental (light-induced), and naturally 
occurring animal models of RD have demonstrated the neuroprotective property of 
CNTF on photoreceptor cells (see Table 1.3). Although CNTF has been effective in all 
four species in which it has been evaluated, its neuroprotective activity is nevertheless 
variable and depends on the animal strain, the disease, and the route of delivery.  
Despite being a potentially promising therapeutic agent, there are a number of 
limitations to the use of CNTF in neurodegenerative diseases, and these are related to 
its pharmacokinetics, bio-availablity, and associated side-effects. After subcutaneous 
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Table 1.3 Studies of the neuroprotective effect of ciliary neurotrophic factor (CNTF) in animal models of retinal degeneration. 
(summary) 
(PR: photoreceptor; ERG: electroretinographic; I.-vitr.: intravitreal; Subret: subretinal; ND: not determined; AAV: adeno-
associated virus; Adv: adenovirus; P: postnatal day) 
Animal model Gene 
mutated 
 
Delivery mode CNTF dose duration PR rescue ERG changes References 
Light-damage in 
Sprague-Dawley rat 
None  I.-vitr. CNTF
I.-vitr. CNTF 
0.5 µg 
0.5-1 µg 
1 week 
1 week 
Yes 
Yes 
ND 
ND 
112 
115 
S334ter-3  
(Transgenic rat) 
rhodopsin  I.-vitr. CNTF
I.-vitr. NTC-201 
1 µg 
∼ 100 ng 
P9-P20 
P9-P20 
Moderate 
Yes 
ND 
ND 
29 
S334ter-4  
(Transgenic rat) 
rhodopsin I.-vitr. AAV-CNTF ND 6 months Yes ↓ b-wave 
amplitude 
153 
P23H line 1 
 (Transgenic rat) 
rhodopsin I.-vitr. AAV-CNTF ND 6 months Yes ↓ b-wave 
amplitude 
153 
RCS rat Mertk Subret. CNTF 
Subret. Adv-CNTF 
0.5 µg 
ND 
P21-P90  Yes
Yes 
ND 
↑ a- and b-wave 
amplitudes 
154 
Light-damage in 
albino BALB/c mouse 
None I.-vitr. CNTF 0.2-0.5 µg 2 weeks Yes ND 115 
rd/rd mouse PDE6β  I.-vitr. CNTF
I.-vitr. Adv-CNTF 
0.2-2 µg 
ND 
1 week 
P12-P30 
Yes 
Yes 
ND 
ND 
115 
113 
rds/rds mouse peripherin I.-vitr. CNTF 
I.-vitr. Adv-CNTF 
 
I.-vitr. AAV-CNTF 
Subret. AAV-CNTF 
 
0.2-2 µg 
ND 
 
ND 
ND 
3 weeks 
P21-P73 
 
8.5-9 months 
P10-6 to 9 
weeks later 
No 
Yes 
 
Yes 
Yes 
ND 
↑ a- and b-wave 
amplitudes 
No 
↓ b-wave 
amplitude 
115 
114 
 
153 
155 
rds+/-P216L mouse peripherin  I.-vitr. CNTF
I.-vitr. AAV-CNTF 
Subret. AAV-CNTF 
 
1 µg 
ND 
ND 
P25-P48 
P28-P90 
P25-P90/P150 
 
No 
moderate 
Yes 
No 
ND 
↓ a- and b-wave 
amplitudes 
156 
 17
17 
Table 1.3 (continued). 
 
 
 
 
 
Animal model Gene 
mutated 
 
Delivery mode CNTF dose duration PR rescue ERG changes References 
nr/nr mouse ND I.-vitr. CNTF 0.2-2 µg 3-4 weeks Yes ND 115 
Q344ter mouse 
(transgenic mouse) 
rhodopsin  I.-vitr. CNTF
 
0.2-2 µg 
 
10 days Yes ND 115 
pcd/pcd mouse ND I.-vitr. CNTF 0.2-2 µg 3-4 weeks No ND 115 
P23H 
(transgenic mouse) 
rhodopsin I.-vitr. CNTF 0.2-2 µg 10 days No ND 115 
VPP 
(transgenic mouse) 
rhodospin I.-vitr. CNTF 0.2-2 µg 3 weeks No ND 115 
opsin-/- mouse rhodopsin Subret. AAV-CNTF ND 3 months Yes ND 157 
Rdy cat ND I.-vitr. CNTF 
(repeated injections) 
2.5-5 µg / 
injection 
4-16 weeks Yes  ND 158 
rcd1 dog PDE6β I.-vitr. CNTF 
 
I.-vitr. ECT-CNTF 
10-15 µg 
(repeated 2X) 
0.1-15 ng/day 
7 weeks 
 
7-14 weeks 
Yes 
 
Yes 
ND 
 
ND 
159 
 
29 
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administration in humans, CNTF is rapidly eliminated from the circulation (half-life: 
3.3hrs), and causes acute physiological effects such as elevation in body temperature, 
activation of the acute phase response,151,152 and increase in total circulating 
leucocytes.142 These non-neurological biological effects of CNTF reflect properties 
that are shared by most members of the IL-6 family of cytokines. The most common 
side effects that were observed in more than 5% of the patients receiving 30µg/kg of 
recombinant human CNTF subcutaneously were, in order of decreasing frequency: 
pain or other reaction at the injection site, asthenia, nausea, flushing, cough, 
generalized aches and pains, tachycardia, and mouth sores.142 In order to by-pass the 
blood-brain barrier, limit the side-effects associated with systemic administration, and 
provide a continuous source of the drug, long-term intrathecal delivery of CNTF was 
tested in Phase I clinical trial in human patients with ALS by means of  a drug 
minipump,144 or encapsulated genetically modified cells.143,145 This latest technology, 
originally developed by CytoTherapeutics Inc., provided nanogram concentrations of 
CNTF  in the patients’ cerebrospinal fluid for at least 17 weeks following implantation 
in the lumbar intrathecal space. No associated side-effects were observed other than a 
mild cough,143 and a slightly elevated leucocyte count145 in some patients. 
Preliminary studies conducted in Aguirre’s group, in collaboration with 
Regeneron Inc., showed that intravitreal injection of CNTF in the rcd1 dog (PDE6B 
deficient) has a very positive photoreceptor rescue effect.159 In these studies, rcd1 
dogs received an intravitreal injection of a recombinant human mutein of full length 
CNTF (Axokine®, 10-15 µg / injection) in one eye at 7 and 10 weeks of age. The 
contralateral eye was vehicle-injected with phosphate buffered saline (PBS). At 14 
weeks of age, the animals were killed, and the retinas collected and processed for 
histological examination. Cell count in the outer nuclear layer showed a significantly 
higher number of photoreceptors in the CNTF-injected eyes, and suggested that cell 
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death had been arrested after the 1st injection at 7 weeks of age. Indeed, the number of 
photoreceptor cells in the treated eyes at 14 weeks was the same as when the treatment 
was delivered (7 weeks of age). Despite this positive rescue effect, ocular 
complications such as corneal epitheliopathy, uveitis, and cataracts were generally 
observed in all CNTF-injected eyes. Similar complications were also reported with 
CNTF in the cat.158 The positive neuroprotective effect of intravitreally injected CNTF 
in the rcd1 dog prompted Neurotech, a biotechnology company that had recently 
acquired the Encapsulated Cell Technology (ECT) from CytoTherapeutics Inc., to test 
the efficacy and safety of this drug-delivery device in a large animal model of retinitis 
pigmentosa. 
A study, conducted in collaboration with Aguirre’s group, demonstrated that 
CNTF delivered intravitreally through the ECT device protects photoreceptors in the 
rcd1 dog in a dose-dependent manner.29 Complete protection is achieved over the 7 
week implantation period with devices that release 5-15 ng/day of CNTF. Minimal to 
no photoreceptor rescue is attained with lower doses (0.2-1 ng/day) of CNTF. A 
pharmacokinetic study conducted in rabbits showed that ECT devices loaded with a 
high CNTF-secreting cell line can release therapeutic doses (4.2-19.9 ng/day) of the 
factor for at least 1 year, and maintain CNTF levels in the vitreous that are between 70 
and 490 pg.160 Although this long-term drug delivery approach eliminates ocular side-
effects that are seen with bolus intravitreal injections of CNTF, histologic and 
electroretinographic changes are observed in rabbits implanted with ECT devices 
delivering high doses (22 ng/day) of CNTF.161 Morphologic alterations of rod 
photoreceptors observed in this study consisted in an increase in nuclear area, and in 
euchromatin content making them appear more like cones. A similar finding was 
reported when delivering CNTF subretinally by means of a rAAV vector in mice 
carrying a dominant-negative point mutation in the rds (peripherin) gene.156 Changes 
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in rod nuclear size and euchromatin content were not observed in rcd1 dogs implanted 
with an ECT device, although it was recently reported that ECT-CNTF causes an 
elevation of the outer limiting membrane suggestive of intracellular swelling of 
photoreceptors, Müller cells, or both.162 Electroretinographic alterations mainly 
consisting in a decrease in b-wave amplitudes have been described by several groups 
in the P23H and S334ter rhodopsin transgenic rats,153 the P216L rds/peripherin and 
rds/rds mice,155,156 and in the normal albino rabbit.97 These ERG changes may be 
partially caused by a decrease in the expression of rhodopsin and other 
phototransduction proteins.162 163 In summary, intravitreal bolus  injections, or 
prolonged-delivery of  CNTF through gene therapy or the ECT device promote the 
survival of photoreceptors in several animal models of RP. Although the severe ocular 
complications (corneal epitheliopathy, uveitis, cataract) associated with high doses of 
CNTF are eliminated with the ECT technology, cellular alterations have nevertheless 
been observed at the lowest therapeutically active doses. 
 
CNTF activates signaling pathways through the binding to its tripartite receptor. 
 CNTF is structurally and functionally related to members of the IL-6 family of 
cytokines that includes interleukin-6 (IL-6), interleukin-11 (IL-11), leukemia 
inhibitory factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), cardiotrophin-
like cytokine [CLC, also known as novel neurotrophin-1/B cell stimulating factor-3 
(NNT1/BSF-3)], and neuropoietin.164 165-167 All these cytokines share a four-α-helix-
bundle topology, a molecular weight of approximately 20 kDa, and use the common 
receptor subunit gp-130 for signal transduction.168 
 The receptor for CNTF is a complex formed by three components:  a CNTF-
specific α subunit (CNTFRα),169 and two β subunits (LIFRβ and gp-130) that are 
shared by receptors of other IL-6-type cytokines.168,170 The CNTFRα subunit is 
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located on the cell’s surface, and is anchored to the plasma membrane through a 
glycosyl phosphatidylinositol (GPI) linkage.169 The binding of CNTF to CNTFRα 
leads to the recruitment of gp-130 and LIFRβ, and the formation of a tripartite 
receptor complex. Recent findings support a hexameric model for the complex formed 
by CNTF bound to its full receptor. The proposed stoichiometry for this model 
involves the binding of two trimers composed, respectively, of CNTF-CNTFRα- gp-
130, and CNTF-CNTFRα-LIFRβ.171  
The heterodimerization of gp-130 and LIFRβ causes the activation of Jak/tyk 
kinases that are pre-associated with the two β subunits. This leads to tyrosine 
phosphorylation of the Jak kinases as well as the cytoplasmic domains of gp-130 and 
LIFRβ, and the recruitment of SH2-containing signal transducing molecules to these 
newly formed docking sites (for review see164). In addition to members of the STAT 
family, numerous signaling molecules such as PLCγ, PTP1D, pp120, Shc, Grb2, ras, 
Raf-1, ERK1 and ERK2 are recruited to the receptor and tyrosine 
phosphorylated.172,173 Thus, CNTF binding to its receptor can lead to the activation of 
the Jak/STAT, ras/MAPK, and PI3K/Akt pathways. Activated STAT molecules 
dimerize and translocate to the nucleus where they bind specific Response Elements, 
causing increased transcriptional activity of responsive genes. There is currently 
limited knowledge about the identity of such genes.  A few reports have nevertheless 
identified neuropeptide genes such as vasoactive intestinal polypeptide (VIP), 
somatostatin, calcitonin gene-related peptide (CGRP), and immediate early genes such 
as SOCS-3, c-fos, and Tis-11 as being overexpressed following administration of 
CNTF.174,175 Negative regulation of CNTF-Jak/STAT signaling is thought to result 
from a combination of tyrosine dephosphorylation of Jaks and STATs by protein 
tyrosine phosphatases (PTP), degradation of phosphorylated STATs by the 
proteasome, and the inactivation of Jaks and STATS by protein inhibitors such as 
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suppressors of cytokine signaling (SOCS) and protein inhibitors of activated STATs 
(PIAS) (for review see 176). 
 Müller glial cells have been identified by several groups as the site of 
endogenous CNTF production in the normal rodent retina.177,178 Following optic nerve 
transection, induction of ocular hypertension,  or exposure to light damage, an increase 
in CNTF levels is seen in Müller cells.178-181 The site of expression of the receptor for 
CNTF (CNTFRα) in the retina, on the other hand, has been a matter of significant 
conjecture in the field of retinal degeneration. When I started working in the year 2001 
on this topic, Wahlin et al.182,183 had shown that exogenous administration of CNTF in 
the rodent eye activates signaling pathways in Müller cells, but not in photoreceptors, 
thus suggesting that rods and cones do not express CNTFRα. Based on these, and 
subsequent studies, it was commonly accepted that photoreceptor neuroprotection by 
CNTF occurred through an indirect mechanism of action that involved the 
contribution of Müller cells.184,185 Because CNTFRα mRNA was found by in situ 
hybridization to be expressed only in ganglion, amacrine and horizontal cells in the rat 
retina,177 it was proposed that CNTF could mediate the rapid release of CNTFRα from 
the plasma membrane of these cells. Müller cells would then bind this soluble form of 
the receptor,186 and subsequently become a direct target of CNTF. The CNTF-
mediated activation of Müller cells would promote the release of other cell survival 
factors that would initiate a secondary neuroprotective signaling event in 
photoreceptors.187 This model of indirect photoreceptor survival by CNTF, 
nevertheless, was challenged by the findings of two studies that reported the 
localization of CNTFRα mRNA in the ONL of rat retina after ischemia-reperfusion,188 
and CNTFRα protein in the outer segments (OS) of a subpopulation of chicken 
photoreceptors.189  These photoreceptors were recently identified as violet-sensitive 
cones.190 These studies suggest that a direct mechanism of CNTF-mediated 
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photoreceptor rescue may occur in some species, or under certain pathological 
conditions. 
 
Research aims. 
Despite the publication of numerous studies reporting CNTF’s photoreceptor 
rescue effect in several animal models of RD, there is currently a lack of 
understanding of the cellular and molecular mechanisms of neuroprotection by this 
survival factor. To begin addressing this issue we used the normal adult canine retina 
as a model system to characterize the expression of the receptor for CNTF (CNTFRα) 
and determine whether it is found on rods and cones (see Chapter 2 and 191). To 
determine whether our findings are specific to the dog, or are also present in other 
mammalian species, we examined the immunolocalization of CNTFRα in the normal 
retinas of mice, rats, cats, sheep, pigs, horse, monkeys, and in human (see Chapter 3 
and 192).  
Although prolonged intraocular delivery of CNTF is currently being 
considered as a means of treating human patients with retinitis pigmentosa, there is 
currently no strong evidence to support or refute the assumption that it will provide a 
cure for all forms of RP irrespective of the genetic cause of the disease.193 To begin to 
address this issue, we evaluated whether CNTF could rescue photoreceptors in 
XLPRA2, an early and rapidly progressive canine model for X-linked retinitis 
pigmentosa that was recently identified.42 We selected this model because the severity 
of disease is comparable to that of rcd1, yet the causative mutations are different. For 
this purpose, we first characterized the morphologic retinal changes that occur during 
the course of the disease, and determined the kinetics of photoreceptor cell death (see 
Chapter 4 and 194). This enabled us to determine the optimal therapeutic time-
windows to test the neuroprotective effect of CNTF in this model (see Chapter 5).  
 24
References 
 
1. Bunker CH, Berson EL, Bromley WC, et al. Prevalence of retinitis pigmentosa 
in Maine. Am J Ophthalmol 1984;97:357-365. 
 
2. Boughman JA, Conneally PM, Nance WE. Population genetic studies of 
retinitis pigmentosa. Am J Hum Genet 1980;32:223-235. 
 
3. Puech B, Kostrubiec B, Hache JC, et al. Epidemiology and prevalence of 
hereditary retinal dystrophies in the Northern France. J Fr Ophtalmol 
1991;14:153-164. 
 
4. Milam AH, De Castro EB, Smith JE, et al. Concentric retinitis pigmentosa: 
clinicopathologic correlations. Exp Eye Res 2001;73:493-508. 
 
5. Klevering BJ, Blankenagel A, Maugeri A, et al. Phenotypic spectrum of 
autosomal recessive cone-rod dystrophies caused by mutations in the ABCA4 
(ABCR) gene. Invest Ophthalmol Vis Sci 2002;43:1980-1985. 
 
6. Maubaret C, Hamel C. Genetics of retinitis pigmentosa: metabolic 
classification and phenotype/genotype correlations. J Fr Ophtalmol 
2005;28:71-92. 
 
7. Chang GQ, Hao Y, Wong F. Apoptosis: final common pathway of 
photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron 
1993;11:595-605. 
 
8. Portera-Cailliau C, Sung CH, Nathans J, et al. Apoptotic photoreceptor cell 
death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci U S A 
1994;91:974-978. 
 
9. Li Z-Y, Milam AH. Apoptosis in retinitis pigmentosa In: Anderson RE, ed. 
Degenerative Diseases of the Retina. New York: Plenum Press, 1995;1-8. 
 
10. Dunaief JL, Dentchev T, Ying GS, et al. The role of apoptosis in age-related 
macular degeneration. Arch Ophthalmol 2002;120:1435-1442. 
 25
11. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed 
degeneration after spinal cord injury in rats and monkeys. Nat Med 1997;3:73-
76. 
 
12. Gwag BJ, Canzoniero LM, Sensi SL, et al. Calcium ionophores can induce 
either apoptosis or necrosis in cultured cortical neurons. Neuroscience 
1999;90:1339-1348. 
 
13. Martin LJ. Neuronal cell death in nervous system development, disease, and 
injury (Review). Int J Mol Med 2001;7:455-478. 
 
14. Zeiss CJ. The apoptosis-necrosis continuum: insights from genetically altered 
mice. Vet Pathol 2003;40:481-495. 
 
15. Chang B, Hawes NL, Hurd RE, et al. Retinal degeneration mutants in the 
mouse. Vision Res 2002;42:517-525. 
 
16. Fauser S, Luberichs J, Schuttauf F. Genetic animal models for retinal 
degeneration. Surv Ophthalmol 2002;47:357-367. 
 
17. Petters RM, Alexander CA, Wells KD, et al. Genetically engineered large 
animal model for studying cone photoreceptor survival and degeneration in 
retinitis pigmentosa. Nat Biotechnol 1997;15:965-970. 
 
18. Li ZY, Wong F, Chang JH, et al. Rhodopsin transgenic pigs as a model for 
human retinitis pigmentosa. Invest Ophthalmol Vis Sci 1998;39:808-819. 
 
19. Curtis R, Barnett KC, Leon A. An early-onset retinal dystrophy with dominant 
inheritance in the Abyssinian cat. Clinical and pathological findings. Invest 
Ophthalmol Vis Sci 1987;28:131-139. 
 
20. Narfstrom K. Progressive retinal atrophy in the Abyssinian cat. Clinical 
characteristics. Invest Ophthalmol Vis Sci 1985;26:193-200. 
 
21. Rah H, Maggs DJ, Blankenship TN, et al. Early-onset, autosomal recessive, 
progressive retinal atrophy in Persian cats. Invest Ophthalmol Vis Sci 
2005;46:1742-1747. 
 26
22. Gerke CG, Hao Y, Wong F. Topography of rods and cones in the retina of the 
domestic pig. Hong Kong Medical Journal 1995;1:302-308. 
 
23. Chandler MJ, Smith PJ, Samuelson DA, et al. Photoreceptor density of the 
domestic pig retina. Vet Ophthalmol 1999;2:179-184. 
 
24. Steinberg RH, Reid M, Lacy PL. The distribution of rods and cones in the 
retina of the cat (Felis domesticus). J Comp Neurol 1973;148:229-248. 
 
25. Gilger BC, Reeves KA, Salmon JH. Ocular parameters related to drug delivery 
in the canine and equine eye: aqueous and vitreous humor volume and scleral 
surface area and thickness. Vet Ophthalmol 2005;8:265-269. 
 
26. Cideciyan AV, Jacobson SG, Aleman TS, et al. In vivo dynamics of retinal 
injury and repair in the rhodopsin mutant dog model of human retinitis 
pigmentosa. Proc Natl Acad Sci U S A 2005;102:5233-5238. 
 
27. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and 
cone vision by single dose rAAV-mediated gene transfer to the retina in a 
canine model of childhood blindness. Mol Ther 2005;12:1072-1082. 
 
28. Willis CK, Quinn RP, McDonell WM, et al. Functional MRI as a tool to assess 
vision in dogs: the optimal anesthetic. Vet Ophthalmol 2001;4:243-253. 
 
29. Tao W, Wen R, Goddard MB, et al. Encapsulated cell based delivery of CNTF 
reduces photoreceptor degeneration in animal models of retinitis pigmentosa. 
Invest Ophthalmol Vis Sci 2002;43:3292-3298. 
 
30. Guven D, Weiland JD, Maghribi M, et al. Implantation of an inactive epiretinal 
poly(dimethyl siloxane) electrode array in dogs. Exp Eye Res 2006;82:81-90. 
 
31. Komaromy AM, Varner SE, de Juan E, et al. Application of the new subretinal 
injection device in the dog. Cell Transplantation 2006 (in press). 
 
32. Acland GM, Pearce-Kelling S, Komaromy AM, et al. Three canine cone-rod 
dystrophies. Invest Ophthalmol Vis Sci 2004;45:ARVO E abstract 3587. 
 
 27
33. Suber ML, Pittler SJ, Qin N, et al. Irish setter dogs affected with rod/cone 
dysplasia contain a nonsense mutation in the rod cGMP phosphodiesterase 
beta-subunit gene. Proc Natl Acad Sci U S A 1993;90:3968-3972. 
 
34. Clements PJ, Gregory CY, Peterson-Jones SM, et al. Confirmation of the rod 
cGMP phosphodiesterase beta subunit (PDE beta) nonsense mutation in 
affected rcd-1 Irish setters in the UK and development of a diagnostic test. 
Curr Eye Res 1993;12:861-866. 
 
35. Buyukmihci N, Aguirre G, Marshall J. Retinal degenerations in the dog. II. 
Development of the retina in rod-cone dysplasia. Exp Eye Res 1980;30:575-
591. 
 
36. Ray K, Baldwin VJ, Acland GM, et al. Cosegregation of codon 807 mutation 
of the canine rod cGMP phosphodiesterase beta gene and rcd1. Invest 
Ophthalmol Vis Sci 1994;35:4291-4299. 
 
37. Acland GM, Fletcher RT, Gentleman S, et al. Non-allelism of three genes 
(rcd1, rcd2 and erd) for early-onset hereditary retinal degeneration. Exp Eye 
Res 1989;49:983-998. 
 
38. Kukekova AV, Nelson J, Kuchtey RW, et al. Linkage Mapping of Canine Rod 
Cone Dysplasia Type 2 (rcd2) to CFA7, the Canine Orthologue of Human 
1q32. Invest Ophthalmol Vis Sci 2006;47:1210-1215. 
 
39. Petersen-Jones SM, Entz DD, Sargan DR. cGMP phosphodiesterase-alpha 
mutation causes progressive retinal atrophy in the Cardigan Welsh corgi dog. 
Invest Ophthalmol Vis Sci 1999;40:1637-1644. 
 
40. Aguirre G. Retinal degenerations in the dog. I. Rod dysplasia. Exp Eye Res 
1978;26:233-253. 
 
41. Acland GM, Aguirre GD. Retinal degenerations in the dog: IV. Early retinal 
degeneration (erd) in Norwegian elkhounds. Exp Eye Res 1987;44:491-521. 
 
42. Zhang Q, Acland GM, Wu WX, et al. Different  RPGR exon ORF15 mutations 
in Canids provide insights into photoreceptor cell degeneration. Hum Mol 
Genet 2002;11:993-1003. 
 28
43. Zeiss CJ, Acland GM, Aguirre GD. Retinal pathology of canine X-linked 
progressive retinal atrophy, the locus homologue of RP3. Invest Ophthalmol 
Vis Sci 1999;40:3292-3304. 
 
44. Aguirre G, Alligood J, O'Brien P, et al. Pathogenesis of progressive rod-cone 
degeneration in miniature poodles. Invest Ophthalmol Vis Sci 1982;23:610-
630. 
 
45. Aguirre GD, Acland GM. Variation in retinal degeneration phenotype inherited 
at the prcd locus. Exp Eye Res 1988;46:663-687. 
 
46. Acland GM, Ray K, Mellersh CS, et al. Linkage analysis and comparative 
mapping of canine progressive rod-cone degeneration (prcd) establishes 
potential locus homology with retinitis pigmentosa (RP17) in humans. Proc 
Natl Acad Sci U S A 1998;95:3048-3053. 
 
47. Kijas JW, Cideciyan AV, Aleman TS, et al. Naturally occurring rhodopsin 
mutation in the dog causes retinal dysfunction and degeneration mimicking 
human dominant retinitis pigmentosa. Proc Natl Acad Sci U S A 
2002;99:6328-6333. 
 
48. Sidjanin DJ, Lowe JK, McElwee JL, et al. Canine CNGB3 mutations establish 
cone degeneration as orthologous to the human achromatopsia locus ACHM3. 
Hum Mol Genet 2002;11:1823-1833. 
 
49. Aguirre GD, Baldwin V, Pearce-Kelling S, et al. Congenital stationary night 
blindness in the dog: common mutation in the RPE65 gene indicates founder 
effect. Mol Vis 1998;4:23. 
 
50. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine 
model of childhood blindness. Nat Genet 2001;28:92-95. 
 
51. Aramant RB, Seiler MJ. Progress in retinal sheet transplantation. Prog Retin 
Eye Res 2004;23:475-494. 
 
52. Lopez R, Gouras P, Kjeldbye H, et al. Transplanted retinal pigment epithelium 
modifies the retinal degeneration in the RCS rat. Invest Ophthalmol Vis Sci 
1989;30:586-588. 
 29
53. Lund RD, Adamson P, Sauve Y, et al. Subretinal transplantation of genetically 
modified human cell lines attenuates loss of visual function in dystrophic rats. 
Proc Natl Acad Sci U S A 2001;98:9942-9947. 
 
54. Thomas BB, Seiler MJ, Sadda SR, et al. Superior colliculus responses to light - 
preserved by transplantation in a slow degeneration rat model. Exp Eye Res 
2004;79:29-39. 
 
55. Mohand-Said S, Hicks D, Simonutti M, et al. Photoreceptor transplants 
increase host cone survival in the retinal degeneration (rd) mouse. Ophthalmic 
Res 1997;29:290-297. 
 
56. Aramant RB, Seiler MJ. Fiber and synaptic connections between embryonic 
retinal transplants and host retina. Exp Neurol 1995;133:244-255. 
 
57. Kwan AS, Wang S, Lund RD. Photoreceptor layer reconstruction in a rodent 
model of retinal degeneration. Exp Neurol 1999;159:21-33. 
 
58. Sakaguchi DS, Van Hoffelen SJ, Young MJ. Differentiation and 
morphological integration of neural progenitor cells transplanted into the 
developing mammalian eye. Ann N Y Acad Sci 2003;995:127-139. 
 
59. Klassen H, Sakaguchi DS, Young MJ. Stem cells and retinal repair. Prog Retin 
Eye Res 2004;23:149-181. 
 
60. Klassen HJ, Ng TF, Kurimoto Y, et al. Multipotent retinal progenitors express 
developmental markers, differentiate into retinal neurons, and preserve light-
mediated behavior. Invest Ophthalmol Vis Sci 2004;45:4167-4173. 
 
61. Qiu G, Seiler MJ, Mui C, et al. Photoreceptor differentiation and integration of 
retinal progenitor cells transplanted into transgenic rats. Exp Eye Res 
2005;80:515-525. 
 
62. Zrenner E. Will retinal implants restore vision? Science 2002;295:1022-1025. 
 
63. Weiland JD, Liu W, Humayun MS. Retinal prosthesis. Annu Rev Biomed Eng 
2005;7:361-401. 
 30
64. Majji AB, Humayun MS, Weiland JD, et al. Long-term histological and 
electrophysiological results of an inactive epiretinal electrode array 
implantation in dogs. Invest Ophthalmol Vis Sci 1999;40:2073-2081. 
 
65. Pardue MT, Stubbs EB, Jr., Perlman JI, et al. Immunohistochemical studies of 
the retina following long-term implantation with subretinal microphotodiode 
arrays. Exp Eye Res 2001;73:333-343. 
 
66. Guven D, Weiland JD, Fujii G, et al. Long-term stimulation by active 
epiretinal implants in normal and RCD1 dogs. J Neural Eng 2005;2:S65-73. 
 
67. Humayun MS, Weiland JD, Fujii GY, et al. Visual perception in a blind 
subject with a chronic microelectronic retinal prosthesis. Vision Res 
2003;43:2573-2581. 
 
68. Mahadevappa M, Weiland JD, Yanai D, et al. Perceptual thresholds and 
electrode impedance in three retinal prosthesis subjects. IEEE Trans Neural 
Syst Rehabil Eng 2005;13:201-206. 
 
69. Chow AY, Chow VY, Packo KH, et al. The artificial silicon retina microchip 
for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol 
2004;122:460-469. 
 
70. Bennett J, Tanabe T, Sun D, et al. Photoreceptor cell rescue in retinal 
degeneration (rd) mice by in vivo gene therapy. Nat Med 1996;2:649-654. 
 
71. Jomary C, Vincent KA, Grist J, et al. Rescue of photoreceptor function by 
AAV-mediated gene transfer in a mouse model of inherited retinal 
degeneration. Gene Ther 1997;4:683-690. 
 
72. Kumar-Singh R, Farber DB. Encapsidated adenovirus mini-chromosome-
mediated delivery of genes to the retina: application to the rescue of 
photoreceptor degeneration. Hum Mol Genet 1998;7:1893-1900. 
 
73. Takahashi M, Miyoshi H, Verma IM, et al. Rescue from photoreceptor 
degeneration in the rd mouse by human immunodeficiency virus vector-
mediated gene transfer. J Virol 1999;73:7812-7816. 
 
 31
74. Ali RR, Sarra GM, Stephens C, et al. Restoration of photoreceptor 
ultrastructure and function in retinal degeneration slow mice by gene therapy. 
Nat Genet 2000;25:306-310. 
 
75. Sarra GM, Stephens C, de Alwis M, et al. Gene replacement therapy in the 
retinal degeneration slow (rds) mouse: the effect on retinal degeneration 
following partial transduction of the retina. Hum Mol Genet 2001;10:2353-
2361. 
 
76. Schlichtenbrede FC, da Cruz L, Stephens C, et al. Long-term evaluation of 
retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene 
replacement therapy. J Gene Med 2003;5:757-764. 
 
77. Pang JJ, Chang B, Kumar A, et al. Gene Therapy Restores Vision-Dependent 
Behavior as Well as Retinal Structure and Function in a Mouse Model of 
RPE65 Leber Congenital Amaurosis. Mol Ther 2006; 13: 565-572. 
 
78. Batten ML, Imanishi Y, Tu DC, et al. Pharmacological and rAAV gene 
therapy rescue of visual functions in a blind mouse model of Leber congenital 
amaurosis. PLoS Med 2005;2:e333. 
 
79. Pawlyk BS, Smith AJ, Buch PK, et al. Gene replacement therapy rescues 
photoreceptor degeneration in a murine model of Leber congenital amaurosis 
lacking RPGRIP. Invest Ophthalmol Vis Sci 2005;46:3039-3045. 
 
80. Vollrath D, Feng W, Duncan JL, et al. Correction of the retinal dystrophy 
phenotype of the RCS rat by viral gene transfer of Mertk. Proc Natl Acad Sci 
U S A 2001;98:12584-12589. 
 
81. Smith AJ, Schlichtenbrede FC, Tschernutter M, et al. AAV-Mediated gene 
transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. 
Mol Ther 2003;8:188-195. 
 
82. Tschernutter M, Schlichtenbrede FC, Howe S, et al. Long-term preservation of 
retinal function in the RCS rat model of retinitis pigmentosa following 
lentivirus-mediated gene therapy. Gene Ther 2005;12:694-701. 
 
83. Hauswirth WW. The consortium project to treat RPE65 deficiency in humans. 
Retina 2005;25:S60. 
 32
84. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin 
Eye Res 2000;19:689-710. 
 
85. Lewin AS, Drenser KA, Hauswirth WW, et al. Ribozyme rescue of 
photoreceptor cells in a transgenic rat model of autosomal dominant retinitis 
pigmentosa. Nat Med 1998;4:967-971. 
 
86. LaVail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue of 
photoreceptor cells in P23H transgenic rats: long-term survival and late-stage 
therapy. Proc Natl Acad Sci U S A 2000;97:11488-11493. 
 
87. Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting 
VEGF effectively inhibits ocular neovascularization in a mouse model. Mol 
Vis 2003;9:210-216. 
 
88. Gorbatyuk MS, Pang JJ, Thomas J, Jr., et al. Knockdown of wild-type mouse 
rhodopsin using an AAV vectored ribozyme as part of an RNA replacement 
approach. Mol Vis 2005;11:648-656. 
 
89. Berson EL, Rosner B, Sandberg MA, et al. A randomized trial of vitamin A 
and vitamin E supplementation for retinitis pigmentosa. Arch Ophthalmol 
1993;111:761-772. 
 
90. Berson EL, Rosner B, Sandberg MA, et al. Clinical trial of docosahexaenoic 
acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch 
Ophthalmol 2004;122:1297-1305. 
 
91. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation of 
docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A 
treatment: subgroup analyses. Arch Ophthalmol 2004;122:1306-1314. 
 
92. Frasson M, Sahel JA, Fabre M, et al. Retinitis pigmentosa: rod photoreceptor 
rescue by a calcium-channel blocker in the rd mouse. Nat Med 1999;5:1183-
1187. 
 
93. Vallazza-Deschamps G, Cia D, Gong J, et al. Excessive activation of cyclic 
nucleotide-gated channels contributes to neuronal degeneration of 
photoreceptors. Eur J Neurosci 2005;22:1013-1022. 
 33
94. Donovan M, Cotter TG. Caspase-independent photoreceptor apoptosis in vivo 
and differential expression of apoptotic protease activating factor-1 and 
caspase-3 during retinal development. Cell Death Differ 2002;9:1220-1231. 
 
95. Pawlyk BS, Li T, Scimeca MS, et al. Absence of photoreceptor rescue with D-
cis-diltiazem in the rd mouse. Invest Ophthalmol Vis Sci 2002;43:1912-1915. 
 
96. Yamazaki H, Ohguro H, Maeda T, et al. Preservation of retinal morphology 
and functions in royal college surgeons rat by nilvadipine, a Ca(2+) antagonist. 
Invest Ophthalmol Vis Sci 2002;43:919-926. 
 
97. Bush RA, Kononen L, Machida S, et al. The effect of calcium channel blocker 
diltiazem on photoreceptor degeneration in the rhodopsin Pro23His rat. Invest 
Ophthalmol Vis Sci 2000;41:2697-2701. 
 
98. Pearce-Kelling SE, Aleman TS, Nickle A, et al. Calcium channel blocker D-
cis-diltiazem does not slow retinal degeneration in the PDE6B mutant rcd1 
canine model of retinitis pigmentosa. Mol Vis 2001;7:42-47. 
 
99. Takano Y, Ohguro H, Dezawa M, et al. Study of drug effects of calcium 
channel blockers on retinal degeneration of rd mouse. Biochem Biophys Res 
Commun 2004;313:1015-1022. 
 
100. Ohguro H, Ogawa K, Maeda T, et al. Retinal dysfunction in cancer-associated 
retinopathy is improved by Ca(2+) antagonist administration and dark 
adaptation. Invest Ophthalmol Vis Sci 2001;42:2589-2595. 
 
101. Tsang SH, Chen J, Kjeldbye H, et al. Retarding photoreceptor degeneration in 
Pdegtm1/Pdegtml mice by an apoptosis suppressor gene. Invest Ophthalmol 
Vis Sci 1997;38:943-950. 
 
102. Chen J, Flannery JG, LaVail MM, et al. bcl-2 overexpression reduces apoptotic 
photoreceptor cell death in three different retinal degenerations. Proc Natl 
Acad Sci U S A 1996;93:7042-7047. 
 
103. Eversole-Cire P, Concepcion FA, Simon MI, et al. Synergistic effect of Bcl-2 
and BAG-1 on the prevention of photoreceptor cell death. Invest Ophthalmol 
Vis Sci 2000;41:1953-1961. 
 34
104. Nir I, Kedzierski W, Chen J, et al. Expression of Bcl-2 protects against 
photoreceptor degeneration in retinal degeneration slow (rds) mice. J Neurosci 
2000;20:2150-2154. 
 
105. Bennett J, Zeng Y, Bajwa R, et al. Adenovirus-mediated delivery of rhodopsin-
promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd 
mouse. Gene Ther 1998;5:1156-1164. 
 
106. Faktorovich EG, Steinberg RH, Yasumura D, et al. Photoreceptor degeneration 
in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 
1990;347:83-86. 
 
107. Faktorovich EG, Steinberg RH, Yasumura D, et al. Basic fibroblast growth 
factor and local injury protect photoreceptors from light damage in the rat. J 
Neurosci 1992;12:3554-3567. 
 
108. Masuda K, Watanabe I, Unoki K, et al. Functional Rescue of photoreceptors 
from the damaging effects of constant light by survival-promoting factors in 
the rat. Invest Ophthalmol Vis Sci 1995;36:2142-2146. 
 
109. Lin N, Fan W, Sheedlo HJ, et al. Basic fibroblast growth factor treatment 
delays age-related photoreceptor degeneration in Fischer 344 rats. Exp Eye Res 
1997;64:239-248. 
 
110. Lewis GP, Erickson PA, Guerin CJ, et al. Basic fibroblast growth factor: a 
potential regulator of proliferation and intermediate filament expression in the 
retina. J Neurosci 1992;12:3968-3978. 
 
111. Perry J, Du J, Kjeldbye H, et al. The effects of bFGF on RCS rat eyes. Curr 
Eye Res 1995;14:585-592. 
 
112. LaVail MM, Unoki K, Yasumura D, et al. Multiple growth factors, cytokines, 
and neurotrophins rescue photoreceptors from the damaging effects of constant 
light. Proc Natl Acad Sci U S A 1992;89:11249-11253. 
 
113. Cayouette M, Gravel C. Adenovirus-mediated gene transfer of ciliary 
neurotrophic factor can prevent photoreceptor degeneration in the retinal 
degeneration (rd) mouse. Hum Gene Ther 1997;8:423-430. 
 35
114. Cayouette M, Behn D, Sendtner M, et al. Intraocular gene transfer of ciliary 
neurotrophic factor prevents death and increases responsiveness of rod 
photoreceptors in the retinal degeneration slow mouse. J Neurosci 
1998;18:9282-9293. 
 
115. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse 
photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol 
Vis Sci 1998;39:592-602. 
 
116. Ogilvie JM, Speck JD, Lett JM. Growth factors in combination, but not 
individually, rescue rd mouse photoreceptors in organ culture. Exp Neurol 
2000;161:676-685. 
 
117. Caffe AR, Soderpalm AK, Holmqvist I, et al. A combination of CNTF and 
BDNF rescues rd photoreceptors but changes rod differentiation in the 
presence of RPE in retinal explants. Invest Ophthalmol Vis Sci 2001;42:275-
282. 
 
118. Carwile ME, Culbert RB, Sturdivant RL, et al. Rod outer segment maintenance 
is enhanced in the presence of bFGF, CNTF and GDNF. Exp Eye Res 
1998;66:791-805. 
 
119. Frasson M, Picaud S, Leveillard T, et al. Glial cell line-derived neurotrophic 
factor induces histologic and functional protection of rod photoreceptors in the 
rd/rd mouse. Invest Ophthalmol Vis Sci 1999;40:2724-2734. 
 
120. McGee Sanftner LH, Abel H, Hauswirth WW, et al. Glial cell line derived 
neurotrophic factor delays photoreceptor degeneration in a transgenic rat 
model of retinitis pigmentosa. Mol Ther 2001;4:622-629. 
 
121. Cayouette M, Smith SB, Becerra SP, et al. Pigment epithelium-derived factor 
delays the death of photoreceptors in mouse models of inherited retinal 
degenerations. Neurobiol Dis 1999;6:523-532. 
 
122. Cao W, Tombran-Tink J, Elias R, et al. In vivo protection of photoreceptors 
from light damage by pigment epithelium-derived factor. Invest Ophthalmol 
Vis Sci 2001;42:1646-1652. 
 
 36
123. Miyazaki M, Ikeda Y, Yonemitsu Y, et al. Simian lentiviral vector-mediated 
retinal gene transfer of pigment epithelium-derived factor protects retinal 
degeneration and electrical defect in Royal College of Surgeons rats. Gene 
Ther 2003;10:1503-1511. 
 
124. Whiteley SJ, Klassen H, Coffey PJ, et al. Photoreceptor rescue after low-dose 
intravitreal IL-1beta injection in the RCS rat. Exp Eye Res 2001;73:557-568. 
 
125. Song Y, Zhao L, Tao W, et al. Photoreceptor protection by cardiotrophin-1 in 
transgenic rats with the rhodopsin mutation s334ter. Invest Ophthalmol Vis Sci 
2003;44:4069-4075. 
 
126. Mohand-Said S, Deudon-Combe A, Hicks D, et al. Normal retina releases a 
diffusible factor stimulating cone survival in the retinal degeneration mouse. 
Proc Natl Acad Sci U S A 1998;95:8357-8362. 
 
127. Leveillard T, Mohand-Said S, Lorentz O, et al. Identification and 
characterization of rod-derived cone viability factor. Nat Genet 2004;36:755-
759. 
 
128. Barbin G, Manthorpe M, Varon S. Purification of the chick eye ciliary 
neuronotrophic factor. J Neurochem 1984;43:1468-1478. 
 
129. Stockli KA, Lottspeich F, Sendtner M, et al. Molecular cloning, expression and 
regional distribution of rat ciliary neurotrophic factor. Nature 1989;342:920-
923. 
 
130. Lin LF, Mismer D, Lile JD, et al. Purification, cloning, and expression of 
ciliary neurotrophic factor (CNTF). Science 1989;246:1023-1025. 
 
131. Lam A, Fuller F, Miller J, et al. Sequence and structural organization of the 
human gene encoding ciliary neurotrophic factor. Gene 1991;102:271-276. 
 
132. Masiakowski P, Liu HX, Radziejewski C, et al. Recombinant human and rat 
ciliary neurotrophic factors. J Neurochem 1991;57:1003-1012. 
 
 37
133. Apfel SC, Arezzo JC, Moran M, et al. Effects of administration of ciliary 
neurotrophic factor on normal motor and sensory peripheral nerves in vivo. 
Brain Res 1993;604:1-6. 
 
134. Lo AC, Li L, Oppenheim RW, et al. Ciliary neurotrophic factor promotes the 
survival of spinal sensory neurons following axotomy but not during the period 
of programmed cell death. Exp Neurol 1995;134:49-55. 
 
135. Blottner D, Bruggemann W, Unsicker K. Ciliary neurotrophic factor supports 
target-deprived preganglionic sympathetic spinal cord neurons. Neurosci Lett 
1989;105:316-320. 
 
136. Kotzbauer PT, Lampe PA, Estus S, et al. Postnatal development of survival 
responsiveness in rat sympathetic neurons to leukemia inhibitory factor and 
ciliary neurotrophic factor. Neuron 1994;12:763-773. 
 
137. Sendtner M, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents 
the degeneration of motor neurons after axotomy. Nature 1990;345:440-441. 
 
138. Forger NG, Roberts SL, Wong V, et al. Ciliary neurotrophic factor maintains 
motoneurons and their target muscles in developing rats. J Neurosci 
1993;13:4720-4726. 
 
139. Sagot Y, Tan SA, Baetge E, et al. Polymer encapsulated cell lines genetically 
engineered to release ciliary neurotrophic factor can slow down progressive 
motor neuronopathy in the mouse. Eur J Neurosci 1995;7:1313-1322. 
 
140. Tan SA, Deglon N, Zurn AD, et al. Rescue of motoneurons from axotomy-
induced cell death by polymer encapsulated cells genetically engineered to 
release CNTF. Cell Transplant 1996;5:577-587. 
 
141. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. A phase I 
study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients 
with amyotrophic lateral sclerosis. Clin Neuropharmacol 1995;18:515-532. 
 
142. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The 
pharmacokinetics of subcutaneously administered recombinant human ciliary 
neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis: 
 38
relation to parameters of the acute-phase response. Clin Neuropharmacol 
1995;18:500-514. 
 
143. Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using 
encapsulated genetically modified xenogeneic cells in amyotrophic lateral 
sclerosis patients. Nat Med 1996;2:696-699. 
 
144. Penn RD, Kroin JS, York MM, et al. Intrathecal ciliary neurotrophic factor 
delivery for treatment of amyotrophic lateral sclerosis (phase I trial). 
Neurosurgery 1997;40:94-99; discussion 99-100. 
 
145. Zurn AD, Henry H, Schluep M, et al. Evaluation of an intrathecal immune 
response in amyotrophic lateral sclerosis patients implanted with encapsulated 
genetically engineered xenogeneic cells. Cell Transplant 2000;9:471-484. 
 
146. Emerich DF, Lindner MD, Winn SR, et al. Implants of encapsulated human 
CNTF-producing fibroblasts prevent behavioral deficits and striatal 
degeneration in a rodent model of Huntington's disease. J Neurosci 
1996;16:5168-5181. 
 
147. de Almeida LP, Zala D, Aebischer P, et al. Neuroprotective effect of a CNTF-
expressing lentiviral vector in the quinolinic acid rat model of Huntington's 
disease. Neurobiol Dis 2001;8:433-446. 
 
148. Regulier E, Pereira de Almeida L, Sommer B, et al. Dose-dependent 
neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-
regulated lentiviral vectors in the quinolinic acid rat model of Huntington's 
disease. Hum Gene Ther 2002;13:1981-1990. 
 
149. Emerich DF, Winn SR, Hantraye PM, et al. Protective effect of encapsulated 
cells producing neurotrophic factor CNTF in a monkey model of Huntington's 
disease. Nature 1997;386:395-399. 
 
150. Mittoux V, Joseph JM, Conde F, et al. Restoration of cognitive and motor 
functions by ciliary neurotrophic factor in a primate model of Huntington's 
disease. Hum Gene Ther 2000;11:1177-1187. 
 
151. Schooltink H, Stoyan T, Roeb E, et al. Ciliary neurotrophic factor induces 
acute-phase protein expression in hepatocytes. FEBS Lett 1992;314:280-284. 
 39
152. Dittrich F, Thoenen H, Sendtner M. Ciliary neurotrophic factor: 
pharmacokinetics and acute-phase response in rat. Ann Neurol 1994;35:151-
163. 
 
153. Liang FQ, Aleman TS, Dejneka NS, et al. Long-term protection of retinal 
structure but not function using RAAV.CNTF in animal models of retinitis 
pigmentosa. Mol Ther 2001;4:461-472. 
 
154. Huang SP, Lin PK, Liu JH, et al. Intraocular gene transfer of ciliary 
neurotrophic factor rescues photoreceptor degeneration in RCS rats. J Biomed 
Sci 2004;11:37-48. 
 
155. Schlichtenbrede FC, MacNeil A, Bainbridge JW, et al. Intraocular gene 
delivery of ciliary neurotrophic factor results in significant loss of retinal 
function in normal mice and in the Prph2Rd2/Rd2 model of retinal 
degeneration. Gene Ther 2003;10:523-527. 
 
156. Bok D, Yasumura D, Matthes MT, et al. Effects of adeno-associated virus-
vectored ciliary neurotrophic factor on retinal structure and function in mice 
with a P216L rds/peripherin mutation. Exp Eye Res 2002;74:719-735. 
 
157. Liang FQ, Dejneka NS, Cohen DR, et al. AAV-mediated delivery of ciliary 
neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout 
mouse. Mol Ther 2001;3:241-248. 
 
158. Chong NH, Alexander RA, Waters L, et al. Repeated injections of a ciliary 
neurotrophic factor analogue leading to long-term photoreceptor survival in 
hereditary retinal degeneration. Invest Ophthalmol Vis Sci 1999;40:1298-1305. 
 
159. Pearce-Kelling SE, Acland GM, Laties A, et al. Survival factors slow inherited 
retinal degeneration in the rcd-1 and erd dog models. Invest Ophthalmol Vis 
Sci 1998;39:S571. 
 
160. Thanos CG, Bell WJ, O'Rourke P, et al. Sustained secretion of ciliary 
neurotrophic factor to the vitreous, using the encapsulated cell therapy-based 
NT-501 intraocular device. Tissue Eng 2004;10:1617-1622. 
 
 40
161. Bush RA, Lei B, Tao W, et al. Encapsulated cell-based intraocular delivery of 
ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG 
and retinal histology. Invest Ophthalmol Vis Sci 2004;45:2420-2430. 
 
162. Zeiss CJ, Allore HG, Towle V, et al. CNTF induces dose-dependent alterations 
in retinal morphology in normal and rcd-1 canine retina. Exp Eye Res 2005. 
 
163. Song Y, Zhao L, Liu Y, et al. Negative regulation of phototransduction 
machinery by CNTF is likely through the photostasis mechanism. ARVO 
2005; E-abstract #163. 
 
164. Heinrich PC, Behrmann I, Muller-Newen G, et al. Interleukin-6-type cytokine 
signalling through the gp130/Jak/STAT pathway. Biochem J 1998;334:297-
314. 
 
165. Senaldi G, Varnum BC, Sarmiento U, et al. Novel neurotrophin-1/B cell-
stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A 
1999;96:11458-11463. 
 
166. Shi Y, Wang W, Yourey PA, et al. Computational EST database analysis 
identifies a novel member of the neuropoietic cytokine family. Biochem 
Biophys Res Commun 1999;262:132-138. 
 
167. Derouet D, Rousseau F, Alfonsi F, et al. Neuropoietin, a new IL-6-related 
cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl 
Acad Sci U S A 2004;101:4827-4832. 
 
168. Ip NY, Nye SH, Boulton TG, et al. CNTF and LIF act on neuronal cells via 
shared signaling pathways that involve the IL-6 signal transducing receptor 
component gp130. Cell 1992;69:1121-1132. 
 
169. Davis S, Aldrich TH, Valenzuela DM, et al. The receptor for ciliary 
neurotrophic factor. Science 1991;253:59-63. 
 
170. Ip NY, McClain J, Barrezueta NX, et al. The alpha component of the CNTF 
receptor is required for signaling and defines potential CNTF targets in the 
adult and during development. Neuron 1993;10:89-102. 
 
 41
171. He W, Gong K, Smith DK, et al. The N-terminal cytokine binding domain of 
LIFR is required for CNTF binding and signaling. FEBS Lett 2005;579:4317-
4323. 
 
172. Boulton TG, Stahl N, Yancopoulos GD. Ciliary neurotrophic factor/leukemia 
inhibitory factor/interleukin 6/oncostatin M family of cytokines induces 
tyrosine phosphorylation of a common set of proteins overlapping those 
induced by other cytokines and growth factors. J Biol Chem 1994;269:11648-
11655. 
 
173. Schwarzschild MA, Dauer WT, Lewis SE, et al. Leukemia inhibitory factor 
and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell 
line and in sympathetic neuron cultures. J Neurochem 1994;63:1246-1254. 
 
174. Symes AJ, Rao MS, Lewis SE, et al. Ciliary neurotrophic factor coordinately 
activates transcription of neuropeptide genes in a neuroblastoma cell line. Proc 
Natl Acad Sci U S A 1993;90:572-576. 
 
175. Kelly JF, Elias CF, Lee CE, et al. Ciliary neurotrophic factor and leptin induce 
distinct patterns of immediate early gene expression in the brain. Diabetes 
2004;53:911-920. 
 
176. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises 
in the Jak/Stat pathway. Cell 2002;109:S121-131. 
 
177. Kirsch M, Lee MY, Meyer V, et al. Evidence for multiple, local functions of 
ciliary neurotrophic factor (CNTF) in retinal development: expression of 
CNTF and its receptors and in vitro effects on target cells. J Neurochem 
1997;68:979-990. 
 
178. Walsh N, Valter K, Stone J. Cellular and subcellular patterns of expression of 
bFGF and CNTF in the normal and light stressed adult rat retina. Exp Eye Res 
2001;72:495-501. 
 
179. Chun MH, Ju WK, Kim KY, et al. Upregulation of ciliary neurotrophic factor 
in reactive Muller cells in the rat retina following optic nerve transection. 
Brain Res 2000;868:358-362. 
 
 42
180. Ji JZ, Elyaman W, Yip HK, et al. CNTF promotes survival of retinal ganglion 
cells after induction of ocular hypertension in rats: the possible involvement of 
STAT3 pathway. Eur J Neurosci 2004;19:265-272. 
 
181. Ju WK, Lee MY, Hofmann HD, et al. Expression of CNTF in Muller cells of 
the rat retina after pressure-induced ischemia. Neuroreport 1999;10:419-422. 
 
182. Wahlin KJ, Campochiaro PA, Zack DJ, et al. Neurotrophic factors cause 
activation of intracellular signaling pathways in Muller cells and other cells of 
the inner retina, but not photoreceptors. Invest Ophthalmol Vis Sci 
2000;41:927-936. 
 
183. Wahlin KJ, Adler R, Zack DJ, et al. Neurotrophic signaling in normal and 
degenerating rodent retinas. Exp Eye Res 2001;73:693-701. 
 
184. Harada T, Harada C, Kohsaka S, et al. Microglia-Muller glia cell interactions 
control neurotrophic factor production during light-induced retinal 
degeneration. J Neurosci 2002;22:9228-9236. 
 
185. Wang Y, Smith SB, Ogilvie JM, et al. Ciliary neurotrophic factor induces glial 
fibrillary acidic protein in retinal Muller cells through the JAK/STAT signal 
transduction pathway. Curr Eye Res 2002;24:305-312. 
 
186. Davis S, Aldrich TH, Ip NY, et al. Released form of CNTF receptor α 
component as a soluble mediator of CNTF responses. Science 1993;259:1736-
1739. 
 
187. Peterson WM, Wang Q, Tzekova R, et al. Ciliary neurotrophic factor and 
stress stimuli activate the Jak-STAT pathway in retinal neurons and glia. J 
Neurosci 2000;20:4081-4090. 
 
188. Ju WK, Lee MY, Hofmann HD, et al. Increased expression of ciliary 
neurotrophic factor receptor α mRNA in the ischemic rat retina. Neurosci Lett 
2000;283:133-136. 
 
189. Fuhrmann S, Kirsch M, Heller S, et al. Differential regulation of ciliary 
neurotrophic factor receptor-α expression in all major neuronal cell classes 
during development of the chick retina. J Comp Neurol 1998;400:244-254. 
 43
190. Seydewitz V, Rothermel A, Fuhrmann S, et al. Expression of CNTF receptor-α 
in chick violet-sensitive cones with unique morphologic properties. Invest 
Ophthalmol Vis Sci 2004;45:655-661. 
 
191. Beltran WA, Zhang Q, Kijas JW, et al. Cloning, mapping, and retinal 
expression of the canine ciliary neurotrophic factor receptor α (CNTFRα). 
Invest Ophthalmol Vis Sci 2003;44:3642-3649. 
 
192. Beltran WA, Rohrer H, Aguirre GD. Immunolocalization of ciliary 
neurotrophic factor receptor α (CNTFRα) in mammalian photoreceptor cells. 
Mol Vis 2005;11:232-244. 
 
193. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for 
human retinal degeneration: Phase I trial of CNTF delivered by encapsulated 
cell intraocular implants. Proc Natl Acad Sci U S A 2006;103:3896-3901. 
 
194. Beltran WA, Hammond P, Acland GM, et al. A frameshift mutation in RPGR 
exon ORF15 causes photoreceptor degeneration and inner retina remodeling in 
a model of X-linked retinitis pigmentosa. Invest Ophthalmol Vis Sci 
2006;47:1669-1681. 
 
 
 
 44
CHAPTER TWO 
 
CLONING, MAPPING, AND RETINAL EXPRESSION OF THE 
CANINE CILIARY NEUROTROPHIC FACTOR RECEPTOR α 
(CNTFRα) * 
 
INTRODUCTION 
Retinal degenerations are a major cause of blindness for which no treatment is 
currently available. Different therapeutic approaches are being investigated; among 
these, the use of survival factors that may slow the rate of photoreceptor death and 
delay the onset of vision loss in various forms of retinal degeneration. Over the past 
decade, a variety of survival factors have been tested in several animal models of 
retinal degeneration.1-4 Ciliary neurotrophic factor (CNTF), a survival factor originally 
isolated from the chick ciliary ganglion, was shown to promote photoreceptor rescue 
when delivered intravitreally or subretinally to the rat (Song Y, ARVO abstract # 964, 
2000), mouse and cat eye.2,3,5-7 Our laboratory has shown a similar neuroprotective  
effect when CNTF was injected into the vitreous of rcd1 dogs, a canine model of early  
onset and rapidly progressing retinal degeneration caused by a mutation in the PDE6B 
gene. Similar to observations made in the rd mouse,3,5 a disease model also caused by 
a mutation in PDE6B, a neuroprotective effect was observed in 14 week-old rcd1 dogs 
when intravitreal injections of CNTF were performed at 7 and 10 weeks of age 
(Pearce-Kelling S, ARVO abstract # 2645, 1998). However, side effects such as 
cataracts were present following intravitreal CNTF injections, but these complications 
 
* Beltran WA, Zhang Q, Kijas JW, Gu D, Rohrer H, Jordan JA, Aguirre GD. Invest. 
Ophthalmol. Vis. Sci. 2003;44 (8):3642-3649. The Association for Research in Vision 
and Ophthalmology is the copyright holder of this publication. 
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were eliminated when CNTF was delivered by means of an encapsulated cell based 
delivery system. In addition, this long-term delivery device allowed prolonged rescue 
of photoreceptors over a period of 7-14 weeks.8 
CNTF is thought to trigger a survival signal by binding to the ciliary 
neurotrophic factor receptor (CNTFR). This receptor is a member of the cytokine 
receptor superfamily, and is composed of three subunits: an α subunit (CNTFRα)9 
which carries the specific CNTF binding site, and two different β-subunits [gp-130 
and Leukemia Inhibitory Factor Receptor (LIFRβ)] 10 that are pre-associated with 
members of the Jak/Tyk family of cytoplasmic tyrosine kinases. The binding of CNTF 
to CNTFRα causes heterodimerization of gp-130 and LIFR, and activation of the 
Jak/Tyk kinases. This, in turn, recruits and activates a variety of downstream signaling 
molecules, turning on different signaling pathways11 that promote a cell survival 
response. 
CNTFRα is an extracellular protein that is attached to the plasma membrane 
by a glycosyl-phosphatidylinositol link. Cleavage of this link by phosphatidylinositol-
specific phospholipase C (PI-PLC) releases a soluble form of CNTFRα.9 CNTFRα 
has been isolated from a variety of tissues including the retina, central nervous system, 
peripheral nervous system, muscle, skin, lung, liver, kidney, and testes.12-14 While 
CNTF’s neuroprotective effect in the retina has been demonstrated in a variety of 
animal models of retinal degeneration,2,3,5-7 the site of expression of its receptor, and 
the mechanism of action by which it rescues photoreceptors, is unknown in 
mammalian species. Several studies have suggested that CNTFRα is not expressed by 
photoreceptor cells, and that the neuroprotective effect of CNTF is mediated by Müller 
cells.15-17 Because of the dramatic rescue effect of CNTF on rcd-1 affected 
photoreceptors, and the lack of knowledge of its cellular targets in the retina, we 
decided to clone CNTFRα and study its expression in the normal adult canine retina. 
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METHODS 
Primer Design 
The human and mouse CNTFRα complete coding sequences (GenBank # M73238, 
NM016673, respectively) were aligned using the Sequencher program (version 4.0.5, 
Gene Codes Corp., Ann Arbor, MI) to generate a consensus sequence. PCR primer 
pairs (Table 1) that amplify the complete coding sequence (exons 3-9) or only 
fragments of the canine gene were designed based on the consensus sequence. 
 
Reverse Transcription - Polymerase Chain Reaction and cDNA Cloning. 
Brain tissue from the frontal cerebral cortex of a 17-week old male beagle dog was 
used as a source of total RNA. The tissue was homogenized in TRIzol® reagent 
(Invitrogen, Carlsbad, CA), and total RNA extracted from the aqueous phase with 
chloroform. First strand cDNA was synthesized using GeneAmp® RNA PCR kit 
(Perkin Elmer, Foster City, CA); the 20 µl reaction volume contained 1 µg total RNA, 
2.5 µM random hexamers, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 5 mM MgCl2, 1 
mM of each dNTP, 20 U RNase inhibitor, and 50 U MuLV reverse transcriptase. After 
10 minutes at room temperature, the reaction mixture was incubated at 42°C for 15 
minutes, and terminated by incubation at 70°C for 15 minutes followed by 5 minutes 
on ice. The resulting cDNA was used as a template for a 20 µl PCR reaction 
containing 0.4 µM of primers CNTFR 1F and CNTFR 1R (Table 1), 1.5 mM MgCl2, 
50 mM KCl, 10 mM Tris-HCl (pH 8.3), 200 µM dNTP, and 0.5 U Taq polymerase. 
PCR amplification with primers CNTFR 1F and CNTFR 1R are expected to generate a 
1272 bp DNA fragment that contains the complete canine CNTFRα coding sequence. 
Reactions were carried out for 36 cycles at an annealing temperature of 53°C for 20 
seconds, a polymerization temperature of 72°C for 40 seconds, and a heat-
denaturation temperature of 94°C for 20 seconds in a thermal cycler (PTC-200, MJ 
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Research, Waltham, MA). The PCR-amplified DNA fragment was cloned in a 
pCR®2.1 vector using the TA-cloning kit (Invitrogen, San Diego, CA) according to 
the manufacturer’s recommendations. Sequencing was done by Taq cycle sequencing 
using DyeDeoxy terminators in an automated sequencer (ABI prism 3700, Applied 
Biosystems, Foster City, CA) at the core sequencing facility of Cornell University. 
The MEGA program (version 2.0, www.megasoftware.net) was used to establish the 
degree of homology between the canine CNTFRα coding sequence (nucleotide and 
amino acid) and that of the human (M73238), mouse (NM016673), rat (S54212) and 
chicken (Z48168). 
The transcription of CNTFRα was examined by RT-PCR on 3 µg of total RNA 
extracted from the retina, brain, spleen, lung, liver, and kidney of a normal adult 
beagle. PCR amplification of a 369 bp product using primers CNTFR 6F and CNTFR 
2R (Table 1) was carried out for 30 cycles at an annealing temperature of 58°C.  
PCR products were analyzed by electrophoresis on an ethidium bromide-stained 
polyacrylamide gel (6%). 
 
Radiation Hybrid (RH) Mapping 
DNA from the RH083000 canine-hamster radiation hybrid panel was purchased from 
Research Genetics (Huntsville, AL). The parental mongrel dog cell line was irradiated 
with 3,000 rads, and fused with A23, a thymidine kinase deficient (TK-) hamster cell 
line with a retention estimate of 28%. CNTFRα maps to human chromosome 9p13.18 
We therefore selected six markers (REN142009, REN275M05, IFNA3, IFNA1, REN174D18, 
REN147002) located on the canine homologous region on canine chromosome 11 (CFA 
11) in the RHDF5000 map19 to generate a framework map, and establish the map 
position of this gene in the dog. Primers CNTFR 9F and CNTFR 9R (Table 1) were 
used to amplify a 112 bp fragment of canine-specific CNTFRα. The map was 
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Table 2.1 PCR primers with position and length of products, and annealing temperature. 
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Primer ID Sequence (5’→ 3’) Position Fragment size (bp) Annealing temperature (°C) 
 
CNTFR 6F ATTGTGAAGCCTGATCCTCCAGA Exon 6-7 369 bp  53 
CNTFR 2R TGGTGGTGCTGGTCGTGGTCT    
 
  
  
   
Exon 9  
 
CNTFR 1F GAGGAGGA(T/G)(A/G)A(T/C)ATTGATGTG
 
5’ UTR 1272 bp 
 
                          58 
CNTFR 1R AAAGGTCCTCCTGCCCGTGTG 3’ UTR
 
CNTFR 9F CAGCACCCTTCTTGATCCATG Exon 9 112 bp                            58 
 CNTFR 9R GTGCGCTGGCATGTCCCTCAC 3’UTR
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constructed using MultiMap software20 based on best two-point analysis, placing 
markers at a lod score of 3.0 for overall order. 
 
Animals and histologic procedures 
Retinas from normal adult beagles were used for both the in situ hybridization and 
immunocytochemistry studies. Dogs were anesthetized with intravenous pentobarbital, 
and the eyes rapidly enucleated in the light. After three hour fixation of the entire 
globe at 4°C in 4% paraformaldehyde in 0.1 M phosphate buffered saline, the 
posterior segment was isolated and fixed for an additional 24 hours at 4°C in 2% 
paraformaldehyde in 0.1 M phosphate buffered saline. The tissue then was trimmed 
and cryoprotected in a solution of 30% sucrose in 0.1 M sodium phosphate and 0.15 M 
sodium chloride, pH 7.2 [BupHTM, Phosphate Buffered Saline, Pierce, Rockford, IL; 
(referred in the text as PBS)] at 4°C for 48 hours, and embedded in OCT. Cryosections 
were cut at 7, 10 or 15 µm thickness. All research conducted was in full compliance 
with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 
 
In situ hybridization 
A 369 bp fragment of canine CNTFRα cDNA encoding exons 7 and 8 was amplified 
using primers CNTFR 6F and CNTFR 2R (Table 1), and subcloned in the dual 
promoter vector pCRII®-TOPO (Invitrogen). After purification using the QIAprep 
miniprep kit (Qiagen, Valencia, CA), the plasmid was linearized using HindIII and 
EcoRV restriction enzymes, and single strand sense and antisense digoxigenin-labeled 
RNA probes were generated by T7 and Sp6 RNA polymerases, respectively, using 
DIG RNA labeling kit (Roche Molecular Biochemicals, Mannheim, Germany). The 
slides were air-dried overnight at 40°C, then washed twice for 5 min in PBS, 100 mM 
glycine in PBS, 0.3% Triton X-100 in PBS, and rinsed with PBS. The 15 µm-thick 
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sections were then permeabilized with 500 ng/ml Proteinase K in 100 mMTris-HCl, 
50 mM EDTA, pH 8.0, for 30 min at 37°C, and post fixed with 4% paraformaldehyde 
in PBS. After two rinses in PBS, the sections were acetylated twice for 5 min with 
0.25% acetic anhydride in 0.1 M triethanolamine, pH 8.0, and incubated for 10 min 
with deionized formamide in 2 x SSC (1 x SSC: 150 mM NaCl, 15 mM sodium 
citrate, pH 7.2). The sections were then hybridized with 100 ng of RNA probe in 
hybridization buffer (In Situ Hyb Buffer, Ambion, Austin, TX) for 16 hours at 50°C in 
a humid chamber. After hybridization, the slides were washed twice in 2 x SSC, and 
twice in 1 x SSC at 37°C. They were then treated with RNase A (20 µg/ml in 500mM 
NaCl, 10 mM Tris, 1 mM EDTA, pH 8.0) for 30 min at 37°C, washed twice in 0.1 x 
SSC for 30 min at 37°C. RNA hybrids were detected by incubation for 30 min with an 
alkaline-phosphatase–conjugated antidigoxigenin antibody (1:500), and then for 16 
hours with the chromogenic substrates 4-nitroblue tetrazolium chloride (NBT) and 5-
bromo-4-chloro-3-indoyl phosphate (BCIP) (DIG nucleic acid detection kit, Roche 
Molecular Biochemicals). Slides were mounted with Acqua poly mount (Polysciences, 
Warrington, PA), and examined with a Zeiss Axioplan microscope with or without 
Differential Interference Contrast (DIC) optics. Images were digitally captured (Spot 
3.3, Diagnostic, Instrument, Inc., Sterling Height, MI) and imported into Adobe 
Photoshop graphics program for display. 
 
Immunoblot analysis 
For western analysis, adult canine retina was homogenized in PBS containing a 
cocktail of protease inhibitors (Sigma, St Louis, MO), and, following sonication, the 
protein level determined by the Bradford method (Bio-Rad protein assay, Bio-Rad, 
Hercules, CA). Samples consisting of dog and chicken retinal protein lysates, and 
recombinant rat CNTFRα (amino acid residues 1-346; R&D systems, Minneapolis, 
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MN) were placed in the sample buffer containing 4% glycerol, 0.4% sodium dodecyl 
sulfate, 1% β-mercaptoethanol, 0.005% bromophenol blue in 12.5 mM Tris-HCl 
buffer (pH 6.8) and heated at 100 °C for 5 minutes. Samples and molecular weight 
standards were separated by SDS-PAGE (4% stacking gel, 10% separating 
gel).Transfer of proteins from gels to PVDF membrane (Immobilon, Millipore, 
Bedford, MA) was performed in pre-chilled transfer buffer (25 mM Tris base, 192 
mM glycine, and 15% methanol), and the membrane was then blocked with 10% skim 
milk in Tris-buffered saline containing 0.5% Tween-20 overnight at 4°C. The 
membrane was incubated for 1.5 hour with a protein A-purified rabbit anti chick 
CNTFRα antibody [(1:100,000; developed by one of the authors (HR)], followed by 
goat anti-rabbit secondary antibody conjugated with horseradish peroxydase 
(1:10,000, Zymed, San Francisco, CA). The blots were developed using the ECL 
method according to the manufacturer’s recommendations (Amersham Biosciences, 
Piscataway, NJ). 
 
Immunocytochemistry 
Tissue sections (7 or 10 µm thick) were washed three times in a 0.3% hydrogen 
peroxide solution in 50% ethanol to inhibit endogenous peroxidase. Sections were 
then treated with 0.25% Triton X-100 in PBS for 5 min followed by 10% normal goat 
serum (NGS) with 0.25% Triton X-100 and 0.05% sodium azide in PBS for 20 min. 
They were then incubated with primary antibodies diluted in PBS with 1.5% NGS, 
0.25% Triton X-100 and 0.05% sodium azide overnight at 4°C. Primary antibodies 
used in this study were: an affinity-purified polyclonal rabbit anti chick CNTFRα 
(1:1,000 dilution), a protein A-purified polyclonal rabbit anti chick CNTFRα (1:2,000 
dilution). These two antibodies were raised in the same rabbit after immunization with 
a large fragment of the chick CNTFRα recombinant protein, as reported previously21. 
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Two commercial polyclonal antibodies raised against human CNTFRα and rat 
CNTFRα (respectively, sc-1913 and sc-1914, Santa Cruz Biotechnology, Santa Cruz, 
CA) were initially evaluated by immunocytochemistry and showed an intense labeling 
at the level of the photoreceptor inner segments. Yet, because of significant 
background labeling on the sections, and the impossibility of blocking the signal on 
both immunoblots and immunocytochemical sections with their respective blocking 
peptides (sc-1913 P, sc-1914 P), we did not pursue further investigations with these 
antibodies.  
After washing in PBS, secondary antibody (biotinylated goat anti-rabbit, 1:200 
dilution; Vector Laboratories, Burlingame, CA) was applied for 30 min at room 
temperature. Antibodies were visualized using the avidin biotin complex (ABC) Elite 
kit (Vector Laboratories) with diaminobenzidine as a substrate. To confirm the cone 
photoreceptor labeling observed with the CNTFRα antibody, we used serial sections 
and immunoreacted each sequential section with CNTFRα antibody, a rabbit affinity-
purified antibody directed against human cone arrestin22 (1:10,000 dilution, kindly 
provided by Dr. Cheryl Craft), and a rabbit affinity-purified antibody directed against 
mouse phosphodiesterase γ (anti-PDEγ, 1:2,000, kindly provided by D.B. Farber)23. 
The antibodies were applied overnight, and visualized with a biotinylated secondary 
antibody and the ABC Elite kit. Control sections were treated in the same way with 
omission of primary antibodies, or replacement by rabbit serum from a non-
immunized animal. Slides were mounted with Gelvatol, and examined as described in 
the previous section. 
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RESULTS 
Cloning of canine CNTFRα cDNA 
RT-PCR using primers which hybridise in the 3’ and 5’ UTR of the CNTFRα gene 
amplified a single 1272 bp size product from brain derived mRNA. Sequence analysis 
revealed the CNTFRα coding sequence (1119 bp) and 26 bp of 5’ UTR, and 86 bp of 
3’ UTR (GenBank # AF529215). Alignment of the nucleotide coding sequence (data 
not shown) showed a cDNA of identical length with human, mouse and rat, and high 
sequence identity of 93%, 89.5%, and 88.7%, respectively. The alignment of the 
predicted amino acid sequence of canine CNTFRα with that of human, mouse and rat 
also showed a high degree of homology between these species (Figure 2.1 B). The 
canine CNTFRα amino acid sequence is longer than that of the chicken (372 vs. 
362aa), and the chicken sequence shares a lower degree of homology with dog 
(69.1%) and other mammals. The amino acid identity was higher between the dog and 
human, and lower between the rat and the chicken sequences. Hallmarks of cytokine 
receptors such as clusters of cysteine residues, putative N-glycosylation sites, and the 
cytokine receptor consensus motif (WSXWS box)24 were conserved in the canine 
CNTFRα amino acid sequence (Figure 2.1 A). 
 
Radiation hybrid mapping 
Radiation hybrid mapping using the RH083000 canine-hamster panel placed CNTFRα 
on canine chromosome 11 (CFA11) in a position approximately 70.41 cR3000 
telomeric to the microsatellite REN275MO5, and 56.19 cR3000 centromeric from the  
gene markers IFNA3/IFNA1 (Figure 2.2). Marker order was supported with a lod 
score of 3.5, and was similar to that obtained with a different radiation hybrid panel 
made with 5000 rad (RHDF5000 map).19 CFA 11 exhibits conserved synteny with the  
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Figure 2.1 Comparison of the dog CNTFRα amino acid sequence with that of the 
human, mouse and rat, and chicken. (A) Alignment of amino acid sequences. 
Conserved cysteine residues and the conserved cytokine receptor motif (WSXSW 
box) are underlined. Putative N-glycosylation sites (ArgXSer/Thr) in the dog sequence 
are boxed. (B) Level of homology between sequences are indicated as percentage. 
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cytogenetic p13 region of human chromosome 9 (HSA 9p13).19 Thus our results are in 
agreement with human mapping data, which localizes CNTFRα to HSA 9p13. 
 
 
 
 
 
Figure 2.2 Radiation hybrid mapping of CNTFRα. CNTFRα was located on CFA 11 
at a lod score of 3.5 for order using MultiMap software. Distances between markers 
are indicated in cR3000. 
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Transcription of CNTFRα in different tissues 
RT-PCR was used to examine the expression of CNTFRα in various tissues. The 
transcript was detected in brain, retina, spleen, lung, liver and kidney tissues (Figure 
2.3). The specificity of the RT product was based on the product size which was 
obtained with control retina treated by DNase I digestion, as well as on the absence of 
any product amplification in tissues processed by omitting the reverse transcriptase 
enzyme (data not shown). 
 
 
Figure 2.3 Detection of CNTFRα in different canine tissues by RT-PCR. All PCR 
products contained the DNA fragment of expected size (369 bp). Marker lanes (M) 
shows DNA markers obtained by digestion of φX174 DNA with HaeIII. 
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Localization of CNTFRα expression in the adult canine retina. 
In situ hybridization was used to determine which retinal cells transcribe canine 
CNTFRα. With the antisense probe, the CNTFRα message was found in the retinal 
pigment epithelium (RPE), photoreceptors, inner nuclear layer (INL), and ganglion 
cells; no labeling was observed with the sense probe, although a very weak 
background was noticed in some sections (Figure 2.4). The labeling was most intense 
in the central retina, and decreased towards the periphery. In the visual cells, labeling 
was present at the level of the external limiting membrane, and in the proximal region 
of the inner segments (myoid region). Labeling was present throughout the INL but 
was most intense in the cells located in the vitreal and scleral borders. 
 
 
 
Figure 2.4 Localization of CNTFRα mRNA in the normal adult canine retina (tapetal 
zone, RPE non-pigmented) by in situ hybridization. 
(A) Expression of CNTFRα mRNA was detected with the antisense probe at the level 
of the RPE (open arrowhead), photoreceptors (at the level of the external limiting 
membrane, see arrowhead), INL, and in ganglion cells (arrow). Labeling was present 
at all levels of the INL but more intense on the scleral and vitreal sides. (B) No signal 
was observed with the sense probe (negative control). RPE: retinal pigment 
epithelium; IS: inner segments; ONL: outer nuclear layer; INL: inner nuclear layer; 
GCL: ganglion cell layer. Calibration bar: 25 µm. 
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To complement the in situ hybridization results, we performed 
immunocytochemical studies using the polyclonal antibodies directed against chick 
CNTFRα. Both antibodies (affinity-purified, and protein A-purified) produced a 
similar and consistent pattern of labeling, which was absent in control sections (Figure 
2.5 C). There was robust staining of all the inner segments in the photoreceptor layer 
(Figure 2.5 D-F), and also distinct labeling of the outer and inner plexiform layers 
(OPL, IPL respectively), cells of the INL, and ganglion cells and their axons (nerve 
fiber layer, NFL) (Figure 2.5  A, D, F). With the affinity-purified antibody, different 
populations of cells, predominantly located at the scleral and vitreal borders of the 
INL, could be identified, but this was not distinct with the protein A-purified antibody 
(Figure 2.5; compare A, D with F). Labeling of the RPE was present but variable in 
intensity (Figure 2.5 B, F). Staining of the photoreceptor inner segments was 
observed, and, in addition, distinct labeling was present throughout a subclass of 
photoreceptor cells whose nuclei where located at the outermost border of the ONL 
(Figure 2.5 E, F). The position and cytologic characteristics of these cells, as well as 
the similar pattern of cone labeling obtained with two antibodies that label only cones 
(anti human cone arrestin) or cones and rods (anti-PDEγ) (Figure 2.5  G,H), suggest 
that, in addition to its localization at the rod inner segment, CNTFRα is present 
throughout most of the cone photoreceptor cell. 
 To verify the specificity of the protein A-purified anti-chick CNTFRα 
antibody, we performed immunoblot analysis. When recombinant rat CNTFRα 
(amino acid residues 1-346) was resolved by SDS-PAGE, the anti-chick CNTFRα 
antibody identified it at an apparent size of approximately 50 kDa, consistent with the 
molecular mass indicated by the manufacturer. In protein lysates from dog retina, the 
antibody recognized a single protein migrating with a molecular weight of 
approximately 62 kDa (Figure 2.6). A similar result was observed with protein lysates 
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from retinas of a two week-old chick resolved by SDS-PAGE under reducing 
conditions (data not shown). This molecular weight was slightly smaller than that 
reported for the chick under non-reducing conditions,25 and could be explained by 
differences in the electrophoresis conditions. Our immunoblot results with the chicken 
and dog retinal lysates are similar to those reported for rat central nervous system and 
retina using a different polyclonal antibody.13 Specificity of the anti-chick CNTFRα 
antibody has been previously demonstrated both on immunoblots and 
immunohistochemical sections of chick dorsal root ganglia.21 The specific labeling 
was inhibited by preincubating the antibody with the recombinant chick CNTFRα 
used to generate the antibody. Because the source of the recombinant chick CNTFRα 
used to block the anti-chick CNTFRα antibody is no longer available, we could not 
repeat these experiments with the dog tissues. 
 
DISCUSSION 
In this study, we cloned the canine CNTFRα cDNA and showed that there was a high 
level of homology, both at the nucleotide and amino acid levels, when comparing it to 
that of the human, mouse and rat. The degree of amino acid homology between dog 
and chicken was lower, however, still sufficient to allow us to use in the dog retina 
polyclonal antibodies that were raised against chicken CNTFRα. Such a level of 
conservation, at least for some domains of the protein, suggests that the CNTFRα 
signaling pathway is conserved across evolution.  
Our results show that in the normal adult canine retina, the RPE, 
photoreceptors, and cells in the INL, and ganglion cell layer (GCL) transcribe the 
CNTFRα gene. We observed a strict concordance between the retinal cells labeled by 
in situ hybridization, and those stained by immunocytochemistry, particularly with the 
affinity-purified antibody. This suggests that all cells that transcribe the CNTFRα 
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Figure 2.5 Immunolocalization of CNTFRα in the normal adult canine retina. (A) 
Labeling pattern of central non-tapetal retina (RPE pigmented) with the affinity-
purified anti-chick CNTFRα antibody (B) Labeling pattern of mid-peripheral tapetal 
retina (RPE non-pigmented) with the affinity-purified anti-chick CNTFRα antibody. 
(C) Negative control. (D) Labeling pattern of mid-peripheral non-tapetal retina with 
the affinity-purified anti-chick CNTFRα antibody. (E) High power view of (D) (F, G, 
H) Serial sections of mid-peripheral tapetal retina labeled with, the protein-A-purified 
anti-chick CNTFRα antibody (F),the anti-human cone arrestin antibody (G), and the 
anti-PDE γ antibody (H). Intense labeling of the entire photoreceptor IS (A, B, D- F) 
was observed with the two antibodies (E is a high power view of D). Labeling of the 
OPL, INL, IPL, ganglion cells (arrowhead), and NFL (long arrows) was also present 
(A, D, F). Labeling of cone perinuclear region (small arrows), axons (arrowheads) and 
synaptic terminals (open arrowheads) was observed with the anti-chick CNTFRα 
antibody (E), and resembled that obtained with the anti-PDE γ (G) and anti-human 
cone arrestin (H) antibodies. RPE: retinal pigment epithelium; OS: outer segments; IS: 
inner segments; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer; NFL: nerve fiber 
layer. Calibration bars: (A) 50 µm; (B,C) 50µm; (D) 25 µm; (E) 15 µm; (F-H) 20 µm.
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Figure 2.6 Immunoblot analysis of CNTFRα protein expression in the normal adult 
canine retina. Total protein (14 µg) of adult canine retina (lane 1) and recombinant rat 
CNTFRα (lane 2: 25 ng, lane 3: 50 ng) were run on a reducing 10% SDS-PAGE gel 
and immunoblotted using a protein A-purified anti chicken CNTFRα polyclonal 
antibody. Binding of the anti-CNTFRα antibody was visualized by using enhanced 
chemiluminescence. Positions and molecular masses (in kilodaltons) of standard 
proteins are indicated on the left. 
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gene also express its protein. However, we cannot exclude the possibility that some of 
these cells also may bind the soluble form of CNTFRα.26 Such a soluble form could 
be released by neighboring cells following cleavage of the glycosyl-
phosphatidylinositol link by PI-PLC.9 Labeling of the INL, both by in situ 
hybridization and immunocytochemistry, was more intense in cells located at the outer 
and innermost part of this layer, suggesting that horizontal, amacrine, and Müller cells 
express CNTFRα. This was consistent with the location of CNTFRα transcript in the 
rat INL.27 However, the use of cell-specific markers, coupled with 
CNTFRα immunolocalization, will be required to specifically identify the cells in the 
INL that express this neurotrophic receptor. 
The antibodies directed against CNTFRα that were used in our study showed 
an intense labeling pattern at the level of the RPE, photoreceptors, OPL, INL, IPL 
GCL and NFL. In addition to the photoreceptor IS labeling, the perinuclear cytoplasm, 
axon, and synaptic terminal of cones also were intensively labeled with the antibodies 
raised against chick CNTFR. Although we did not use any antibodies specific to rods, 
the labeling pattern of the entire IS layer was very different to that obtained with 
antibodies that solely stain cone photoreceptor cells (see Fig 2.5. H), confirming that 
CNTFRα is present in both cone and rod inner segments. 
Our results show that both rod and cone photoreceptor cells express CNTFRα. 
It is still to be determined, however, that the two other subunits (gp-130 and LIFR) of 
the receptor complex are also expressed in photoreceptors. If such were the case, as 
has been recently suggested by Schulz-Key et al.,28 our findings would imply that an 
effect of CNTF on photoreceptors is mediated through a direct rather than indirect 
mechanism of action. This is in contrast with studies in rodents that suggest that 
protection of photoreceptors occurs indirectly through the activation of Müller cells or 
other INL cells.15-17 The results of those studies, however, are based on the absence of 
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immunoreactivity for downstream signal transduction molecules, as well as a lack of 
expression of the immediate early gene c-fos in photoreceptors exposed to CNTF. 
While a species specificity may explain the discrepancy between these results and 
ours, it also is possible that binding of CNTF to its receptor in photoreceptors activates 
signaling pathways other than those examined. A number of in situ hybridization 
studies have examined the expression of CNTFRα mRNA in the retina of the normal 
adult rat, and have shown labeling at the GCL and INL, but not in the 
photoreceptors.27,29 However, after ischemia and reperfusion of the retina, labeling 
was observed at the outermost part of the ONL,29 suggesting that rat photoreceptors do 
express CNTFRα, at least after injury. 
In the chick, CNTFRα is expressed in several retinal layers, and was shown by 
immunocytochemistry to be present in rod outer segments.25 While a recent study 
showed the expression of CNTFRα by immunoblot analysis on protein lysates of rat 
photoreceptor inner and outer segments,28 to our knowledge there are no reports in the 
literature characterizing the expression and localization of CNTFRα by 
immunocytochemistry in mammalian photoreceptors. This lack of information may 
result from negative immunolocalization results. In this regard, we caution that tissue 
fixation is critical in these procedures, at least for the canine retina. Our findings are 
based on using a "very mild" fixation protocol; however, we have observed (data not 
shown) a reduced to absence of labeling of the inner retina, but not of the 
photoreceptor inner segments, with more prolonged fixation (24 hours in 4% PAF). In 
an attempt to evaluate whether the expression of CNTFRα by photoreceptors is 
specific to the dog or is common to a wide variety of species, we are currently 
undertaking similar studies in several other mammalian species. 
Determining the localization of the expression of the receptor for CNTF is 
critical since this survival factor is being considered as a potential treatment for retinal 
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degenerations. Its sustained delivery is currently in late preclinical development and 
clinical trials are expected to begin in human patients with retinitis pigmentosa 
(www.neurotech.fr/presse/index.htm). If CNTFRα is also found in human 
photoreceptors, then evaluating its level of expression during the course of retinal 
degeneration may be a valid approach for evaluating the potential therapeutic role of 
CNTF. 
 In conclusion, we have shown the expression of CNTFRα in photoreceptor 
cells of the normal, adult canine retina. These results suggest that, at least in the dog, 
CNTF may act through a direct mechanism to rescue photoreceptors in the rcd1 model 
of retinal degeneration. If such a site of action is also present in the human retina, this 
may lead to novel therapeutic approaches for RP. 
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CHAPTER THREE 
 
IMMUNOLOCALIZATION OF CILIARY NEUROTROPHIC 
FACTOR RECEPTOR α (CNTFRα) IN MAMMALIAN 
PHOTORECEPTOR CELLS * 
 
INTRODUCTION 
Ciliary neurotrophic factor (CNTF) rescues photoreceptors in several genetic1-7 
and in light-induced models of retinal degeneration.1,8 Its photoreceptor survival effect 
was demonstrated in vivo in a variety of animal species that includes mouse, 1-5 rat,4,8 
cat,6, and dog,7 as well as in mouse retinal explants 9,10. Although its mechanism of 
action on photoreceptor cells is not fully understood, CNTF is thought to initiate a 
survival response by binding to the plasma membrane of retinal cells that express its 
receptor, ciliary neurotrophic factor receptor (CNTFR). CNTFR is composed of an α 
subunit (CNTFRα) that specifically binds CNTF, and two β subunits (LIFR, gp-130) 
that are shared by other members of the IL-6 R family.11 Binding of CNTF to 
CNTFRα causes heterodimerization of the α and β subunits and activation of various 
signaling pathways that promote cell survival.12 
It has been shown that in the rat retina CNTFRα mRNA is expressed in 
horizontal cells, and in subpopulations of amacrine and ganglion cells, but not in 
photoreceptors.13 In addition, intravitreal delivery of CNTF to the rodent eye triggers 
the activation of signaling pathways predominantly in Müller cells, and also in other 
 
 
* Beltran WA, Rohrer H, Aguirre GD. Mol. Vis. 2005; 11: 232-244 
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inner nuclear layer (INL) cells, ganglion cells and astrocytes, yet fails to activate 
photoreceptors. 14-16 These studies suggest that in the rat and mouse retina, the CNTF 
photoreceptor rescue effect is mediated through an indirect mechanism of action. It 
has been proposed that microglia-derived CNTF could prevent photoreceptor cells 
from undergoing degeneration by promoting the release of direct-acting photoreceptor 
survival factors such as bFGF, and GDNF by Müller cells.17 
We have recently shown that in the normal adult canine retina both the 
CNTFRα transcript and protein are expressed by photoreceptors, INL, and ganglion 
cells.18 The immunolocalization of CNTFRα to rods and cones suggests that, at least 
in the dog, the photoreceptor rescue effect observed with CNTF in the rcd1 model of 
retinal degeneration 7 may be mediated through a direct mechanism of action. 
Determining whether photoreceptors are the direct targets of CNTF has 
become increasingly important since this survival factor is currently being tested in 
Phase 1 clinical trials in humans with retinitis pigmentosa 
(www.neurotech.fr/news_press_100803.asp).To address the differences between dogs 
and rodents and determine if CNTFRα is localized to photoreceptors in other species, 
we performed immunocytochemical studies on retinas from a variety of mammalian 
species.  
 
METHODS 
Animals and tissue fixation 
Normal adult retinas from the following mammalian species were used for the study: 
mouse (balb/c, 6 months), rat (AO derived, 6 months), dog (Beagle, adult), cat (DSH, 
adult), sheep (adult), horse (Pony of America, 7 years), pig (adult), monkey 
(cynomolgus and rhesus macaques, adult), and human (52-year-old male). In addition, 
we also collected immature retinas from 3 day-old (PD3) Lewis rats, and 6 day-old 
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(PD6) AO rats. With the exception of the sheep, horse, and human for which one 
single individual was available, retinas from at least two individuals were obtained for 
each of the other species. 
While under anesthesia (mouse, rat), or less than 10 minutes after euthanasia 
(dog, cat, sheep, pig, horse), eyes were enucleated. Retinas were then processed at our 
facility as follows: a slit was done at the level of the ora serrata and the entire globe 
was fixed for 3 hours in 4 % paraformaldehyde in 0.1 M phosphate buffered saline at 
4°C. The posterior segment was isolated and fixed for an additional 24 hours at 4°C in 
2 % paraformaldehyde in 0.1 M phosphate buffered saline. The tissue then was 
trimmed and cryoprotected sequentially for 24 hours in a solution of 15 % and 30 % 
sucrose in 0.1 M sodium phosphate and 0.15 M sodium chloride, pH 7.2 [BupHTM, 
Phosphate Buffered Saline, Pierce, Rockford, IL; (referred in the text as PBS)] at 4°C, 
and embedded in OCT. Cryosections were cut at 7 or10 µm thickness and stored at - 
80°C. The human eye was a surgical specimen that had been enucleated for orbital 
exenteration of an extraocular tumor. The rhesus macaque and human retina 
specimens (kindly provided by Drs Bob Fariss and Ann Milam, respectively) were 
fixed in 4 % paraformaldehyde + 0.5 % glutaraldehyde in 0.1 M phosphate buffered 
saline for 4 hours followed by 2 % paraformaldehyde in 0.1 M phosphate buffered 
saline for 2.5 years (monkey), or in 4 % paraformaldehyde in 0.1 M phosphate 
buffered saline for several days followed by 2 % paraformaldehyde in 0.1 M 
phosphate buffered saline for approximately 3 years (human). The cynomolgus 
macaque retina (obtained from the New England Primate Research Center) was fixed 
for 24 hours in 4 % paraformaldehyde in 0.1 M phosphate buffered saline. Monkey 
and human retinas were then cryoprotected and processed as indicated above.  
For immunoblot analysis, neuroretinas from several adult species (rat, dog, cat, 
pig, and human) were dissected following death, and stored at -80°C until processed 
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for total protein extraction. The human retina came from a 68 year-old Caucasian 
female that died of multi-system organ failure, and was provided by the Cooperative 
Human Tissue Network which is funded by the National Cancer Institute. All research 
conducted was in full compliance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research, and the tenets of the declaration of Helsinki. 
 
Immunocytochemistry 
To visualize the retinal localization of CNTFRα, both immunoenzymatic and 
immunofluorescence methods were used. For enzymatic immunocytochemistry, tissue 
sections were washed three times in a 0.3% hydrogen peroxide solution in 50% 
ethanol to inhibit endogenous peroxidase. Sections were then treated with 0.25% 
Triton X-100 in PBS for 5 min followed by 10% normal goat serum (NGS) with 
0.25% Triton X-100 and 0.05% sodium azide in PBS for 60 min. They were then 
incubated overnight at 4°C with a protein A-purified polyclonal rabbit anti-chick 
CNTFRα antibody diluted (1:2,000) in PBS with 1.5% NGS, 0.25% Triton X-100 and 
0.05% sodium azide. This antibody was raised in a rabbit after immunization with a 
large fragment of the chick CNTFRα recombinant protein, and has been described 
previously.19 After washing in PBS, secondary antibody (biotinylated goat anti-rabbit, 
1:200 dilution; Vector Laboratories, Burlingame, CA) was applied for 30 min at room 
temperature. Antibodies were visualized using the avidin biotin complex (ABC) Elite 
kit (Vector Laboratories) with diaminobenzidine as a substrate. A non-specific 
staining of the photoreceptor layer, and in particular of the outer segments, has been 
previously reported using this immunoenzymatic method,20 and was observed in this 
study on the mouse sections and occasionally in sections from other species as well. 
To confirm the absence of labeling of mouse photoreceptor cells, and particularly of 
cones with the CNTFRα antibody, we compared the staining pattern of the 
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photoreceptor layer to that obtained on a sequential section with an antibody directed 
against mouse cone arrestin (LUMIJ, 1:10,000; 21). Conversely, to confirm the cone 
photoreceptor labeling observed with the CNTFRα antibody in the pig, monkey, and 
human retinas, we used serial sections and immunoreacted each sequential section 
with CNTFRα antibody, or a rabbit affinity-purified antibody directed against human 
cone arrestin (LUMIf, 1:10,000;22). 
In addition to using the anti-chick CNTFRα antibody, we also tested several 
commercially available antibodies directed against mammalian CNTFRα. The 
following antibodies were used on retinal cryosections of the collected species: goat 
polyclonal anti-human CNTFRα (Cat#: AF303NA, 1: 100; R&D systems Inc., 
Minneapolis, MN), mouse monoclonal anti-human CNTFRα (Cat#: MAB303, 1:100; 
R&D systems Inc.), and goat polyclonal anti-rat CNTFRα (Cat#: AF559NA, 1:100; 
R&D systems Inc.). The ABC immunoenzymatic method was performed as described 
above using the appropriate biotinylated secondary antibodies. 
To further characterize the subpopulation of cones in the dog, pig, monkey, 
and human retinas that express CNTFRα, we performed double immunofluorescence 
labeling using antibodies that identify M/L (COS-1, 1:10; 23), or S wavelength 
sensitive cones (OS-2, 1:1,000; 23). For immunofluorescence, sections were 
permeabilized with 0.25% Triton X-100 in PBS for 5 min, and then blocked with 10% 
normal goat serum with 0.25% Triton X-100 and 0.05% sodium azide in PBS for 20 
min. The sections were then incubated overnight at 4°C with the anti-chick CNTFRα 
antibody (1:500) followed with a red fluorochrome-labeled goat anti-rabbit secondary 
antibody (Alexa Fluor 568, 1:200; Molecular Probes, Eugene, OR) for 90 min, and 
then with the COS-1 or OS-2 antibodies for approximately 5 hours, followed by a 
FITC-labeled horse anti-mouse secondary antibody (1:50; Vector Labs) for 90 min. 
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Sequential retinal sections from rats (PD3, PD6, and 6 month-old) were 
incubated for immunofluorescence with either the anti-chick CNTFRα antibody 
followed by a red-fluorochrome labeled secondary antibody (as described above), or 
with polyclonal rabbit anti-rat calbindin D-28 K antibody (C 2724, 1:1,000; Sigma, St 
Louis, MO) followed by a green fluorochrome-labeled goat anti-rabbit secondary 
antibody (Alexa Fluor 488, 1:200; Molecular Probes). To better distinguish the 
location of the photoreceptor layer, rhodamine-labeled peanut agglutinin (1:1,000; 
Vector Laboratories) was used on some sections as a marker of cone extracellular 
matrix domain. DAPI nuclear stain (5µM for 15 min) was used to visualize the nuclear 
layers. Double immunofluorescence labeling of adult rat retinas with the anti-chick 
CNTFRα antibody and a mouse monoclonal anti-recombinant CRALBP antibody 
(provided by Dr J. Saari; 1: 40,000) was done to determine whether Müller cells 
express CNTFRα . To determine labeling specificity, control sections were treated in 
the same way with omission of primary antibodies, and also by substitution with an 
unrelated primary antibody. Slides were mounted with gelvatol, a medium composed 
of polyvinyl alcohol and DABCO (Sigma), and examined with an epifluorescent 
microscope (Axioplan, Carl Zeiss Meditech, Oberkochen, Germany) with or without 
Differential Interference Contrast (DIC) optics. Images were digitally captured (Spot 
3.3 camera, Diagnostic Instruments, Inc., Sterling Heights, MI) and imported into a 
graphics program (Photoshop; Adobe, Mountain View, CA) for display. 
 
Western blot analysis 
Adult rat, dog, cat, pig, and human retinas were homogenized in PBS containing a 
cocktail of protease inhibitors (Cat#: P8340, Sigma, St Louis, MO), and, following 
sonication, the protein levels were determined by the Bradford method (Bio-Rad 
protein assay, Bio-Rad, Hercules, CA). Protein lysates (60 or 120 µg) were placed in 
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the sample buffer containing 4% glycerol, 0.4% sodium dodecyl sulfate, 1% β-
mercaptoethanol, 0.005% bromophenol blue in 12.5 mM Tris-HCl buffer (pH 6.8), 
and heated at 100 °C for 5 minutes. Samples and molecular weight standards (Cat#: 
RPN2107; Amersham Biosciences, Piscataway, NJ) were separated by SDS-PAGE 
(4% stacking gel, 12% separating gel).Transfer of proteins from gels to PVDF 
membrane (Immobilon, Millipore, Bedford, MA) was performed in pre-chilled 
transfer buffer (25 mM Tris base, 192 mM glycine, and 15% methanol), and the 
membranes were then blocked with 10% skim milk in Tris-buffered saline containing 
0.5% Tween-20 overnight at 4°C. The membranes were incubated for 1.5 hour with 
either a protein A-purified rabbit anti chick CNTFRα antibody (1:100,000), a goat 
polyclonal anti-human CNTFRα antibody (Cat#: AF303NA, 1:500, R&D Systems 
Inc.), or a mouse monoclonal anti-human CNTFRα antibody (Cat#: 558783, 1:500; 
BD Pharmingen, San Diego, CA) followed by the appropriate secondary antibody 
conjugated with horseradish peroxydase (1:10,000, Zymed, San Francisco, CA). The 
blots were developed using the ECL method according to the manufacturer’s 
recommendations (Amersham Biosciences), and exposed on autoradiograph film 
(Eastman Kodak, X-oMAT; Rochester, NY) 
 
RESULTS 
Immunolocalization of CNTFRα in mammalian retinas. 
Immunolabeling of retinal cells with the polyclonal antibody raised against chick 
CNTFRα was detected in all species except in the horse in which staining was absent 
in all retinal layers (data not shown). Results obtained with this antibody are 
summarized in Table 3.1. A similar pattern of labeling of the nerve fiber (NFL), 
ganglion cell (GCL), and INL was observed across all species (Figure 3.1 B; Figure 
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Table 3.1 Pattern of immunolabeling in retinas of mammalian species with the anti-chick CNTFRα antibody.  
Intensity of labeling was graded as intense (+++), moderate (+), weak (+), or absent (0); RPE staining was not determined (ND) in 
some species. In mouse RPE, nonspecific labeling could also be observed on negative control sections. Labeling was intense in 
PD3 and PD6 rats. Data for “Dog” are taken from a previous study.18 For dog and human outer nuclear layer (ONL), labeling was 
limited to cone soma, axon, and pedicle. For cat ONL, labeling was limited to cone soma and some cone axons. For sheep and pig 
ONL, labeling was limited to cone soma. Retinal pigment epithelium (RPE) pigmentation and autofluorescence precluded assessing 
the presence of specific labeling in pig, monkey, and human. In pig, inner segments (IS), labeling was limited to the inner portion 
of the IS. 
 
 
 
 
Retinal 
layer 
Mouse       Rat Dog Cat Sheep Pig Monkey Human
RPE ND 0 +++   +++ +++ ND ND ND 
OS 0        
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IS 0 0 +++ +++ +++ ++ +++ +++
ONL 0 0 +++ ++ + +++ ++ +++ 
OPL ++ ++ +++ ++ ++ +++ +++ +++
INL +++ +++ +++ +++ +++ +++ +++ ++
IPL ++ ++ + ++ + + + +
GCL +++ +++ +++ +++ +++ +++ +++ +++
NFL +++ ++ +++ +++ ++ +++ +++ +++
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3.2 H; Figure 3.3 B; Figure 3.4 C; Figure 3.5 B; Figure 3.6 B). Also, less intense 
staining of the inner plexiform layer (IPL) was observed in all species (Figure 3.1 B; 
Figure 3.2 H; Figure 3.3 B; Figure 3.4 C; Figure 3.5 B; Figure 3.6 B). In the INL of 
the adult mouse, rat, and pig, labeling was predominantly observed in cells located at 
the vitreal and scleral borders of this layer, suggesting that the cells expressing 
CNTFRα could be amacrine and horizontal cells, respectively (Figure 3.1 B,C; Figure 
3.2 H; Figure 3.4 B).  
A significant difference was observed when comparing the labeling pattern of 
the outer nuclear layer (ONL) and photoreceptor layer in the adult mouse and rat, to 
that observed in the non-rodent mammals. No labeling of adult rodent photoreceptors 
was detected by either immunoenzymatic or immunofluorescence methods (Figure 3.1 
B,C,E; Figure 3.2 G,H), and this was observed with all four CNTFRα antibodies (see 
Table 3.2). In the developing rat retina (PD3 and PD6), all cells located in the GCL 
were labeled (Figure 3.2 B-D). In addition, the CNTFRα antibodies labeled the inner 
6-7 rows of cells of the outer neuroblastic layer (Figure 3.2 B-D). A population of 
cells located at the edge of the presumptive outer plexiform layer (OPL), was also 
distinctively labeled. These cells were regularly spaced and disposed in a linear 
fashion from the ora serrata to the optic nerve at approximately 50 µm from the 
external limiting membrane (ELM) (Figure 3.2 B-D). Immunofluorescence studies 
showed that these cells had extended horizontal processes, suggesting that they could 
be horizontal cells (Figure 3.2 E,F). To confirm this hypothesis, sequential serial 
sections were labeled with either the anti-chick CNTFRα antibody or with an antibody 
directed against calbindin D-28kDa, an epitope located on horizontal, amacrine, and 
ganglion cells in the adult and developing rat retina 24,25. We observed a similar pattern 
of labeling with both antibodies (Figure 3.2 F,G) suggesting that horizontal cells 
 express CNTFRα as early as PD 3. This expression persists in the adult (Figure 3.2 
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I,J). 
In both the developing and mature rat retina, as well as in the adult mouse 
retina, labeling of CNTFRα was not detected in either the photoreceptor cell bodies in 
the ONL, in the inner or in the outer segments. Since CNTFRα labeling was not 
absent in rodents (it was observed in other retinal layers such as NFL, GCL, IPL, INL) 
the most likely conclusion is that rodent photoreceptors do not express CNTFRα. In 
the adult rat, double immunofluorescence studies did not show any co-localization of 
CNTFRα with CRALBP suggesting that Müller cells do not express CNTFRα either 
(Figure 3.2 K-M). 
Recently, we reported that CNTFRα transcript and protein are expressed in dog 
photoreceptor cells.18 Here, using a different antibody directed against human 
CNTFRα we obtained a similar pattern of labeling (Figure 3.7 F). In addition, we 
show by double immunofluorescence studies that CNTFRα co-localized to both M/L 
and S wavelength sensitive cones of the dog retina (Figure 3.7 D,E). Similarly to what 
we have observed in the dog, labeling of sequential sections with CNTFRα or human 
cone-arrestin antibodies in pig, monkey and human, confirmed that both rod and cone 
photoreceptors express CNTFRα, and that the cellular distribution of the receptor for 
CNTF differs between the two classes of photoreceptors (Figure 3.4 C,D; Figure 3.5 
C,D; Figure 3.6 B-D). In non-rodent mammals, labeling of rods was limited to their 
inner segments (IS), while cones showed a distinct pattern of staining that involved 
their IS, and soma, with variable labeling of their axon and pedicle (Figure 3.7 F, 
Figure 3.3 B; Figure 3.4 B; Figure 3.5 C,G,H; Figure 3.6 B,C). Like in the dog, double 
immunofluorescence studies, showed that CNTFRα co-localized to the two  
subpopulation of cones in pig, monkey and human retinas (Figure 3.4 E,F; Figure 3.5 
E,F; Figure 3.6 E,F). 
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Figure 3.1 Immunolocalization of CNTFRα in the adult mouse retina. (A) Negative 
control. (B) Pattern of immunoenzymatic labeling with the anti-chick CNTFRα 
antibody. (C) Pattern of immunoenzymatic labeling with the anti-rat CNTFRα 
antibody (AF559NA) (D) Sequential section to (B) labeled with mouse cone arrestin 
antibody. (E) Immunofluorescence labeling (overlaid images) with the anti-chick 
CNTFRα antibody (green), DAPI (blue), and peanut agglutinin (red). Intense labeling 
with the CNTFRα antibodies was limited to ganglion cells, nerve fibers, and cells 
located predominantly at the vitreal and scleral borders of the INL (B, E). Less intense 
labeling was also present at the IPL and OPL. Non-specific staining was observed at 
the photoreceptor layer (A, B, C), and was distinct from the specific cone inner 
segment labeling (arrows) obtained with the mouse cone arrestin antibody (D). 
Fluorescence immunocytochemistry confirmed the absence of photoreceptor labeling 
with the anti- chick CNTFRα antibody (E). PR: photoreceptor layer; ONL: outer 
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer. Scale bars: (A-D) 20 µm; (E) 40 µm. 
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Figure 3.2 Immunolocalization of CNTFRα in the developing and adult rat retina. (A) 
Negative control. (B-C) Pattern of immunoenzymatic labeling with the anti-chick 
CNTFRα antibody in the 3- (B), and 6-day old (C) retinas. (D) Pattern of 
immunoenzymatic labeling with the anti-human CNTFRα antibody (AF303NA) (E) 
Immunofluorescence labeling (overlaid images) with the anti-chick CNTFRα antibody 
(red), and DAPI (blue) on a 6-day-old retina. Intense labeling with the CNTFRα 
antibodies (B-E) was observed in the developing retina at the level of the GCL, RPE, 
as well as in two distinct areas of the outer neuroblastic layer: the inner 6-7 rows of 
nuclei (bracket), and in horizontal cells (arrows).(F) High power view of (E) showing 
only CNTFRα labeling. Distinct horizontal processes (arrowheads) were seen 
extending from the labeled cell bodies (arrows) of the horizontal cells. (G) 
Immunofluorescence labeling of horizontal cells with the calbindin antibody showing 
a similar pattern as observed in (F). (H) Pattern of immunoenzymatic labeling with the 
anti-chick CNTFRα antibody in an adult rat retina. Intense labeling was present at the 
level of the GCL and cells at the inner and outer most border of the INL. No labeling 
of photoreceptor cells was observed. (I) Immunofluorescence labeling (overlaid 
images) with the anti-chick CNTFRα antibody (red), and DAPI (blue) on the same 
adult retina. Absence of staining in photoreceptors and RPE was confirmed. Note that 
this individual’s RPE is pigmented (H), but that no labeling is observed by 
immunofluorescence (I). (J) Sequential section labeled with the calbindin antibody. 
(K-M) Double immunofluorescence with the anti-chick CNTFRα (K) and rCRALBP 
(L) antibodies. Note the absence of co-localization (M: overlay) of CNTFRα 
immunoreactive cells in the INL with the soma of Müller cells (arrows). RPE = retinal 
pigment epithelium; ONbL = outer neuroblastic layer; ONL = outer nuclear layer; PR 
= photoreceptor layer; INL = inner nuclear layer; IPL = inner plexiform layer; GCL = 
ganglion cell layer; NFL = nerve fiber layer. Scale bars: (A-E, H-J) 40 µm, (F, G, K-
M) 20 µm. 
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Figure 3.3  Immunolocalization of CNTFRα in the adult cat retina. (A) Negative 
control. (B) Pattern of immunoenzymatic labeling with the anti-chick CNTFRα 
antibody. (C) Immunoenzymatic labeling of photoreceptors with the anti-human 
CNTFRα antibody (AF303NA). Intense labeling with the anti-chick CNTFRα 
antibody was seen at the RPE, IS, INL, GCL and NFL (B). With longer incubation 
times in the enzyme substrate (DAB), labeling of cone cell bodies and their extending 
axons (arrow) could be detected (inset to B and C). RPE = retinal pigment epithelium; 
OS = outer segments; IS = inner segment; ONL = outer nuclear layer; INL = inner 
nuclear layer, IPL = inner plexiform layer; GCL = ganglion cell layer; NFL = nerve 
fiber layer. Scale bars: (A, B, inset) 20 µm, (C) 10 µm. 
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 Figure 3.4 Immunolocalization of CNTFRα in the adult pig retina. (A) Negative 
control (pigmented RPE). (B, C) Pattern of immunoenzymatic labeling with the anti-
chick CNTFRα antibody at 1:2,000 (B), or 1: 10,000 (C) dilutions. (D) Sequential 
section labeled with human cone arrestin antibody. (E, F) Double 
immunofluorescence labeling (overlaid images) with the anti-chick CNTFRα (red) 
and COS1 [green, (E)] or OS2 [green, (F)] antibodies. Intense immunoenzymatic 
labeling with the CNTFRα antibody (1:2,000 dilution) was seen at the IS, ONL (cone 
cell bodies), OPL, INL, GCL and NFL (B). Labeling with the CNTFRα antibody at a 
1:10,000 dilution was still present in the cone cell bodies (arrows) (C), and resembled 
that obtained with the human cone arrestin antibody (arrows) (D). CNTFRα 
immunolabeling of M/L (E) and S (F) cones was localized to their inner segments, cell 
bodies (arrows), axons (arrowheads), and pedicles (open arrowheads). 
RPE: retinal pigment epithelium; OS: outer segments; IS: inner segments; ONL: outer 
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer; NFL: nerve fiber layer. Scale bars: (A-F) 
20 µm. 
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Figure 3.5 Immunolocalization of CNTFRα in the adult monkey retina. (A) Negative 
control (pigmented RPE). (B) Pattern of immunoenzymatic labeling in the rhesus 
macaque with the anti-chick CNTFRα antibody. (C) High power view of (B). (D) 
Sequential section labeled with human cone arrestin antibody. (E, F) Double 
immunofluorescence labeling (overlaid images) in the rhesus macaque with the anti-
chick CNTFRα (red) and COS1 [green, (E)] or OS2 [green, (F)] antibodies. (G) 
Pattern of immunoenzymatic labeling in the cynomolgus macaque with the 
monoclonal anti-human CNTFRα antibody (MAB303). (H) Pattern of 
immunoenzymatic labeling in the rhesus macaque with the anti-rat CNTFRα antibody 
(AF559NA). Intense labeling with the CNTFRα antibodies was seen at the IS, ONL 
(cone cell bodies), OPL, INL, GCL and NFL (B, G). Labeling was present at both rod 
and cone IS, and at cone cell bodies (arrow), axons (arrowheads), and pedicles (open 
arrowheads) (C, E, F, G, H). Both M/L (E) and S (F) cones were labeled by the 
CNTFRα antibody. 
RPE: retinal pigment epithelium; OS: outer segments; IS: inner segments; ONL: outer 
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer; NFL: nerve fiber layer. Scale bars: (A, B) 
40 µm, (C-H) 20 µm. 
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Figure 3.6 Immunolocalization of CNTFRα in the adult human retina. (A) Negative 
control (pigmented RPE). (B) Pattern of immunoenzymatic labeling with the anti-
chick CNTFRα antibody. (C) Pattern of immunoenzymatic labeling with the anti-rat 
CNTFRα antibody (AF559NA) (D) Sequential section to (B) labeled with human 
cone arrestin antibody. (E, F) Double immunofluorescence labeling (overlaid images) 
with the anti- chick CNTFRα (red) and COS1 [green, (E)] or OS2 [green, (F)] 
antibodies. Intense labeling with the CNTFRα antibody was seen at the IS, ONL (cone 
cell bodies), OPL, GCL and NFL (B). Labeling was present at both rod and cone IS, 
and at cone cell bodies (arrow), axons (arrowheads), and pedicles (open arrowheads) 
(B, C, E, F). Both M/L (E) and S (F) cones were labeled by the anti- chick CNTFRα 
antibody. 
RPE: retinal pigment epithelium; OS: outer segments; IS: inner segments; ONL: outer 
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner 
plexiform layer; GCL: ganglion cell layer; NFL: nerve fiber layer. Scale bars: (A-F) 
20 µm. 
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Figure 3.7 Immunolocalization of CNTFRα in cone photoreceptor cells of the dog. (A) Negative control. (B) Negative control 
with DIC optics. (C) Immunofluorescence labeling with the anti-chick CNTFRα antibody. (D, E) Double immunofluorescence 
labeling (overlaid images) with the anti-chick CNTFRα (red) and COS1 [green, (D)] or OS2 [green, (E)] antibodies. (F) Pattern of 
immunoenzymatic labeling with the anti-human CNTFRα antibody (AF303NA). Intense labeling was present at the level of the IS 
of both rod and cones, OPL, INL, GCL, and NFL. CNTFRα immunolabeling of M/L (D) and S (E) cones was localized to their 
inner segments, cell bodies (arrows), axons (arrowheads), and pedicles (open arrowheads). Scale bars: (A-F) 20 µm. 
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 Western blot analysis of CNTFRα in mammalian retinas. 
Using a polyclonal goat anti-human CNTFRα antibody (AF303NA) on total retinal 
protein extracts of several mammalian species (rat, dog, cat, pig, and human), we 
detected under reducing conditions a common band at a molecular weight varying 
between 61 and 64 kDa (Figure 3.8). A similar band was detected in the rat and human 
when immunoblots were analyzed using the polyclonal rabbit anti-chick CNTFRα, 
and the monoclonal anti-human CNTFRα antibodies (data not shown). However, with 
these two antibodies, several additional non-specific bands were detected. 
 
DISCUSSION 
We have shown that CNTFRα protein is expressed in the retina in a variety of 
mammalian species including primates. While a similar pattern of CNTFRα 
expression could be observed across species in the inner retina, a distinct difference 
between rodent and non-rodent species was observed in photoreceptors. 
Our results (summarized in Tables 3.1, and 3.2) suggest that the mechanism by 
which CNTF stimulates photoreceptor survival may depend on the expression of 
CNTFRα by photoreceptor cells, and thus on the animal species examined. 
Recently, we reported that normal adult canine photoreceptor cells express 
CNTFRα when using a polyclonal antibody directed against chick CNTFRα.18 Here,  
we have extended our work using this same antibody to examine the expression of 
CNTFRα in the retina of several other mammals. Since, the degree of homology 
between the amino acid sequence of chicken CNTFRα and that of dog and other 
mammals is relatively low,18 we also used three other antibodies raised against 
mammalian CNTFRα to verify our results. While the intensity and the quality of the 
immunolabeling were higher with the anti-chick CNTFRα antibody, a similar pattern
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 Figure 3.8 Western blot analysis of CNTFRα in retinas of mammalian species. 
Total protein extracts were run on a reducing 12 % SDS-PAGE gel and immunoblotted with a polyclonal antibody raised against 
human CNTFRα (AF303NA). (A) Detection in the rat of a major band at approximately 63 kDa. (B) Detection in the dog of a 
major band at approximately 61 kDa. (C) Detection in the cat of a band at approximately 64 kDa. (D) Detection in the pig of a 
major band at approximately 63 kDa. (E) Detection in the human of a band at approximately 62 kDa. 
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Table 3.2 Photoreceptor immunolabeling with different CNTFRα antibodies in mammalian retina 
The table summarizes the level of immunodetection of CNTFRα in the photoreceptor cells of several mammalian species, with the 
four antibodies used in this study. Intensity of photoreceptor labeling was characterized as strong (+++), moderate (++), weak (+), 
absent but with labeling in other retinal layers (0), nonspecific background labeling (BG), nonreactive  with an absence of labeling 
throughout the retina (NR), or indeterminate due to binding of secondary antibody to the tissue (IN). 
CNTFRα 
antibodies 
Mouse Rat 
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6d 
Rat  
adult
Dog      Cat Sheep Pig Horse Cynomolgus
macaque 
Rhesus 
macaque 
 
Human 
 
rabbit anti-chick 
 
0 
 
0 
 
0 
 
+ + + 
 
+ + + 
 
+ + + 
 
+ + + 
 
NR 
 
BG 
 
+ + + 
 
+ + + 
 
goat anti-human 
(AF303NA) 
 
0 
 
0 
 
0 
 
+ + 
 
+ + + 
 
IN 
 
+ + 
 
+ + 
 
+ 
 
+ 
 
+ 
 
mouse anti-
human 
(MAB303) 
 
IN 
 
0 
 
0 
 
BG 
 
+ 
 
+ + 
 
+ 
 
NR 
 
+ + + 
 
+ 
 
+ 
 
goat anti-rat 
(AF559NA) 
 
 
0 
 
0 
 
0 
 
BG 
 
+ + 
 
IN 
 
+ + 
 
BG 
 
+ 
 
+ + + 
 
+ + + 
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could be observed with the other antibodies, thus confirming the specificity of the 
labeling detected in mammalian species with the anti-chick CNTFRα antibody. It 
must be noted, that the manufacturer of these three antibodies (AF303NA, MAB303, 
AF559NA) does not advertise them for immunocytochemical use, yet we were able to 
detect some labeling by using the immunoenzymatic method described above. 
Our findings support previous observations that suggest that CNTFRα is not 
expressed by rodent photoreceptors. In both mouse and rat adult retinas, CNTFRα 
immunolabeling was restricted to some INL, and ganglion cells. This pattern 
resembled that observed for CNTFRα mRNA in the rat.13 We showed that 
photoreceptor expression of CNTFRα was absent in both the mature normal rodent 
retina as well as in the developing rat retina at PD3 and PD6. This is in contrast to a 
study that claimed that CNTFRα expression could be detected in photoreceptors at 
PD5 and PD8.26 In that report, the authors analyzed on immunoblots the expression of 
CNTFRα in both the outer and inner retina. Since the horizontal cut made to isolate 
the outer retina (on flatmounted retinas) was done at a thickness of 140 µm from the 
vitreal surface, it is likely that the “outer retina” defined by the authors contained a 
portion of the developing INL that included CNTFRα-expressing horizontal cells. 
Indeed, on our sections the distance separating the horizontal cells from the internal 
limiting membrane was approximately 200-250 µm in the PD3 rat, and 170-200 µm in 
the PD6 rat.  
Another study has suggested that rat photoreceptor cells express CNTFRα.27 
While high magnification views showed punctate immunolabeling exclusively limited 
to the photoreceptor outers segments, no labeling was observed in ganglion, and INL 
cells. Since negative controls were not performed using a pre-, or non-immunized 
serum, or an unrelated primary antibody from the same species in which the CNTFRα 
antibody was raised, it cannot be excluded that outer segment staining was non-
specific and due to “antibody stickiness” to the photoreceptor outer segments. A 
similar phenomenon has been reported when performing enzymatic 
immunocytochemistry on the retina,20 and can be a source of false positive 
immunolabeling when appropriate antibody controls are not used. We were not able to 
verify the specificity of the commercial CNTFRα antibody used in that study, as it has 
not been commercially available for over three years [Personal communication, 
Research Diagnostics Inc, Flanders, NJ; 11/2003]. 
In a recent study, Rhee and Yang reported that CNTFRα immunolabeling of 
the inner and outer segments of mouse photoreceptors could be observed as early as 
postnatal day 10, and persisted in the mature retina.28 The commercial goat polyclonal 
antibody raised against CNTFRα (R-20) (sc-1914, Santa Cruz Biotechnology, Santa 
Cruz, CA) that the authors used in their study was one that we had tested previously in 
the dog, rat, mouse, and other mammalian retinas.18 We had observed (data not 
shown) in both the mature mouse and rat retinas a similar pattern of labeling as that 
described by the authors. In addition, by double immunofluorescence, we observed a 
colocalization of both PNA and the CNTFRα antibody (sc-1914) in the mouse retina, 
suggesting that murine cones express CNTFRα (data not shown). Yet, as we have 
reported previously, 18 we were not able to block the labeling obtained with the sc-
1914 antibody by preincubating it with its blocking peptide (sc-1914P) on either 
immunoblots or immunohistochemical sections. We tested two different lots of the 
blocking peptide as well as a lyophilised peptide preparation provided by the 
company, at concentrations 5-100 folds higher (10-200 µg/ml) than that of the 
antibody, and for several different preincubation periods (2 hours-overnight). While 
we cannot fully exclude the possibility of a manufacturing defect in the preparation of 
the blocking peptide, we have questioned the specificity of the sc-1914 antibody. In 
their study, Rhee and Yang 28 have omitted to report the results of the negative 
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controls used to verify the specificity of the sc-1914 antibody while providing 
thorough details for the other antibodies tested. 
RT-PCR analysis of CNTFRα expression in the ONL of normal and light-
reared PD35 rat retinas failed to detect CNTFRα gene expression.17 Similarly, single 
cell RT-PCR detected CNTFRα transcript in a fraction of mouse Müller cells but 
never in rod photoreceptor cells.29 These results contrast with those from Ju  et al.30 
that report increased CNTFRα mRNA expression in rat photoreceptors following 
retinal ischemia and reperfusion. These apparently contradicting observations may 
suggest that under normal conditions, mature rodent photoreceptors do not express 
CNTFRα, but that under conditions of stress such as ischemia and reperfusion, 
CNTFRα expression occurs. 
Several reports have failed to show any CNTF-mediated activation of signaling 
pathways in juvenile and adult rodent photoreceptor cells,14-16 and our results support 
the idea that direct activation of these cells may not occur in the absence of CNTFRα. 
Yet, very recent studies show that CNTF can trigger the activation of cytokine 
signaling events in photoreceptor precursor cells and differentiating rods in the early 
postnatal rodent retina.31-33 It is therefore possible, that immature photoreceptor cells 
express low levels of CNTFRα that escape detection by immunocytochemistry, yet are 
critical to the development of these cells. Alternatively, CNTF may act directly on 
these photoreceptor precursor cells by binding a different member of the cytokine-
receptor family.34 
A striking difference in the retinal expression of CNTFRα in non-rodent 
mammals has been the observation that CNTFRα immunolocalizes to photoreceptors. 
Similarly to our previous findings in the normal adult canine retina,18 photoreceptors 
of the adult cat, sheep, horse, pig, monkey and human express CNTFRα. A similar 
pattern of photoreceptor staining was observed across these species, and is 
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characterized by the labeling of rod and cone IS, cone soma, axon and pedicle. 
Labeling with the anti-chick CNTFRα did not appear to be restricted to the cell 
membrane, particularly at the level of the cone IS and soma. Recently, it was reported 
that CNTFRα immunostaining of neurons in the rat cochlear nucleus revealed its 
presence at the level of the cell membrane and at the soma; ultrastructural analysis 
localized it to the endoplasmic reticulum.35 The localization of CNTFRα to 
photoreceptors would suggest that endogenous or exogenously administered CNTF 
could bind directly to CNTFRα expressed at the surface of these cells. To determine 
whether CNTFRα is capable of transducing a survival signal to photoreceptors, or 
whether it plays the role of a CNTF sink, further studies are needed. Examining in 
non-rodent mammalian photoreceptor cells the expression of the other two β 
components (LIFR, and gp-130) of the complete CNTF receptor, as well as the 
downstream signaling pathways is necessary. This would allow characterization of a 
potential direct mechanism of photoreceptor rescue by CNTF. In parallel, 
investigations on the indirect mechanism of photoreceptor rescue by CNTF in rodent 
species need to be pursued. Indeed, at this stage, it cannot be excluded that CNTF 
protects non-rodent mammalian photoreceptors through both a direct and indirect 
mechanism of action. 
There is evidence that CNTF triggers the activation of signaling pathways in 
Müller cells of the rodent retina.14-16,36 Yet, our results fail to identify adult rat Müller 
cells as a site of CNTFRα expression. In addition, in both the adult rat and mouse, 
immunolabeling of the INL was mainly restricted to cells located at the vitreal and 
scleral borders, consistent with the location of horizontal and amacrine cells, 
respectively. A similar observation has been made when assessing the sites of 
expression of CNTFRα mRNA in the INL by in situ hybridization.13 This may suggest 
that Müller cells are also activated indirectly by CNTF, or, as proposed by Peterson 
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and associates,14 that Müller cells have the potential to bind the soluble form of 
CNTFRα. Yet, by single cell RT-PCR, CNTFRα mRNA was detected recently in no 
more than 30 % of isolated mouse Müller cells.29 In our study, repeated double 
immunofluorecence labeling experiments have failed to show any localization of 
CNTFRα to rat Müller cells. Although this discrepancy may be explained by a species 
specificity issue, it is also plausible that a low level of CNTFRα expression in Müller 
cells of normal adult rats is not detected by our current immunofluorecence method. In 
all other non-rodent mammals, with the exception of the pig in which distinct cell 
populations predominantly located at the scleral and vitreal borders of the INL were 
labeled, CNTFRα was found throughout most of the INL. This precluded 
distinguishing particular cell populations located in the INL, and determining in these 
species whether Müller cells express CNTFRα. 
We previously reported that the anti-chick CNTFRα antibody used in this 
study detected on immunoblots of canine and chick retina a protein of approximately 
62kDa.18 This value was slightly lower than that previously reported,13,19 and may be 
due to different electrophoresis conditions. In the present, we have confirmed our 
initial finding using antibodies raised against mammalian CNTFRα, and now show 
that in other mammalian species a protein with a similar molecular weight is detected. 
Our results are consistent with those of others on rat 37 and bovine 38 tissues. 
 
In summary, we have shown that CNTFRα is expressed as a protein with an 
apparent molecular weight of approximately 61-64 kDa in the retina of a wide variety 
of mammalian species. To the best of our knowledge we provide the first 
immunocytochemical evidence that CNTFRα is not expressed by rodent 
photoreceptor cells, while it is found on photoreceptors of non-rodent mammalian 
species. A previous study by one of the co-authors had shown in the chicken retina 
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that CNTFRα expression was present in photoreceptor cells,39 and it was recently 
shown to be restricted to violet-sensitive cones.40 This further illustrates that caution 
needs to be used when extrapolating results from one animal species to another. 
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CHAPTER FOUR 
 
A FRAMESHIFT MUTATION IN RPGR EXON ORF15 CAUSES 
PHOTORECEPTOR DEGENERATION 
 AND INNER RETINA REMODELING IN A MODEL OF 
 X-LINKED RETINITIS PIGMENTOSA* 
 
INTRODUCTION 
X-linked retinitis pigmentosa (XLRP) is a group of diseases that comprises 
some of the most severe and early-onset forms of inherited retinal degeneration in 
humans with partial or complete blindness in the third or fourth decade of life, or 
earlier.1-3 Mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene 
account for more than 70% of patients with XLRP, and most of these mutations are 
found in exon ORF15.4 A spectrum of disease phenotypes is associated with RPGR 
mutations. The most common reflect the typical rod-cone degeneration encountered in 
most forms of RP and consist first in night blindness and loss of mid-peripheral visual 
field followed by loss of day vision and central visual acuity.1,2 Yet, some other  
mutations result in equal rod-cone abnormalities,5 cone-rod dystrophies,6 or macular 
degeneration.7 
To understand the retinal function of the RPGR protein, as well as the 
pathogenic mechanisms that link mutations in RPGR with the death of photoreceptor 
cells, several animal models have been used. These comprise two transgenic murine 
 
 
* Beltran WA, Hammond P, Acland GM, Aguirre GD. Invest. Ophthalmol. Vis. Sci. 
2006; 47 (4): 1669-1681. The Association for Research in Vision and Ophthalmology 
is the copyright holder of this publication. 
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models (RPGR knockout mouse,8 and a dominant gain-of-function mutant9), and two 
naturally-occurring canine mutations in exon ORF1510 that cause two forms of X-
linked progressive retinal atrophy (XLPRA). 
In XLPRA1, a five-nucleotide deletion (del1028-1032) in exon ORF15 causes 
an immediate premature stop codon that results in a protein truncated of its 230 C- 
terminal amino acids. This mutation causes a loss of function of RPGR. 
Morphological characterization showed that photoreceptor cells develop and function 
normally, but then undergo progressive rod-cone degeneration. The earliest 
histological signs of rod degeneration are detected at 11 months of age, and are 
followed at later stages by cone death.10,11 
In XLPRA2, preliminary results from our group have shown that the disease is 
a much more severe and earlier form of retinal degeneration than XLPRA1.10 A two 
nucleotide deletion (del 1084-1085) in exon ORF15 results in a frameshift that 
changes the deduced peptide sequence by the inclusion of 34 additional basic residues 
and increases the isoelectric point of the truncated protein.10 In addition, the mutant 
ORF15 protein was also shown to accumulate in the endoplastic reticulum of 
transfected COS7 cells. These results suggest that the mutation in XLPRA2 causes a 
toxic gain of function and is comparable to the severe human phenotype resulting from 
microdeletions that cause a frameshift.12 
Although the precise subcellular location of the RPGR ORF15 protein in 
photoreceptor cells is still debated,13,14 findings in the null mutant mouse suggest that 
it may play a role in maintaining a polarized distribution of proteins between inner 
(IS) and outer (OS) segments.8 Yet, it is still unclear how the loss of function of RPGR 
or the expression of a toxic mutant RPGR protein in XLPRA2, may initiate a cascade 
of molecular events that ultimately lead to photoreceptor cell death. To begin to 
address this question, we examined the retinal structural alterations that occur in 
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XLPRA2 and characterized the time course of photoreceptor disease, degeneration, and 
death and the subsequent alterations that occur in the inner retina. We found an early 
onset of photoreceptor disease leading to cell death, as well as early inner retina 
remodeling. Our results identify the critical stages in the pathogenesis of the disease 
and define the time windows for testing novel therapies. 
 
METHODS 
Animals 
Thirty-five dogs were used in the study (Table 4.1). This included 25 crossbred 
XLPRA2 affected dogs (age range, 2-40.6 weeks), and 10 nonaffected beagles that 
were used as normal control subjects (age range, 2-24 weeks). All affected dogs (11 
hemizygous males, 14 homozygous females) were bred at the Retinal Disease Studies 
Facility (RDSF; University of Pennsylvania, New Bolton Center, Kennett Square, 
PA), and their genotype was determined either from the known status of their 
progenitors or from genetic testing for the disease-causing mutation.10 All nonmutant 
beagles came from the Baker Institute colony of specific pathogen-free dogs. After an 
ocular examination to identify abnormalities not associated with the primary retinal 
disease, all animals were anesthetized by intravenous injection of pentobarbital 
sodium, the eyes enucleated, and the dogs euthanatized. All procedures involving 
animals were done in compliance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. 
 
Retinal histology 
The left eyes of 16 XLPRA2 dogs (age range, 2-40.6 weeks) were used for 
morphologic examination of disease expression using plastic embedding (Table 4.1, 
morphology). The retinas of 3 normal beagles (ages: 2.3, 5.4, and 8.3 weeks) were 
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used as control specimen. By 8 weeks of age the canine retina is structurally 
mature.15,16 Immediately after enucleation, the posterior segments were isolated and 
fixed, using a triple fixative protocol (3% glutaraldehyde-2% formaldehyde; 2% 
glutaraldehyde-1% osmium tetroxide; and 2% osmium tetroxide) as previously 
reported.15 The posterior segments were then trimmed into pieces that extended from 
the optic nerve to the ora serrata along the superior and inferior meridians, 
dehydrated, and embedded in epoxy resin (PolyBed 812, Polysciences, Warrington, 
PA). Tissues were sectioned with glass knives at 1 µm with a supercut microtome 
(Reichert Jung model 2065; Leica, Deerfield, IL), stained with azure II-methylene 
blue and a paraphenylenediamine counterstain. 
 Sections from both the superior and inferior meridians were examined with a 
40X objective under light microscopy (Axioplan; Carl Zeiss Meditech GmbH, 
Oberkochen, Germany). The sections were examined in contiguous fields from the 
optic disc to the ora serrata. This included evaluation of the retinal pigment 
epithelium (RPE), the rod and cone OS and IS, and the thickness and density of the 
outer (ONL) and inner (INL) nuclear layers. For each dog, a single section from both 
quadrants was used for quantitative evaluation of the photoreceptor cells, and INL 
cells at three specific locations: S1, 2,000 ± 500 µm from the optic nerve; S3, 2,000 ± 
500 µm from the ora serrata; and S2 midway (± 500 µm) between these 2 points. At 
each of these sites, the number of rows of nuclei in the ONL and INL were counted in 
at least 3 areas of a 40X field and averaged. For the same areas, the thickness (in µm) 
of the ONL and INL were measured on digitally captured images. 
 The kinetics of photoreceptor cell loss were analyzed by fitting the ONL 
thickness data to solutions of the following differential equations reported by Clarke et 
al.17. We are also reporting below the integral equations used for the statistical 
analysis, since we found typographical errors confirmed by the authors (Geoff Clarke, 
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personal communication, 11/29/05) in the integral equations provided in the 
supplementary information that accompanied their paper 
(http://www.nature.com/nature/journal/v406/n6792/suppinfo/406195a0.html). 
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Data-fitting was performed with nonlinear regression analysis (with PROC NLIN in 
SAS 9.1 software; SAS Institute Inc., Cary, NC, USA). This is a least-squares 
procedure for estimating parameters in nonlinear models. The parameter estimates 
(using the Gaussian method) and 95% confidence intervals, along with probabilities 
(based on the Wald test) were computed. The R2 was used to assess the overall 
goodness of fit of the model. Please note that it was not possible to fit our data to 
mathematical models that account for the time period between birth and onset of cell 
death (called the “delay” parameter by Clarke et al.17), because there were insufficient 
data at early time points, which prevented us from getting an estimate for the “delay” 
parameter. 
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 Phagocytic cells present in the photoreceptor layer were counted throughout 
the entire length of both the superior and inferior retinal meridians and expressed as 
the number of phagocytic cells per unit length of retina. The unit length was set as 
10,000 µm. Pyknotic photoreceptor nuclei were counted in the ONL in both the 
superior and inferior meridians and expressed as the number of pyknotic nuclei per 
unit area of ONL. The unit area was set as 1 million µm2 (1 M µm2) of ONL. A 
similar count was used to quantify TUNEL-positive photoreceptor cells. 
 
TUNEL assay 
In 18 XLPRA2-affected dogs, one eye was processed immediately after enucleation for 
TUNEL assays and/or immunohistochemistry (Table 4.1: TUNEL, IHC). After 
enucleation, a slit was made through the globe at the level of the ora serrata, and the 
entire globe was fixed for 3 hours in 4% paraformaldehyde in 0.1 M phosphate- 
buffered saline at 4°C. The posterior segment then was isolated, the vitreous gently 
removed, and the eyecup fixed for an additional 24 hours at 4°C in 2% 
paraformaldehyde in 0.1 M phosphate-buffered saline. The tissue then was trimmed, 
cryoprotected sequentially for 24 hours in a solution of 15% and 30% sucrose in 0.1 M 
sodium phosphate and 0.15 M sodium chloride, pH 7.2 (BupHTM, Phosphate Buffered 
Saline, Pierce, Rockford, IL; referred in the text as PBS) at 4°C, and embedded in 
OCT medium. 
Cryosections (7 µm thick) along the superior meridian of 17 XLPRA2 dogs 
(age range, 3.9-40.6 weeks) were used for TUNEL assay, according to the 
manufacturer’s protocol (In situ cell death detection kit, Roche, Indianapolis, IN) and 
stained with DAPI. Sections along the superior meridian of three normal beagles 
(ages, 4, 5, and 6 weeks) were also used. Positive control specimen included sections 
pretreated with DNAse I (3 U/ml in 50 mM Tris-HCl, pH 7.5, 1 mg/ml BSA for 10 
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Table 4.1: Status, gender and age of dogs used for the morphologic, TUNEL, and 
immunohistochemical (IHC) studies. M: male; F: female; +: done. 
ID Gender Age (weeks) Morphology TUNEL IHC 
      
Affected      
Z215 F 2 +   
Z210 M 2 +  + 
Z201 M 3.9 + + + 
Z266 F 4.1  +  
Z212 M 4.9 +   
Z202 M 5 + + + 
Z203 F 6 + + + 
Z253 F 6.1  +  
Z254 F 6.7  +  
Z255 F 6.7  +  
Z207 F 7.9 + + + 
Z250 M 8  +  
Z251 M 8  +  
Z216 M 8.3 +   
Z211 M 11.9 + + + 
Z219 F 12.1  +  
Z226 F 16 + + + 
Z194 M 17.3 +   
Z195 F 17.3 +   
Z193 M 17.7 +   
Z208 F 19.9 +   
Z204 M 19.9  +  
Z209 F 23.7  +  
Z181 F 26 + + + 
Z178 F 40.6 + + + 
      
Normal      
7304 F 2   + 
2327-2 M 2.3 +   
7306 F 4  + + 
7307 M 5  +  
2297-1 F 5.4 +   
7308 F 6  + + 
7310 F 8.1   + 
2298-1 M 8.3 +   
7312 F 12   + 
7299 M 24   + 
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min at room temperature). For negative control subjects, the terminal transferase 
enzyme was omitted from the TUNEL reaction mixture. Sections were examined from 
the optic disc to the ora serrata by epifluorescence microscopy with the 40X 
objective. TUNEL-labeled cells in the ONL were counted throughout the entire length 
of the section (i.e., from disc to ora serrata). In determining the proportion of 
photoreceptor cells that undergo cell death as a function of time, we expressed our 
results as the number of TUNEL-labeled photoreceptor cells per 1 M µm2 of ONL. 
The area of the ONL of each section was obtained by measuring the entire length of 
the ONL from optic disc to ora serrata, and multiplying it by the average thickness of 
the ONL throughout the section (mean value of the thickness measured in the three 
locations S1, S2, and S3). This method may slightly underestimate, in areas of 
decreased photoreceptor density, the proportion of cell that are TUNEL positive. Yet, 
it was selected because individual cell count could not be determined on 7-µm-thick 
DAPI-stained cryosections. For each dog, this procedure was performed in triplicate 
with sequential sections from the superior meridian. The values were averaged and 
reported as the mean ± SD. 
 
Immunohistochemistry 
Sections along the superior retinal meridian of 9 XLPRA2 dogs (age range, 2-
40.6 weeks) and 6 normal dogs (age range, 2-24 weeks) that were processed as 
described earlier were used for fluorescent immunohistochemistry. We used a battery 
of cell-specific primary antibodies9,18-30 of which more than half worked on canine 
retina (see details in Table 4.2). Because of the lack of specific antibodies directed 
against all subpopulation of ganglion cells in the dog, our study did not include 
assessment of their density or morphology. Because previous testing of RPGR and 
RPGRIP antibodies conducted in our laboratory failed to show any cross-reactivity or 
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Table 4.2: List of primary antibodies tested and used in this study. 
 
 
Highlighted in gray are the antibodies that cross-reacted on canine retina, and were successfully used as cell-specific markers in 
this study. The other antibodies (non-highlighted) were tested but did not cross react on canine retina when used overnight at the 
indicated concentrations. 
†: This same antibody was used in this reference. 
*: A different antibody raised against the same antigen was used in this reference.
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Antigen Host Source, catalog # or name Working 
concentration 
Normal retinal localization 
(reported in rodents) 
 
Refs. 
RPE65 Rabbit T.Michael Redmond 1:10,000 Retinal pigment epithelium 18† 
Human cone arrestin Rabbit Cheryl Craft, LUMIF 1:10,000 Cone photoreceptors 19† 
M/L cone opsin Rabbit Chemicon, AB5405 1:10,000 OS of M/L cones 20* 
S cone opsin Rabbit Chemicon, AB5407 1:5,000 OS of S cones 20* 
Rod opsin Mouse Paul Hargrave, R2-12N 1:300 OS of rods 21† 
Synaptophysin Rabbit DakoCytomation, A0010 1:100 Neuron synapses, OPL, IPL 22†, 23* 
Calbindin D-28K Rabbit Sigma, C2724 1:1,000 Horizontal, amacrine cells 24†, 23* 
Protein Kinase C (PKCα) Mouse BD Biosciences, 610107 1:100 Rod bipolar cells 25*, 24* 
Goα Mouse Chemicon, MAB3073 1:5,000 ON (rod and cone) bipolar cells 26† 
Tachykinin receptor 3 (=NK3R, NKBR) Rabbit
Rabbit 
Novus biologicals, NLS4043 
Abcam, ab13278 
1:100 
1:50 
Cone bipolar cells 24† 
Metabotropic glutamate receptor (GRM6) Rabbit Abcam, ab13362 1:10 – 1:200 Postsynaptic sites of ON bipolar cells 24*, 25* 
γ-amino butyric acid (GABA) Rabbit Chemicon, AB5016 1:50 GABAergic amacrine cells 27* 
Choline acetyl transferase (ChAT) 
 
Rabbit
Rat 
Chemicon, AB143 
Oncogene, NB05L 
1:500 
1:100 
Cholinergic amacrine cells 28†, 29* 
 
Tyrosine hydroxylase (TH) Rabbit Chemicon, AB152 1:500 Dopaminergic amacrine cells 24†, 25† 
Disabled 1 (Dab1) Rabbit Chemicon, AB5840 1:50 - 1:100 AII amacrine cells 25* 
CRALBP Mouse John Saari,  1:5,000 Müller cells, RPE 9† 
Glial Fibrillary acidic protein (GFAP) Rabbit DakoCytomation, Z0334 1:1,000 Astrocytes, Müller cells (reactive) 30† 
Glutamine synthetase Mouse Chemicon, MAB302 1:20,000 Müller cells 25† 
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specificity on canine retina, we did not include them in this study.10 Cryosections (7-
10 µm-thick) were incubated overnight with the primary antibodies after a blocking 
step with 10% normal serum from the appropriate species. The antigen-antibody 
complexes were visualized with fluorochrome-labeled secondary antibodies (Alexa 
Fluor, 1:200; Molecular Probes, Eugene, OR). DAPI stain was used to detect cell 
nuclei. Slides were mounted with a medium composed of polyvinyl alcohol and 
DABCO (1,4 diazobizyklo-[2.2.2]oktan) (Gelvatol; Sigma-Aldrich, St Louis, MO), 
and examined with an epifluorescent microscope (Axioplan; Carl Zeiss Meditec). 
Images were digitally captured (Spot 4.0 camera; Diagnostic Instrument, Inc.) and 
imported into a graphics program (Photoshop; Adobe, Mountain View, CA) for 
display. 
 
RESULTS 
Photoreceptor Disease 
Gross examination of the eyes at the time of enucleation did not reveal significant 
differences in size between affected and normal dogs. Measurements of retinal length 
between the optic disc and the ora serrata along the superior meridian confirmed that 
in XLPRA2 the growth of the eye was not affected by the disease (data not shown). 
 Normal retinal development in the dog is complete at approximately 7 to 8 
weeks of age.15,16 At birth, photoreceptor cells have not completely differentiated and 
are located in the sclerad portion of the outer neuroblastic layer, which then give rise 
to the outer nuclear layer (ONL). Maturation of photoreceptors occurs in waves from 
central to peripheral retina.31 IS are first seen as short bulges of cytoplasm protruding 
from the external limiting membrane between 1 day and 1 week after birth.32 At 
approximately 2 weeks of age, IS are visible throughout the entire length of the retina, 
and OS formation is underway centrally (Figure 4.1 A). By 5.4 weeks of age, OS are 
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formed and begin to elongate (Figure 4.1 B). Full maturation of photoreceptors is 
reached at approximately 8 weeks of age, at which time the retina resembles that of 
the adult (Figure 4.1 C). Pyknotic figures in the ONL were extremely rare (0 to 1 per 1 
M µm2 of ONL) at all ages examined. Concurrent with the maturation of the 
photoreceptors, there are changes in the inner retinal layers which are most prominent 
in the INL. These primarily consist of a decrease in the number of nuclei, presumably 
because of an increase in eye size (see Figure 4.1 A-C). 
 Disease stages of XLPRA2 were defined at early time points on the basis of the 
structural changes observed in the photoreceptor layer (IS, OS). At later ages, 
reduction in ONL thickness was also taken into account. Because no major differences 
in the course of the disease were observed between the superior and inferior retina, the 
description is provided for the superior meridian (Figure 4.1). Table 3 provides more 
specific details (phagocyte count, ONL thickness, pyknosis in ONL, and INL 
thickness) for both the superior and inferior meridians. 
 The earliest time point examined in the affected dogs was 2 weeks of age 
(Figure 4.1 D), and no evidence of abnormal development or arrested differentiation 
was observed (Stage 0; normal). The typical layering of the neuroretina was preserved 
from the optic disc to the ora serrata along both superior (tapetal) and inferior 
(nontapetal) meridians. Nuclei in the ONL were elongated, which is a normal 
characteristic of immature photoreceptor cells. Nuclear pyknosis was negligible in the 
ONL (Table 4.3). Cone and rod IS were present throughout the photoreceptor layer. In 
the central retina, elongating IS, with budding OS, were observed, whereas in the 
periphery, short IS were in close contact with the apical RPE. 
 At 3.9 weeks of age, there was a moderate increase in the number of pyknotic 
cells in the ONL (Table 3), and very subtle changes in the morphology of the OS. This 
early stage of OS disruption and misalignment was better seen when dogs were
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Figure 4.1: Stages of development and photoreceptor degeneration in normal and 
mutant retinas. Images are from the mid-periphery of the superior meridian. (A-C) 
Normal retina. (A) By 2.3 weeks, photoreceptor nuclei were elongated, IS were 
visible, and short OS began to form. (B) By 5.4 weeks, OS were formed and 
elongated, and (C) photoreceptor maturation was complete by 8.3 weeks. (D-I) 
XLPRA2 mutant retina. (D) Stage 0, 2.2 weeks. Photoreceptor development was 
normal and comparable to the control. (E) Stage 1, 5 weeks. OS were misaligned and 
partially fragmented (*). Pyknotic nuclei were visible in the ONL (arrow). (F) Stage 
2, 7.9 weeks. OS were disintegrating (*), and there was pyknosis in the ONL 
(arrows). ONL, eight t nine rows of nuclei. (G) Stage 3, 16 weeks. The subretinal 
space was narrowed, rod IS were very short (arrow), and remaining but distorted rod 
and cone OS were visible. Phagocytic cells were present in the subretinal space 
(arrowhead). ONL, six rows of nuclei. (H) Stage 4, 26 weeks. The subretinal space 
wass narrowed further, but distorted OS remained (arrow). Both rod and cone IS 
were shortened, and cone IS were broader than normal. Spaces were visible in the IS 
layer secondary to rod loss (arrowheads). ONL, five rows of nuclei with increased 
spacing between photoreceptor somas (*). (I) Stage 5, 40.6 weeks. The 
interphotoreceptor space had open areas, yet some photoreceptors appeared to retain 
their distorted OS (arrows). ONL, two to three rows of nuclei. RPE, retinal pigment 
epithelium; PR, photoreceptor layer; OS, outer segments; IS, inner segments; ONL, 
outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer. Scale bar: 
20 µm. 
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Table 4.3: Changes in the XLPRA2 retina associated with disease stages. 
a: Number of phagocytic cells in the subretinal space per 10,000 µm of retinal length; 
b: Thickness of the ONL or INL measured in number of rows of nuclei; 
 c: Number of pyknotic nuclei in the ONL per 1 million µm2 of ONL;  
S1: central retina (2,000 µm ± 500 µm from optic disc); S3: peripheral retina (2,000 
µm ± 500 µm from ora serrata); S2: mid-peripheral retina (midpoint of S1 and S3, ± 
500 µm). 
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 Stage 0  Stage 1  Stage 2  Stage 3  Stage 4  Stage 5 
 2 wk 
(Z215) 
2 wk 
(Z210) 
  3.9 wk
(Z201) 
4.9 wk 
(Z212) 
5 wk 
(Z202) 
 7.9 wk 
(Z207) 
   11.9 wk 
(Z211) 
16 wk 
(Z226) 
26 wk 
(Z181) 
40.6
wk 
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slightly older (≈ 5 weeks of age; Stage 1; Figure 4.1 E). At that age, nuclear pyknosis 
had increased in the ONL (Table 3). 
 By 7.9 weeks of age (Stage 2; Figure 4.1 F), there was severe OS 
disintegration, with abundant disorganized and disoriented membranous material 
persisting in the photoreceptor layer. ONL thickness was moderately reduced, and the 
number of pyknotic nuclei in the ONL had decreased (Table 3). A similar decline in 
INL thickness as seen in the normal retina was observed between 2 and 7.9 weeks of 
age (see Figure 4.1 A-F) and reached approximately 3 to 4 rows of nuclei (Table 3). 
 By 11.9 and 16 weeks, there was narrowing of the subretinal space with 
shortening or loss of rod IS, and these abnormalities were comparable at both time 
points (Stage 3; Figure 4.1 G). Distorted OS persisted in the photoreceptor layer. 
There was marked rod loss, with the ONL reduced to approximately 60 % of its 
original thickness. Pyknosis in the ONL was further reduced. A few phagocytic cells 
located in the subretinal space in close apposition to the RPE were first seen in the 
11.9-week-old retina. Their number increased at 16 weeks (Table 4.3). Disease-
associated thinning of the INL was observed at both ages and was most pronounced in 
the peripheral retina (Table 4.3). 
 There was a clear decrease in the density of both rod and cone photoreceptors 
by 26 weeks of age (Stage 4; Figure 4.1 H). This decrease was seen at the level of the 
photoreceptor layer, where there were areas devoid of any rod and cone IS, and also in 
the ONL where internuclear spacing was increased. ONL thickness was less than 50 % 
of its original thickness. In the photoreceptor layer, the remaining rod and cone IS 
appeared broader and, although the subretinal space was severely narrowed, shortened, 
and distorted OS were still present. Cone nuclei displaced into the IS and extruding 
into the subretinal space were first seen at this age. Phagocytic cells persisted in the 
subretinal space. 
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 The latest stage of disease examined was at 40.6 weeks (Stage 5; Figure 4.1 I). 
At that time point, there were approximately 2 to 3 rows of nuclei left in the ONL, and 
the remaining cone and rod IS were short and broad. Numerous photoreceptor cells 
maintained a shortened and misaligned OS, and RPE cytoplasmic processes extended 
towards them. Phagocytes remained in the subretinal space, but were not migrating in 
the ONL or inner retina. Nuclear pyknosis persisted in the ONL but was not observed 
in the INL, despite a decrease in its thickness (Table 4.3). 
 To illustrate the rate of photoreceptor cell loss that occurs during the course of 
the disease along both the superior and inferior retinal meridians, we plotted the 
average thickness of the ONL (expressed as either the number of nuclei per column, or 
in µm) as a function of age. These graphs (Figure 4.2) show a major and rapid early 
cell loss occurring from 4 to 12 weeks of age. Subsequently, the number of remaining 
photoreceptors continued to decrease but at a slower rate. The kinetics of 
photoreceptor cell loss was best described by a model of constant risk of cell death 
when the ONL thickness was measured as number of nuclei. When the ONL thickness 
was measured in µm, the data was best fit by both a model of constant risk and of 
decreasing risk of cell death. 
 To determine whether the disease and degeneration of photoreceptor cells was 
uniformly distributed throughout the retina, or if there was a topographic distribution 
of the disease, we examined all sections from optic disc to ora serrata. We observed 
that a comparable disease process occurred throughout the entire length of the retina 
along both the superior and inferior meridians. In the normal retina, there is a normal 
gradient in ONL thickness from central (10-14 nuclei) to peripheral (3-6 nuclei) 
retina.33 A similar trend in ONL thickness occurred in young mutant retinas and 
therefore should not be considered as several different stages of the disease coexisting 
along the same retinal meridian. 
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Figure 4.2: Rate of photoreceptor cell loss in mutant retinas as a function of age. ONL 
thickness was measured as the number of rows of photoreceptor nuclei (A, C) or in 
µm (B, D) along both the superior (A, B) and inferior (C, D) retinal meridians. 
Reported values are the mean of three measurements taken in the central, 
midperipheral and peripheral region of the superior or inferior retinal meridian. The 
kinetics of photoreceptor cell loss are best fit by a model of constant or exponentially 
decreasing risk of cell death. ONL: outer nuclear layer. 
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Cell Death 
Because of the uniform distribution and rate of disease along the superior and inferior 
meridians, we determined cell death by using TUNEL assays in sections from the 
superior meridian. The earliest age when cell death was examined by TUNEL assay 
was 3.9 weeks, because this was the age when the first morphological signs of disease 
were detected. Approximately 31 to 48 TUNEL-labeled cells per 1 M µm2 of ONL 
were counted. The proportion of photoreceptors undergoing cell death was higher at 5 
and 6 weeks, and reached a peak value of more than 300 TUNEL-positive cells per 1 
M µm2 of ONL at 6.7 weeks of age. In normal retinas of 4, 5, and 6 week-old beagles, 
the number of TUNEL-positive cells per unit area of ONL was significantly lower and 
did not exceed six per 1 M µm2 of ONL. At 8 weeks of age, the proportion of 
photoreceptors undergoing cell death in the mutant retina had decreased to about half 
that occurring at 6.7 weeks (approximately 150 TUNEL-positive cells per  
1 M µm2 of ONL). At any given time after 12 weeks of age, the proportion of dying 
photoreceptors was significantly reduced and close to 80 cells / 1 M µm2 of ONL 
(Figure 4.3). TUNEL-labeled cells were equally distributed throughout the length of 
the retina, but it appeared that at the earlier ages, there were more dying cells located 
in the vitreous half of the ONL. (Figure 4.4 A1) Yet, although, TUNEL-positive 
photoreceptors were seen in the outer half of the ONL, it was extremely rare before 26 
weeks of age to detect any labeling in the outermost row of ONL nuclei where cone 
somas are located (Figure 4.4 A1, A2). In 26-and 40.6-week-old XLPRA2 retinas, it 
was frequent to observe, particularly in the retinal periphery, cone nuclei that were 
ectopically located in the IS (Figure 4.4 A3). Double fluorescent labeling showed that 
a few displaced cone nuclei were TUNEL-positive (Figure 4.4 A4). Rare TUNEL-
positive cells were also present in the INL and GCL in both mutant and normal young 
retinas (4-6 weeks), and this was therefore considered a normal finding not associated  
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Figure 4.3: Number of TUNEL-labeled photoreceptor cell nuclei per unit area (1 
million µm2) of ONL as a function of age in the superior retinal quadrant of affected 
and normal dogs. Symbols : the mean ± SD of 3 counts made on three sections from 
the superior retinal meridian of each animal. 
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with disease. At later time points in the mutants, there was a relative absence of 
TUNEL-labeling in those layers. 
 
Immunohistochemical analysis of photoreceptors and inner retinal changes with 
disease. 
To further characterize the effects of the disease on the morphology, location, and 
density of several retinal cell populations, we tested a battery of antibodies that are 
commonly used as cell-specific markers (see Table 4.2) on retinas of mutants and 
normal age-matched control subjects. 
 The integrity of the RPE was evaluated with an antibody directed against 
RPE65. There was no loss in RPE65-immunoreactivity in 16- and 26-week-old mutant 
retinas and the numerous phagocytic cells present in the subretinal space were not 
labeled by the RPE65 antibody (data not shown). Double-fluorescence 
immunolabeling with rod opsin and human cone arrestin antibodies showed partial 
mislocalization of the rod photopigment to the ONL as early as 2 weeks of age in 
mutant retinas (data not shown). Although rod opsin labeling was restricted to the OS 
in normal subjects (Figure 4.4 B1), distinct staining of the plasma membrane around 
the rod somas also was visible throughout the entire length and thickness of the ONL 
in affected dogs at all ages (Figure 4.4 B2). In the 7.9-week-old mutant retina, short 
rod-opsin-positive neurites originating from rod somas extended into the inner retina 
(Figure 4.4 B2), and, in older animals, the sprouting was more prominent and 
extended deeper into the inner retina, reaching the inner plexiform layer (IPL; Figure 
4.4 B3; 40.6 weeks of age). In contrast, cone neurite sprouting was not observed at any 
stages of the disease examined. 
 To confirm further that these opsin-positive projections were rod neurites, we 
performed double immunofluorescence labeling with rod opsin and synaptophysin 
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antibodies (Figures 4.4 C). Anti-synaptophysin labeled both plexiform layers in 
normal subjects (Figure 4.4 C1), but, in mutant retinas, outer plexiform layer (OPL) 
labeling was thinned, and punctuate staining in the INL colocalized with the rod-
opsin-positive neurites (Figure 4.4 C2). Colocalization occurred at beaded varicosities 
along the neurites and at their terminals. These had either a bulb-shaped appearance or 
that of a typical rod spherule (Figure 4.4 C3). Although rod opsin and cone arrestin 
labeling persisted in the 40.6-week-old affected retina, we observed a decrease in cone 
arrestin immunoreactivity at the level of the cone axons and pedicles (Figure 4.4 B3) 
that was first visible at 26 weeks of age. Because of the thinning of the ONL at that 
age (approx 3 rows of nuclei), the lengths of the remaining rod and cone axons were 
significantly shorter than in a normal adults. Even though thinning and disruption of 
the photoreceptor layer caused occasional retinal separation artifacts during tissue 
fixation and processing in older retinas, distinct rod opsin and arrestin labeling was 
observed, respectively, in some of the remaining rods and cone OS (Figure 4.4 B3). 
 To characterize better the two subpopulations of cone photoreceptor cells 
during the course of disease, we used antibodies raised against short (S)- and medium 
(M)/long (L)- wavelength cone opsin on retinas at various ages and disease stages. 
Both S and M/L cone opsin labeling were present in young and older (40.9 weeks) 
affected dogs. In normal retinas, labeling was restricted to the cone OS (Figures 4.4 
D1, D3), but in mutant retinas there was partial mislocalization of the two types of cone 
opsins to the IS, perinuclear area, axon, and pedicles (Figures 4.4 D2, D4). 
Mislocalization of S opsin was observed in some S cones, distributed throughout the 
entire length of the retina, as early as 3.9 weeks of age. By 6 weeks, S opsin 
mislocalization was found mainly in some peripheral cones (Figure 4.4 D2). At later 
ages S opsin localization was normal. Although the M/L opsin antibody that we used 
caused some non-specific background staining of the INL and faint labeling of cone 
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somas and axons, we observed a similar transient and partial mislocalization of the 
photopigment, particularly in the peripheral retina of 3.9 and 6-week-old affected dogs 
(Figure 4.4 D4). At 8 weeks of age, M/L opsin mislocalization was essentially 
restricted to the perinuclear area of the cones and did not extend into the axons and 
pedicles; in older animals, M/L opsin localization was normal. 
 Because we observed OPL thinning and rod neurite sprouting, we decided to 
use several inner retina cell markers to determine whether photoreceptor disease and 
degeneration were also associated with inner retinal changes. A variety of antibodies 
that label subpopulations of horizontal, bipolar, and amacrine cells, as well as Müller 
cells were tested in either single or double immunofluorescence analysis. 
 Anti-calbindin antibody labeled horizontal cells and, to a lesser extent, 
amacrine and RPE cells in both affected and normal retinas at 4 weeks of age. At later 
time points in disease, immunostaining was predominantly found in horizontal cells 
somas and processes. This pattern persisted throughout the course of the disease. 
Because of the variability in the intensity of calbindin-labeling in the dog we were not 
able to quantify with certainty the number of horizontal cells present throughout the 
length of a retinal section and compare these counts at different stages of the disease. 
Nevertheless, we were able to observe in older affected retinas a flattening of their 
axonal arborization associated with the thinning of the OPL (Figures 4.5 A1-3). 
PKCα staining of rod bipolar cells showed that these second-order neurons 
develop normally (Figure 4.5 B1) in the diseased retina (data not shown). At 11.9 
weeks of age there was a mild reduction in the density of their dendritic arborization, 
which was followed by progressive shortening and total atrophy at later stages 
(Figures 4.5 B2, B3). By performing double-immunofluorescence experiments with 
PKCα and Goα (a cell-marker for ON bipolar cells) antibodies, we were able to 
distinguish rod bipolar cells that coexpress PKCα and Goα from ON-cone bipolar 
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Figure 4.4: Characterization of photoreceptor cell death and disease in XLPRA2. 
(A) Photoreceptor cell death in XLPRA2. (A1) TUNEL-labeling (green) of rod 
photoreceptor cells in a 5-week-old affected retina with DAPI nuclear counterstain 
(blue). (A2) TUNEL-labeling (green) of a cone nucleus in a 40.6-week-old retina 
(arrow). An ectopically located cone nucleus that is not TUNEL-positive is 
highlighted (arrowhead). Cone photoreceptors were labeled with anti-human cone 
arrestin (red), and DAPI (blue) was used as a nuclear counterstain. (A3) Plastic section 
from peripheral retina of a 26-week-old retina shows a morphologically normal cone 
nucleus displaced in the IS (arrow and inset). (A4) TUNEL-labeling (green) of a 
fragmented ectopic cone nucleus (arrow) in a 40.6-week-old retina. Cone 
photoreceptors were labeled with anti-human cone arrestin (red), and DAPI (blue) was 
used as a nuclear counterstain.  
(B) Double immunofluorescent labeling of rod and cones with, respectively, anti-rod 
opsin (green) and anti-human cone arrestin (red) in normal (B1, 8.1 weeks) and 
affected (B2, B3) retinas. (B2) In 7.9 week-affected rod opsin was mislocalized to the 
IS and ONL, and there was early rod neurite sprouting (arrows). (B3) In a 40.6-week 
affected, rod opsin-positive neurites extended deep into the inner retina. Rod opsin and 
cone arrestin expression persisted at this stage of disease, but there was a decrease in 
cone arrestin immunoreactivity at the level of the cone axons and pedicles, even 
though the cone IS and OS were present.  
(C) Double immunofluorescent labeling with anti-rod opsin (green) and anti-
synaptophysin (red) in normal (C1) and affected (C2, C3) retinas. (C1) In a 12-week 
normal retina, both the OPL and IPL were labeled with the synaptophysin antibody. 
(C2) In a 12-week affected retina, there was OPL thinning and punctuate 
synaptophysin-positive labeling that colocalized with rod opsin-positive neurites 
(arrows). (C3) A 40.6-week affected retina. A higher-magnification view showing 
colocalization of synaptophysin and rod opsin along beaded varicosities of rod 
neurites (arrowheads) and at their terminal ends (arrows).  
(D) Immunofluorescent labeling of cones with anti-S opsin (D1, D2), and anti-M/L 
opsin (D3, D4). (D1) In a 4-week normal retina, S opsin labeling was restricted to the 
OS of S cones. (D2) In a 3.9-week affected retina, S opsin was mislocalized to the IS 
(horizontal arrows), soma (vertical arrows), and axons (arrowheads) of some S cones. 
(D3) In a 6-week normal retina, M/L opsin labeling wass predominantly restricted to 
the OS of M/L cones, although faint background labeling of the M/L cone somas and 
axons was present. (D4) In a 6-week affected retina, M/L opsin was mislocalized to the 
somas (vertical arrows), axons (arrowheads), and pedicles (oblique arrows) of most 
M/L cones in the peripheral retina. Scale Bars: (A1) 40 µm; (A3) 10 µm; (A2, A4, B-D) 
20 µm. 
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cells that are only Goα immunoreactive (Figure 4.5 C1). We confirmed that rod 
bipolar cell dendrites underwent retraction with time, but did not observe a similar 
change in ON-cone bipolar cells (Figures 4.5 C2-C 4). Indeed, even at the latest time-
point examined (40.6 weeks), there was distinct labeling of the dendrites of cone 
bipolar cells that appear as a continuous layer in the OPL (Figure 4.5 C4). 
 Although we tested a variety of antibodies (anti-ChAT, anti-TH, anti-Dab1, 
anti-γ-aminobutyric acid [GABA], see Table 2) reported to label different 
subpopulations of amacrine cells in rodents, we were successful only in detecting 
GABAergic amacrine cells in the canine retina. Labeling of amacrine cell bodies with 
the GABA antibody was limited to the central retina in the normal adult, yet intense 
staining of the IPL laminae was seen throughout the entire retina (Figure 4.5 D1). A 
similar pattern was seen in the mutant retina until 11.9 weeks of age. Thereafter (26 
and 40.6 weeks), there was a significant increase in the number of GABA-
immunoreactive amacrine cells. These were located both at the inner border of the 
INL as well as displaced into the ganglion cell layer (GCL), and they were found all 
along the length of the retina. In addition, there was a thinning of the IPL and a loss of 
its normal lamination (Figures 4.5 D2, D3). The GABA antibody also labeled the 
somas and processes of horizontal cells in the normal canine retina (Figure 4.5 D1). 
This was also observed in young affected retinas until 8 weeks of age. In the 11.9-
week-old mutant retina there was decrease in the intensity of the labeling, and, after 26 
weeks, no staining of any horizontal cell was observed, although it was distinct in the 
normal. (Figure 4.5, compare D1 with D2, D3). 
Because the cellular retinaldehyde-binding protein (CRALBP) antibody that we used 
to examine Müller cells did not label canine retina, we used instead an antibody 
directed against glutamine synthetase. With this antibody, we found a decrease in 
Müller cell length in mutant retinas associated with the thinning of the ONL; however, 
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there was no apparent reduction in their density at 11.9 weeks of age. By 26 weeks of 
age there was a significant reduction in Müller cell immunoreactivity, and by 40.6 
weeks, immunolabeling was almost absent (data not shown). This precluded 
assessment of glial cell loss at later stages of the disease. GFAP immunolabeling was 
used to evaluate the level of glial reactivity in Müller cells. GFAP staining was limited 
to astrocytes and Müller cell end feet in normal retinas of all ages (Figure 4.5 E1) as 
well as in the youngest (3.9 weeks) retina. A gradual increase in GFAP 
immunoreactivity began at 5 weeks and peaked at 8–12 weeks of age (Figure 4.5 E2). 
Minimal GFAP reactivity was seen in older retinas when outer retinal atrophy was 
more advanced (Figure 4.5 E3). 
 
DISCUSSION 
XLPRA2 is a severe canine retinal degeneration of early onset that affects both rods 
and cones. The two nucleotide deletion in RPGR ORF15 causes a frameshift in the 
translation of the putative protein that changes the glutamic-acid-rich ORF15 domain 
to one containing many arginine residues.10 This, presumably, causes a toxic gain of 
function in photoreceptor cells that results in early and severe disease. Although signs 
of disease are detected in both classes of photoreceptor cells before their complete 
maturation, rods start dying at a much earlier stage than do cones. Furthermore, early 
remodeling of the OPL and INL suggest that photoreceptor disease and death alter the 
synaptic connections with inner retinal neurons. 
Evaluation of mutant retinas showed that this was a very early-onset disease 
characterized by visible abnormalities in both rods and cones before their maturation. 
At 3.9 weeks of age, the earliest signs of OS disruption were detectable on 1-µm-thick 
plastic-embedded sections, and mislocalization of rod and cone opsins was seen by 
immunohistochemistry. At this same age, there was clear evidence of rod 
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Figure 4.5:  Inner retina remodeling in XLPRA2. 
(A) Immunofluorescent labeling of horizontal cells with anti-calbindin (green) in 
normal (A1; 12 weeks) and affected (A2, A3) retinas. In the 12-week affected retina 
(A2), the horizontal cell processes were flattened by the narrowing of the OPL. This 
was more evident at 40.6 weeks of age, although there was persistent labeling of the 
horizontal cell somas (A3). DAPI (blue) was used as a nuclear counterstain. 
(B) Immunofluorescent labeling of rod bipolar cells with anti-PKCα (green) in normal 
(B1, 12 weeks) and affected (B2, B3) retinas. (B2) 12-week affected. There was early 
retraction of the dendritic arborization of rod bipolar cells (arrows); (B3) 40.6-week 
affected. Note the almost total loss of dendritic arborization in OPL (arrows). DAPI 
(blue) was used as a nuclear counterstain. 
(C) Double immunofluorescent labeling of ON  bipolar cells with anti-Goα (red), and 
rod bipolar cells with anti-PKCα (green) in the normal (C1, 12 weeks) and affected 
(C2, C3, C4) retinas. Rod bipolar cells were colabeled with both Goα and PKCα and 
appear yellow-orange, whereas ON cone bipolar cells were only labeled with Goα and 
appeared red; (C1) 12-week normal. Note the extensive yellow-orange dendritic 
arborization of rod bipolar cells (arrowheads), and just below, the dendrites of ON 
cone bipolar cells that form a continuous red layer (arrows). (C2) 12-week affected. 
Note the shortening of the rod bipolar cell dendrites (arrowheads) in comparison to 
the age-matched normal. (C3) In a 26-week affected retina, there was an overall 
decrease in PKCα immunoreactivity in rod bipolar cells and a significant retraction of 
their dendritic arborization (arrowheads). (C4) In a 40.6-week affected retina, there 
was weak labeling of rod bipolar cell somas and axons with PKCα and complete 
retraction of dendrites. There was persistence of Goα-IR in rod bipolar and ON cone 
bipolar cells, as well as the presence of the cone bipolar cell dendrites (arrows). 
(D) Immunofluorescent labeling with anti-GABA in normal (D1, 24 weeks) and 
affected (D2, D3) retinas. (D1) GABA-IR was present in the mid-peripheral retina in 
several laminae of the IPL and in horizontal cells (arrowheads) and their processes. 
There was no labeling of amacrine cells, other than in the central region of the normal 
retina. (D2) 26 week affected midperipheral retina. There was loss of the IPL 
lamination, but increased immunoreactivity of putative amacrine cells located at the 
vitreal border of the INL and displaced in the GCL (arrows). There was also loss of 
horizontal cell labeling. (D3) In a 40.6 week affected mid peripheral retina, IPL 
thickness was significantly reduced, and GABA-IR was increased in amacrine cells 
(arrows). 
(E) Immunofluorescent labeling of Müller cells with GFAP (red) in normal (E1, 12 
weeks) and affected (E2, E3) retinas. (E1) 12-week normal. GFAP labeling was weak 
and limited to astrocytes and Müller cell end feet (arrow). (E2) In a 12-week affected 
retina, intense GFAP-IR was present throughout the entire length of Müller cells. (E3) 
In a 40.6-week affected, GFAP labeling was almost absent. Scale Bars: 20 µm.
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photoreceptors undergoing cell death. We confirmed that this differed from the normal 
developmental cell death process, which was found at 2 weeks of age in both normal 
and mutant retinas (data not shown). In the mutant retina the number of TUNEL-
labeled photoreceptor cells was significantly higher than in age-matched control 
subjects. Over the ensuing weeks, there was an increase in the proportion of TUNEL-
labeled photoreceptors that resulted in a peak of cell death between 6 and 7 weeks. 
After this early burst of cell death, the rate was significantly decreased after 12 weeks 
of age. Our findings are similar to that reported in the Rdy cat, a model of autosomal 
dominant rod/cone dysplasia, in which an early onset of photoreceptor death begins at 
5 weeks of age and peaks at about 9 weeks of age.22 Our results clearly suggest that 
the risk of death in a single photoreceptor cell is not the same at all ages and that the 
mathematical model of a constant or decreasing risk of photoreceptor  death, as 
suggested by Clarke et al.17, may not be applicable to this class of RPGR mutations, at 
least during the initial course of the disease. 
 Although the data on the ONL thickness (Figure 4.2, Table 4.4) are best fit 
with an exponentially declining curve that would be consistent with the kinetics of a 
constant or decreasing risk of photoreceptor death in XLPRA2, the TUNEL data 
(Figure 4.3) do not support this model. We saw (Figure 4.3) two distinct phases of cell 
death. An initial phase, from 3.9 to 7 weeks of age, showed an increased risk for 
photoreceptors to die (peak of TUNEL-positive cells at 6 to 7 weeks of age). This was 
followed by a second phase of rapid (from 7 to 12 weeks) and then a more gradual 
decrease (after 12 weeks) in the number of TUNEL-positive cells per unit area of 
ONL. It is therefore possible that the limited number of observations between 3.9 and 
7 weeks of age fails to show an early sigmoidal decline in photoreceptor cell number, 
which we would have expected to observe with an increased risk of cell death. This 
initial phase of photoreceptor death does not appear to be unique to XLPRA2. Indeed,  
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a group of investigators used TUNEL assay to look at the kinetics of cell death in the 
rd mouse and recorded a similar increase in photoreceptor death that reached its peak 
by 16 days of age.34 Not surprisingly, in their study, Clarke et al. reported that the rd 
mouse was the only animal model for which an increased risk of cell death could not 
be excluded, since the data fit equally well to mathematical models of constant and 
exponentially increasing risk.17,35 
 Several hypotheses may explain this biphasic pattern of cell death in XLPRA2: 
(1) the coexistence of two populations of photoreceptor cells that differ in their 
response to a same death stimulus. (2) the existence of a single population of 
photoreceptors that acquire an increased resistance to death after the early 
degeneration of some cells. Supporting this hypothesis is evidence for the endogenous 
release of survival factors (bFGF, CNTF) in the degenerating retina that protect the 
remaining photoreceptors from undergoing cell death36,37; and (3) the existence of a 
single population of photoreceptors that is affected at different ages by two distinct 
cell death stimuli. Based on the toxic gain-of-function hypothesis as being causal to 
the disease mechanism,10 it may be that during photoreceptor maturation, rods are 
particularly sensitive to the toxicity of the mutant RPGR protein. This may lead to a 
burst of rod photoreceptor death, the release of survival factors, and the acquired 
resistance of the remaining photoreceptors to the endogenous mutant toxic protein. 
The second phase of death, after 12 weeks of age, could then be the result of either an 
incomplete resistance to the toxic mutant RPGR protein, or of sensitivity to the 
absence of the normal isoform. In this case, photoreceptor cells may be dying through 
a mechanism caused by the loss of function of the normal RPGR retinal isoform. If 
such is the case, this may open the possibility of rescuing photoreceptor cells that have 
survived the first phase of cell death in XLPRA2 through a gene replacement approach. 
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 The mislocalization of opsins in both rods and cones at the early stages of the 
disease suggests that RPGR is expressed in both populations of photoreceptors, and 
lends additional support to the hypothesis that RPGR is involved in the trafficking of 
proteins from the IS to the OS, or in their retention in the OS.13 A similar 
mislocalization of both rod and cone opsins has been reported recently in a human 
carrier (Adamian M, et al. IOVS 2005;46:ARVO E-Abstract 3400), yet, in the mouse, 
only cone opsins appear to mislocalize.8  In the present study, we found early signs of 
cone disease both in plastic-embedded sections and in cryosections treated for 
immunohistochemistry; however, we did not detect any features of cone cell death 
before the age of 26 weeks. This raises the question of whether the mechanism of cone 
death is directly caused by the RPGR mutation or is non-cell-autonomous and 
secondary to rod degeneration. In animal models of retinitis pigmentosa caused by 
mutations in rod-specific genes, the delayed cone loss is thought to be caused by the 
death of rods that induces structural alterations in the photoreceptor layer and ONL, 
the release of toxic by-products, and/or a decrease in the secretion of cone survival 
factors.38,39 
 Contrary to implications of the results in immunocytochemical studies on 
human retinas with advanced stages of retinitis pigmentosa,23,40 inner retinal 
remodeling is not, at least in the dog, a late response to photoreceptor degeneration. 
Our observations showed that synaptic connectivity in the OPL was altered at early 
stages of the disease. Rod neurite sprouting was first apparent within 1 to 2 weeks 
after the peak of photoreceptor cell death that occurred at approximately 7 weeks of 
age. Although this is the first report of rod neurite sprouting in the canine retina, it has 
been observed in two other animal models of retinitis pigmentosa: the rhodopsin 
transgenic pig,41 and the Rdy cat with autosomal dominant rod/cone dysplasia.22 
Neurite sprouting of cones has been described in the rd mouse as an early-onset 
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change that starts at P8, when rod degeneration begins.42 Neither this abnormality, nor 
elongation and branching of cone axons as previously described in humans40 were 
observed in the XLPRA2 retina at any studied age, but these changes may occur in 
much older animals with more advanced disease. Concomitant to the onset of rod 
neurite sprouting, there was a loss in synaptophysin immunoreactivity of the OPL as 
early as 7.9 weeks of age. This illustrates the possible rapid and early disorganization 
in synaptic connectivity that could seriously hamper retinal function at a stage of 
disease when photoreceptor loss is limited. 
 Another early change that occurred throughout the entire thickness of the 
neuroretina was the increased reactivity of Müller cells. An increase in GFAP labeling 
of Müller cells occurred approximately two weeks before the peak of photoreceptor 
cell death and reached its highest level in the following weeks. These glial cells, which 
somas are located in the INL, have apical radial processes extending to the external 
limiting membrane (ELM). It is therefore possible that Müller cells detect early 
structural or chemical modifications in the photoreceptor layer and/or ONL caused by 
the degeneration of photoreceptor cells and relay this change in the outer retina 
environment to deeper retinal layers. GFAP reactivity in Müller cells had decreased at 
26 weeks of age and was like normal by 40.6 weeks. These findings are different from 
those reported in human retinas with advanced disease where GFAP reactivity 
persists.43 This difference may be explained by the fact that we did not collect retinas 
from the very advanced stages of disease. Thus, it may be that GFAP reactivity in 
Müller cells occurs both at the onset of photoreceptor degeneration and during the 
terminal stages of retina atrophy. 
 After these early changes in the inner retina, there was progressive retraction of 
rod bipolar cell dendrites that began by approximately 12 weeks of age. Contrary to 
what had been described in the rd mouse,44 rod bipolar cells developed dendritic 
 138
arborizations. This may be because in XLPRA2, unlike in the rd mouse, most 
photoreceptor cells reach a stage of functional and structural maturation, albeit 
abnormal, that allows the formation of synapses with second-order neurons. We did 
not observe any significant loss in the arborization of ON-cone bipolar cells, as occurs 
in the rd mouse at later stages of the disease, when cones undergo cell death.25 The 
most probable explanation of this difference is that, at the latest time point that we 
examined ON-cone bipolar cells (40.6 weeks), there was still a significant number of 
cone photoreceptors in the ONL that had not degenerated. This may suggest that the 
cone-mediated pathway remains functional at more advanced stages of the disease. 
Although more extensive electroretinographic testing is needed to verify this 
hypothesis, our previous study has shown the presence of robust cone signals at a time 
when there is significant loss of rod-mediated responses.10 
 Information on the histopathologic changes that occur in retinas of human 
patients with RPGR exon ORF15 mutations has currently only been reported in a 
carrier.12 Yet, it appears that frameshift mutations in RPGR exon ORF15 have a 
comparably severe phenotype in both canine and human retinas. 
The findings reported in this study have several important implications for the 
development of therapeutic approaches for retinal degeneration in humans. Among 
these, the use of survival factors (e.g., ciliary neurotrophic factor [CNTF] and brain-
derived neurotrophic factor [BDNF]) as well as a gene-silencing approach, via 
ribozymes or siRNA, are currently being investigated in our laboratory. The results of 
this present study suggest that a first strategy should consist in initiating therapy 
before the burst of photoreceptor cell death that occurs in the dog between 6 and 7 
weeks of age. Delivering the therapeutic agent at approximately 4 weeks of age may 
prevent or delay the onset of photoreceptor degeneration. Intraocular injection of 
survival factors that are immediately biologically active is feasible at such a young 
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age. Alternatively, another potential strategy would be to target the rescue of the 
photoreceptor cells that survived the initial burst of cell death. Indeed, we have shown 
that after this event, the rate of cell death is considerably slowed down, and that even 
in the most advanced stages of disease, the morphology of the remaining 
photoreceptor cells is reasonably preserved. We have observed that some 
photoreceptors maintain their IS and OS and continue to express proteins involved in 
the phototransduction pathway unlike what has been reported in humans with more 
advanced retinitis pigmentosa caused by rhodopsin gene mutations.30 From this 
perspective, 12 weeks of age may be an optimal time-window to initiate therapy 
because, at that age, approximately 60% of photoreceptor cells remain. 
 Another important aspect that future studies should address is whether rescuing 
photoreceptor cells also allows reversal of inner retinal changes that occur secondary 
to rod and cone disease and degeneration. Modification of the inner retina after 
photoreceptor degeneration does not appear to be dependent on the genetic cause of 
the disease. Indeed, in addition to the two-nucleotide deletion in RPGR ORF15 that 
occurs in the XLPRA2 dog, recent studies have shown inner retina remodeling in the 
rd and crx-/- mice, two models of retinal degeneration caused, respectively, by a 
mutation in the PDE6B and CRX genes.24,44 In addition to these morphologic changes, 
a switch in neurotransmitter sensitivity of rod bipolar cells has been demonstrated in 
the rd mouse.45 All these recent findings suggest, that if a similar phenomenon occurs 
in the human with early stages of retinal degeneration, then novel therapeutic 
approaches must to be evaluated not solely on their protective effect on photoreceptor 
cells, but also on their capacity in maintaining functional synaptic connections 
between photoreceptor cells and inner retinal neurons. 
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 In conclusion, we have characterized the structural changes that occur in the 
XLPRA2 retina, an early-onset canine model of X-linked retinitis pigmentosa caused 
by a microdeletion in RPGR exon ORF15 with resultant frameshift. This is a valuable 
spontaneous animal model that may provide a better understanding of the retinal 
function of the RPGR protein and the pathogenic mechanisms that lead to 
photoreceptor death. It also may provide a tool to assess the in vivo efficacy of novel 
therapies. 
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CHAPTER FIVE 
 
CILIARY NEUROTROPHIC FACTOR (CNTF) FAILS TO 
RESCUE PHOTORECEPTORS AND CAUSES PERIPHERAL 
REMODELING IN RPGR MUTANT RETINA. 
 
INTRODUCTION 
Retinitis pigmentosa (RP) is a genetically heterogeneous group of diseases that 
constitutes one of the leading causes of blindness worldwide, with an incidence of 
approximately 1: 4,000.1,2 Despite the identification over the past 20 years of more 
than 50 genes responsible for RP (http://www.sph.uth.tmc.edu/Retnet/), currently there 
is no treatment available that can either prevent, or slow-down the course of 
photoreceptor cell death. A promising therapeutic approach, for which proof of 
principle has been demonstrated in various animal models, is the use of corrective 
gene therapy.3,4 Yet, such a strategy requires the identification of the mutated gene, 
and is therefore aimed at targeting diseases in a gene-specific manner.  
 An approach that could potentially bypass the inherent limitation of gene-
based therapy is the use of neuroprotective agents that can rescue photoreceptors 
regardless of the genetic and/or environmental causes of the retinal degeneration. Over 
the past 15 years, numerous survival factors have been tested in a variety of animal 
models of RP (e.g. see 5-7). Among these agents, ciliary neurotrophic factor (CNTF) 
has been shown to rescue photoreceptors in several rodents and large animal models 
(for review see 8). Because of the inability for CNTF to cross the blood-retina barrier 
following systemic administration, the necessity for sustained bioavailablity of the 
agent in the eye, and the ocular side-effects associated with bolus intravitreal injection, 
a long-term intraocular delivery system has been developed.9 This encapsulated cell-
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based  technology (ECT) allows for the continuous release of small quantities of 
CNTF into the vitreous, and was evaluated in experimental animal models,10,11 and 
more recently in Phase I clinical trial in humans.12  
 Previous work has shown that CNTF delivered through intravitreal injections 
(Pearce-Kelling, unpublished study), or by means of an ECT device,10 rescues 
photoreceptors in the rcd1 dog, an early and rapidly progressing large animal model of 
RP caused by a stop mutation in PDE6B. The purpose of the present study was to 
determine whether intravitreal injections of recombinant human CNTF could provide 
a similar neuroprotective effect in XLPRA2, an early onset model of X-linked RP 
caused by a frameshift mutation in RPGR exon ORF15.13 Recently, we reported the 
morphologic retinal changes, and the  kinetics of photoreceptor cell death, that occur 
during the course of this disease.14 Death of rods occurs in a biphasic manner, 
beginning as early as 4 weeks of age, and reaching a peak at 6-7 weeks. Following this 
initial burst, the rate of cell death is considerably slowed down, yet persists at an 
approximately constant rate for at least 9 months. 
Based on these findings, the initial phase of cell death was selected as a time-
window to evaluate the neuroprotective effect of CNTF. Results show that intravitreal 
injections of CNTF at the onset and/or peak of cell death do not provide any 
significant rescue in XLPRA2, but cause prominent remodeling in the peripheral retina.   
 
METHODS 
Expression and purification of recombinant CNTF protein 
The open reading frame of human CNTF cDNA was PCR-cloned into the pQE30 
expression vector (Qiagen, Valencia, CA), and fused to a 6x His tag at the amino-
terminus to generate plasmid pQE-CNTF. Recombinant human CNTF protein was 
expressed in E. coli (XL-blue, Stratagene, La Jolla, CA), and purified by immobilized-
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metal affinity chromatography on Ni-NTA Agarose columns (Qiagen) under native 
conditions. Eluted protein was buffer-exchanged to phosphate buffered saline (PBS), 
and the protein concentration determined by the BCA protein assay (Pierce, Rockford, 
IL). The CNTF solution was then diluted with PBS to a concentration of 0.4 µg/µl, 
sterile filtered (Acrodisc Syringe filter 0.2 µm, Pall Corporation, Ann Harbor, MI), 
and aliquots of 30 µl (12 µg) were stored at -80°C.  
 
Animals  
A total of 16 affected XLPRA2, 3 affected rcd1, and 1 non-mutant dog was used for 
this study. All animals were bred and housed at the Retinal Disease Studies Facility 
(RDSF, University of Pennsylvania, New Bolton Center, Kennett Square, PA). Their 
genotype was determined either from the known status of their progenitors, or from 
genetic testing for the disease-causing mutation.13,15 All animals underwent an initial 
ocular examination that confirmed the absence of clinically evident abnormalities. 
Twelve XLPRA2 dogs were used to evaluate the neuroprotective effect of CNTF on 
photoreceptors, and the animals were allocated to one of the following treatment 
groups: 
• Treatment Group #1 (n = 3): one single injection of CNTF at 4 weeks of age (see 
below), termination at 8 weeks of age (Inj. 4wk; Ter. 8 wk). 
• Treatment Group #2 (n = 3 ): injection of CNTF at 4 and 8 weeks of age, termination 
at 12 weeks of age (Inj. 4 & 8 wk; Ter. 12 wk). 
• Treatment Group #3 (n = 3): injection of CNTF at 7 and 10 weeks of age, termination 
at 14 weeks of age (Inj. 7 & 10 wk; Ter. 14 wk.). 
• Treatment Group #4 (n = 3 ): one single injection of CNTF at 12 weeks, termination 
at 15.6 weeks of age (Inj. 12 wk; Ter. 15.6 wk). 
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As positive controls for the biological activity of CNTF, we treated 3 rcd1 dogs (rcd1 
control goup) following a protocol that achieves photoreceptor rescue in this model 
(CNTF injection at 7 and 10 weeks of age, termination at 14 weeks of age). This work, 
reported in abstract form but never published, served as a basis for choosing the dose 
of CNTF that was administered in this study, and was evaluated in XLPRA2 dogs 
(treatment Group #3). A single non-mutant dog also was treated in the same way to 
verify whether any potential CNTF-mediated biological effects are disease-specific, or 
also occur in the physiologically normal retina. 
 Because we observed marked peripheral remodeling in the retinas of XLPRA2 
dogs treated with CNTF, a separate set of studies was carried out to further 
characterize these alterations. For this, 4 affected XLPRA2 dogs were used following 
protocols detailed below (see under “Histologic procedures”, and “Cell proliferation 
assays” sections). 
All intravitreal injections were performed in eyes that had their pupils 
previously dilated by topical application of atropine, phenylephrine and tropicamide. 
Under general anesthesia (isoflurane), dogs underwent a 1 minute massage of their 
globes to reduce the intraocular pressure (IOP). A 29-gauge needle mounted on an 
insulin syringe was then inserted in the supero-temporal quadrant approximately 5 mm 
behind the limbus, and the tip was directed towards the center of the vitreous to inject 
in the left eye (OS) 12 µg of CNTF in 0.1 M PBS (Total volume injected:30 µl). The 
right eye (OD) served as a control, and was injected with 30 µl of the PBS diluent. 
Immediately following the injections, both eyes were examined by slit-lamp 
biomicroscopy and indirect ophthalmoscopy to verify that no lesions were caused to 
the lens and/or retina during the procedure. All animals underwent additional ocular 
examinations 2-4 days following the intravitreal injections and subsequently, at least 
once a week, for the remaining of the treatment period. This included IOP 
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measurements by applanation tonometry (TonoPen XL, Medtronic Ophthalmics, 
Jacksonville, FL). At the end of the treatment period, the animals were euthanatized 
by intravenous injection of pentobarbital sodium, enucleated, and the eyes processed 
as indicated below. All procedures involving animals were done in compliance with 
the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 
 
Histologic procedures 
The eyes of the 16 dogs (12 XLPRA2, 3 rcd1, 1 non-mutant) used in the assessment of 
CNTF’s photoreceptor rescue effect were processed after enucleation as previously 
published.14 A slit was made at the level of the ora serrata, and the entire globe was 
fixed for 3 hours in 4% paraformaldehyde in 0.1 M PBS at 4°C. The posterior segment 
was isolated and fixed for an additional 24 hours at 4°C in 2% paraformaldehyde. The 
tissue then was trimmed into four pieces that extended from the optic disc to the ora 
serrata along the superior, inferior, nasal, and temporal meridians. Following 
sequential cryoprotection for 24 hours in solutions of 15% and 30% sucrose in PBS at 
4°C, the tissues were embedded in optimal cutting temperature (OCT) medium. 
Cryosections were cut at 7 or 10 µm thickness, air-dried, and stained with hematoxylin 
& eosin (H&E), or used for immunohistochemistry (see below). The anterior segments 
of some animals were post-fixed in Bouin’s solution, and paraffin embedded. Paraffin 
sections were cut at 6 µm thickness, H&E stained, and used to examine the pathology 
in the cornea, iris and lens. 
 Retinal cryosections stained with H&E were examined by light microscopy 
(Axioplan; Carl Zeiss Meditec GmbH, Oberkochen, Germany) in contiguous fields 
extending from the optic disc to the ora serrata with 10X and 40X objectives. For 
each animal, quantitative evaluation of the outer nuclear layer (ONL) thickness was 
done on sections from the 4 meridians of both eyes at 3 specific locations: S1, 2000 ± 
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500 µm from the optic disc; S3, 2000 ± 500 µm from the ora serrata; and S2, midway 
± 500 µm between these 2 points. At each of these sites, the number of rows of nuclei 
in the ONL was counted in at least 3 representative areas and averaged. The field that 
was viewed with the 40X objective covered a retinal length of 290 µm. Significant 
alterations in the ONL, that included an abnormal increase in thickness, were observed 
in the retinal periphery of CNTF-injected eyes. Since these changes frequently 
involved and extended beyond site S3, we excluded ONL data collected at this site, 
and restricted the analysis of photoreceptor rescue to the central (S1) and mid-
peripheral (S2) regions of the retina. For each quadrant, the average ONL thickness 
(mean of ONL thickness at S1 and S2) was calculated, and compared to that of the 
contralateral eye. The paired Student t-test was used to analyze the differences in ONL 
thickness between the CNTF- and the PBS-injected eyes. Statistical analysis was 
performed using a commercial software (Statistix 8; Analytical Software, Tallahassee, 
FL). 
 To better characterize the peripheral retinal alterations observed following 
CNTF treatment, and determine the cause of the increase in ONL thickness, we 
examined in semi-thin plastic sections the retinal morphology of two additional 
XLPRA2 dogs that were injected intravitreally with CNTF. One dog was treated 
following the same protocol as for Group #1 (Inj. 4 wk, Ter. 8 wk); the second dog 
received the same treatment as Group #2 (Inj. 4 & 8 wk; Ter 12 wk). Eyes were 
collected, fixed, and trimmed as described above, and processed for epoxy resin 
embedding as previously reported.14 Retinal sections extending along all 4 meridians 
were cut at 1 µm with glass knives using a supercut microtome (Reichert Jung model 
2065; Leica, Deerfield, IL), and stained with azure II-methylene blue with or without 
paraphenylenediamine counterstain. For each meridian, the site of highest ONL 
thickness in the peripheral retina of the CNTF-injected eyes was located, and its 
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distance from the ora serrata measured. This was used to locate the corresponding site 
in the contralateral PBS-injected eye. Using the 40X objective, digitally captured 
images (Spot 4.0 camera; Diagnostic Instruments, Inc., Sterling Heights, MI) that 
encompassed a 290 µm length of retina, were printed to manually count the total 
number of photoreceptor nuclei at these two sites. For each meridian, the counts were 
performed in triplicate on sequential sections, and the values averaged. 
 
Immunohistochemistry 
Fluorescence immunohistochemistry on 7 or 10 µm thick retinal cryosections of dogs 
from all four treatment groups was used to examine CNTF-mediated modifications 
with cell-specific markers. Cryosections were air-dried, blocked in a solution 
containing 10% normal serum from the appropriate species, and incubated overnight 
at 4°C with the primary antibody.  Primary antibodies used in this study are listed in 
Table 5.1. Species-specific secondary antibodies conjugated to fluorochromes (Alexa 
Fluor, Invitrogen, Carlsbad, CA, 1: 200 dilution) were then applied to the sections for 
1 hour. The antibodies were used at the appropriate dilution in 1.5% normal serum, 
0.25% Triton X-100, 0.05% sodium azide in PBS. DAPI stain was used to label cell 
nuclei. Slides were mounted with a medium composed of polyvinyl alcohol and 
DABCO (1,4 diazabicyclo-[2.2.2]octane) (Gelvatol; Sigma-Aldrich, St. Louis, MO), 
and examined with an epifluorescence microscope (Axioplan; Carl Zeiss Meditec). 
Digitally captured images were imported into a graphics program (Photoshop; Adobe, 
Mountain View, CA) for display. When double fluorescence immunohistochemistry 
was done, primary antibodies (followed by their secondary) were applied sequentially.  
 In order to determine whether the α subunit of the CNTF receptor (CNTFRα) 
is expressed in normal and mutant photoreceptors during postnatal retinal maturation, 
as well as during the course of retinal degeneration, archival collections of normal and 
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Table 5.1 List of primary antibodies used. 
 
 147
Antigen Host Source, catalog # or name Working 
concentration 
Specificity 
 
Rod opsin Mouse monoclonal Paul Hargrave, R2-12N 1:300 OS of rods 
Rod opsin Mouse monoclonal IgG1 Chemicon, MAB5316 1:1,000 OS of rods 
Human cone arrestin Rabbit polyclonal Cheryl Craft, LUMIF 1:10,000 Cone photoreceptors 
Protein Kinase C (PKCα) Mouse monoclonal IgG2b BD Biosciences, 610107 1:100 Rod bipolar cells 
Goα Mouse monoclonal IgG1 Chemicon, MAB3073 1:5,000 ON (rod and cone) bipolar cells 
Calretinin Rabbit polyclonal Sigma, C7479 1:500 Horizontal, amacrine, ganglion cells
CRALBP Rabbit polyclonal John Saari  1:1,500 Müller cells, RPE 
Glial fibrillary acidic protein (GFAP) Rabbit polyclonal DakoCytomation, Z0334 1:1,000 Astrocytes, Müller cells (reactive) 
CNTFRα Rabbit polyclonal Hermann Rohrer 1:2,000 IS of rods & cones, INL, GCL 
Bromodeoxyuridine (BrdU) Mouse monoclonal IgG1 Chemicon, MAB4072 1:100 Cells that have incorporated BrdU 
Ki67 Mouse monoclonal IgG1 
 
BD Biosciences, 550609 
 
1:20 Proliferating cells 
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mutant retinas developed by our lab were used. These included retinas of normal, 
rcd1, and XLPRA2 dogs (age: 4-24 weeks); some of these tissues have been used in 
previous studies.14 Enzymatic immunohistochemistry was performed on 7 µm thick 
cryosections from the superior meridian of these retinas as previously described.16 A 
rabbit protein A-purified polyclonal antibody raised against a large fragment of the 
chicken CNTFRα recombinant protein (1:2,000 dilution; kindly provided by H. 
Rohrer)17 was used for this study. This antibody cross reacts in the dog as well as in 
other mammalian species.16,18 
 
Cell proliferation assays 
To determine whether the increase in ONL thickness in the retinal periphery could be 
explained by a proliferative event, we conducted BrdU pulse-labeling experiments in 
two XLPRA2 dogs. At 4 weeks of age both dogs were anesthetized with isoflurane 
and injected intravitreally in the left eye with 30 µl of a 0.1 M PBS solution containing 
12 µg of CNTF and 10 µg of 5-Bromo-2’-Deoxyuridine (Sigma, St-Louis, MO); the 
contralateral eye was injected with 30 µl of a 0.1 M PBS solution containing 10 µg of 
BrdU. The dose of BrdU injected was extrapolated from the dose used in chick eyes.19 
Twenty four hours later, one dog was euthanatized and the eyes processed as 
described below. The second dog was re-injected under isoflurane anesthesia in both 
eyes with 30 µl of a 0.1 M PBS solution containing 10 µg of BrdU at 24 and 96 hours 
following the initial injection. At 5 weeks of age, this animal was killed, and the eyes 
collected. Following enucleation, the anterior and posterior segments were separated 
and the vitreous was gently removed from the posterior eyecup. The tissues were then 
fixed for 30 min in 4% paraformaldehyde with 3% sucrose in 0.1 M PBS at 4°C. 
Following three washes in PBS, tissues were cryoprotected, trimmed and embedded in 
OCT as described above. Immunohistochemical detection of BrdU incorporation was 
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done on 7 µm thick cryosections that were pretreated in 4 M HCl for 10 min, followed 
by overnight incubation with the primary monoclonal anti-BrdU antibody (see Table 
5.1). BrdU-positive cells were counted throughout the entire length (i.e. from optic 
disc to ora serrata) on a least three retinal sections for each of the superior, inferior 
and temporal meridians.  Values for each meridian were averaged and expressed as the 
number of BrdU-positive cells per unit length of retina. The unit length was set at 
10,000µm. Expression of the nuclear cell proliferation marker Ki67 (see Table 5.1) 
was also examined in the retinas of these two dogs by immunohistochemistry.  
 
RESULTS 
Clinical findings and CNTF-mediated side effects. 
Ocular examinations performed immediately after the intravitreal injections did not 
reveal any lesions caused by the procedure. Yet, several ocular abnormalities were 
visible clinically within a few days following intravitreal injection of CNTF in both 
XLPRA2 and rcd1 dogs (Table 5.2). None of these changes were seen in any of the 
PBS-injected eyes. Therefore, the following description only applies to the CNTF-
treated eyes. 
Clinical signs of uveitis were the first to appear, and consisted mainly of miosis, 
intraocular hypotension, and occasional iridal changes (see below). Aqueous humor 
flare was not detected by slit lamp biomicroscopy during the first week following the 
injection. Later, examination of the aqueous humor transparency was hampered by 
development of corneal haze (see below). Miosis that was refractory to dilatation with 
topical mydriatics was seen in all dogs that were reexamined 2 days after the first 
CNTF injection, and persisted for approximately 2 weeks. 
In 2 XLPRA2 dogs (treatment Group # 4) that had lightly pigmented irides, 
vascular engorgement was seen 48 hours following injection. Anterior displacement of 
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Table 5.2 Summary of clinical findings observed in eyes following intravitreal injection with CNTF (OS) or PBS (OD). 
Numbers for each category reflect the number of dogs affected in each treatment group. 
 
 
   Group 1   Group 2   Group 3   Group 4   rcd1 control 
Clinical observations 
OD 
(n = 3) 
OS 
(n = 3)   
OD 
(n = 3) 
OS 
(n = 3)   
OD 
(n = 3) 
OS 
(n = 3)   
OD 
(n = 3) 
OS 
(n = 3)   
OD 
(n = 3) 
OS 
(n = 3) 
                              
Miosis           
              
               
               
               
              
0 3  0 3  0 3  0 3  0 3
Iris vascular congestion 0 0 0 0 0 0 0 2 0 0
Iris hyperpigmentation 0 3 0 3 0 0 0 0 0 0
Intraocular hypotension 0 3 0 3 0 3 0 3 0 3
Corneal epitheliopathy
 
0 3 0 3 0 3 0 3 0 3
Cataract 0 3 0 3 0 3 0 2 0 3
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the iris, causing a reduction in anterior chamber depth, was also seen 2 days post-
injection in 2 rcd1 dogs. An increase in iris pigmentation was observed in 1 dog 
(treatment Group #3), and in 3 dogs from (treatment Group #2), respectively, at 17 and 
51 days after the 1st injection of CNTF. Combined IOP values of XLPRA2 (all 
treatment groups) and rcd1 dogs, measured between post-injection days 2-4, were 
significantly lower (P<0.0001, paired Student t test) in CNTF- injected (mean: 7.1 mm 
Hg , min:4 mm Hg, max: 12 mm Hg; n= 15) versus PBS-injected (mean: 13.5 mm Hg, 
min:8 mm Hg, max:22 mm Hg; n= 15) eyes. All CNTF-injected eyes were 
hypotensive (IOP < 8 mm Hg, or IOP at least 5 mm Hg lower than in the PBS-treated 
eye) after the first or second injection.  A steep decrease in IOP was seen during the 
first 4-7 days following CNTF injection, but values returned to pre-injection levels 
within 20 days. In PBS-injected eyes, a slight increase in IOP occurred that remained 
within normal levels (19.2 ± 5.9)20 was observed for 10-14 days following injection. 
Similarly, IOP values returned to pre-injection values within approximately 20 days. 
Figure 5.1 illustrates the IOP changes observed in a subset of the experimental dogs. 
Corneal epithelial abnormalities were observed by external and slit-lamp 
examination in 15/16 of the eyes injected with CNTF (Figure 5.2 A). Discrete lesions 
that caused a hazy patch in the corneal epithelium could be observed in some animals 
as early as 3-4 days following CNTF injection. By post-injection day 11, the corneal 
epithelial haze was present in all 15 affected animals. These epithelial changes 
progressed with time, and could involve more than 75% of the corneal surface.  
However, a peripheral band located in the superior part of the cornea was 
never affected, and remained optically clear. The lesions persisted throughout the 
entire treatment period, and were never associated with corneal ulceration. 
Histological examination revealed thinning of the epithelium with attenuation of the  
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Figure 5.1 Values (mean, and range) of intraocular pressure in CNTF- and PBS-
treated eyes. Data is provided for XLPRA2 (n=3), and rcd1 (n=3) dogs that were 
injected at 7 and 10 weeks of age. Pre-injection values of intraocular pressure are 
indicated at time 0. In the days following both CNTF injections a decrease in IOP was 
observed. The intraocular hypotension was transient, since IOP values returned to pre-
injection values within approximately 20 days. 
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Figure 5.2 Ocular lesions caused by intravitreal injection of CNTF. (A) Corneal epithelial haze (arrowheads), and posterior 
subcapsular cataracts (arrows) 7 weeks post-injection. A corneal haze and sutural cataract had been detected in this dog 11 days 
following the first CNTF injection. (B) The earliest lens changes involved the extremities of the posterior Y sutures (arrows). (C) 
Immature cataract with anterior and posterior cortical opacification. 
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basal and suprabasilar (wing) cell layers (Figure 5.3 A, B). No corneal abnormalities 
were observed in any of the PBS-injected eyes. 
Cataracts were commonly observed following CNTF injection (15/16 eyes). 
Examination of the lens was hampered during the first 2 weeks by the intense miosis 
and difficulty in fully dilating the pupil. By post-injection day 14, posterior sutural 
cataracts could be observed in CNTF-injected eyes of XLPRA2 (8/12 eyes), rcd1 (3/3 
eyes), and non-affected (1/1 eye) dogs (Figure 5.2 B). Cataracts often progressed by 
involving the posterior and anterior cortex (Figure 5.2 C). Histological examination of 
some cataractous lenses confirmed the predominant involvement of the posterior 
suture lines and cortex (Figure 5.3 C, D). No lenticular opacities were detected in any 
of the PBS-injected eyes. 
A thorough funduscopic examination was difficult to conduct in the CNTF-
injected eyes, initially because of the associated miosis, and later on due to the loss of 
transparency of the ocular media caused by corneal epitheliopathy and lens opacities. 
In those animals in which areas of the fundus were visible, no abnormalities were 
detected. One exception was seen in the non-mutant control dog that had multiple 
small “doughnut” shaped foci scattered throughout both the tapetal and non-tapetal 
regions of the fundus (data not shown). Although this was an isolated observation in 
this study, we saw a similar type of lesion in a normal dog injected with a similar dose 
of CNTF in a previous pilot study. 
 
Lack of photoreceptor rescue in XLPRA2 with CNTF 
The average ONL thickness in each quadrant was determined as a means of assessing 
the photoreceptor survival effect of CNTF. Using this measure, there was no 
statistically significant difference in any of the 4 treatment groups between the CNTF 
and PBS-injected eyes (Figure 5.4 and 5.5). The mean difference in ONL thickness of 
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Figure 5.3 Histological lesions of the cornea and lens present after intravitreal injection of CNTF. (A) Normal aspect of the corneal 
epithelium in a PBS-injected eye. Note the presence of normal basal cells (arrows). (B) Cornea of the contralateral eye that was 
injected with CNTF. Note the thinning of the corneal epithelium due to the loss of the basal and suprabasilar (wing) cells. (C) 
Cataract caused by CNTF. Swelling and disorganization of lens fibers was observed in the posterior cortex, and was associated 
with the retention of lens fiber nuclei (arrows). (D) High magnification of the posterior subcapsular region of the same lens as in 
(C). Note the presence of large vacuoles that contain eosinophilic material (asterisks), and swollen lens fibers. H&E stain; scale 
bars: (A, B) 20 µm; (C) 80 µm; (D) 40 µm. 
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0.79 rows of nuclei (Group #1: 0.98 ± 0.52; Group #2: 0.77 ± 0.69; Group #3: 0.94 ± 
0.63; Group #4: 0.48 ± 0.51) between the CNTF versus PBS-treated eyes also was not 
biologically relevant. Based on the kinetics of photoreceptor cell loss,14 a difference of 
at least 2 rows of nuclei (treatment Groups #1 and #3), 3 rows of nuclei (Group #2), 
and 1 row of nuclei (Group #4), would have been expected in both the superior and 
inferior meridians if CNTF had caused a complete rescue of photoreceptors from the 
time of the first injection. Further confirming the absence of any significant 
neuroprotective effect of CNTF in the XLPRA2 retina was the presence of 
morphological alterations at the level of the photoreceptor inner (IS) and outer (IS) 
segments that were characteristic of progression of the disease. Disruption of the OS, 
shortening and broadening of the IS, and reduction of the subretinal space was seen in 
all groups, either CNTF- or PBS-treated, and suggested that the natural course of the 
disease had not been arrested or modified. 
In the rcd1 control group, we observed a statistically significant rescue of 
photoreceptors with CNTF (Figure 5.4 and 5.5) The mean (± SD) difference in ONL 
thickness between the CNTF and PBS injected retinas was of 1.5 ± 0.56 rows of 
nuclei, and consistent with findings previously observed (Pearce-Kelling, 
unpublished). In the 7 week-old rcd1 retina, the ONL has already lost approximately 
40% - 50% of its photoreceptors, and has an average thickness of 5 to 6 rows of nuclei 
along the superior meridian.21 In this study, the mean ONL thickness of the superior 
retina at 14 weeks of age was 4.4 and 2.5 rows of nuclei in the CNTF- and PBS-
injected eyes, respectively. This indicates that although statistically significant, there is 
not a total rescue of photoreceptor cells in this model following an intravitreal 
injection of CNTF at 7 and 10 weeks of age. 
 To determine whether the lack of CNTF-mediated rescue in XLPRA2 could be 
explained by the absence of expression of the α subunit of the CNTF
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Figure 5.4 Scatter plots comparing the mean ONL thickness (measured as rows of 
nuclei) along the four meridians of eyes injected with CNTF or PBS. No statistically 
significant difference in ONL thickness was seen in any of the XLPRA2 treatment 
Groups #1 - #4. CNTF caused a statistically significant increase in ONL thickness in 
rcd1. No major difference was seen in the single normal control dog. *: < 0.05; **: < 
0.001; ND: not determined; OS: left eye; OD: right eye. 
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Figure 5.5 Illustration of the effect of CNTF on outer nuclear layer thickness in the 
mid-peripheral retina of a 14 week-old XLPRA2 (A2) and rcd1 (B2) dog. Contralateral 
eyes served as controls and were injected with PBS (A1, B1). CNTF caused an increase 
in the number of photoreceptor nuclei in rcd1 (compare B2 to B1), but no differences 
were seen in XLPRA2 (compare A2 with A1). CNTF often caused the vitreal border of 
the ONL to appear wavy (A2, B2). On these cryosections, RPE separation from the 
neuroretina was an artifact.  H&E stain; scale bars: 20 µm. 
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receptor, immunolocalization of CNTFRα was done on retinas from XLPRA2 as well 
as in rcd1 and normal dogs, at ages ranging from 4 to 24 weeks. The pattern of 
labeling was similar to that previously reported for the normal adult canine retina.16, 
and was characterized by an intense staining of the IS, inner nuclear layer (INL), 
ganglion cell layer (GCL) and nerve fiber layer (NFL). At the earliest age examined (4 
weeks; Figure 5.6 A1-A3), CNTFRα-immunoreactivity was present in both rod and 
cone IS. With progression of both diseases, the shortening of rod IS, and their 
subsequent disappearance, photoreceptor labeling was restricted to the remaining cone 
IS (Figure 5.6 B2, C2, C3). 
 
CNTF causes peripheral remodeling in XLPRA2 retinas. 
A consistent finding in all 4 quadrants of CNTF-injected eyes of XLPRA2 dogs 
enrolled in treatment Groups #1, #2, and #3 was abnormal changes in the retinal 
periphery. These alterations included a loss of IS and OS, an increase in ONL 
thickness, and misplaced rod-like nuclei in the INL (Figure 5.7 and Table 5.3). These 
changes were disease- (XLPRA2) and age-specific, since they were not present in 
either the rcd1 control group, the single non-mutant dog, or the XLPRA2 mutants 
treated for the first time at 12 weeks of age (Group #4). 
A remarkable feature associated the with peripheral ONL remodeling was the 
loss of both photoreceptor IS and OS that caused, in some areas, the retinal pigment 
epithelium (RPE) to be in direct apposition with the external limiting membrane 
(ELM) (Figure 5.7 A2, B2, C2). This loss of the photoreceptor layer (PRL) extended 
over distances that were usually shorter, although occasionally equal, than the lengths 
over which an increase in ONL was noted. In animals from Group #4, there was never 
a complete loss of the PRL, yet loss of OS and significant shortening of IS was 
occasionally seen (Figure 5.7 D2). 
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Figure 5.6 Immunohistochemical localization of CNTFRα in the retinas of normal, 
rcd1, and XLPRA2 dogs of different ages. Strong immunoreactivity for CNTFRα was 
seen in the GCL, INL and inner segments (IS, arrows) in the normal and mutant 
retinas at 4 weeks of age (A1-A3). At 8 weeks of age, intense labeling is seen 
throughout the IS of rods and cones in the normal retina (B1). In the mutant retinas, 
labeling persists in the IS of both rods and cones in XLPRA2 (B3), but is essentially 
limited to cone IS in rcd1 which is the predominant cell class remaining in the PRL at 
this stage of disease (B2). (C1-C3) At 24 weeks of age, CNTFRα-positive cone IS and 
somas are still seen in rcd1 and XLPRA2 despite substantial loss of photoreceptors. 
Negative controls (A4, B4, C4) were XLPRA2 retinas that were treated with the 
omission of the primary antibody. Scale bars: 20 µm. 
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Figure 5.7 Illustration of the morphologic changes observed in the peripheral 
retina of XLPRA2 dogs following intravitreal injection with CNTF. An example from 
each of the 4 treatment groups is shown at the site where the measured ONL thickness 
was maximal. This same location in the contralateral (PBS-injected eye) is shown for 
comparison. The boxed areas in the low power photographs are shown in higher 
magnification. (A1, A2) Inferior periphery (1,000 µm from the ora serrata) in an 8 
week-old dog (Z263; Group #1; Inj. 4 weeks; Ter. 8 weeks). (B1, B2) Superior 
periphery (3,900 µm from the ora serrata) in a 12 week-old dog (Z 259; Group #2; 
Inj. 4 & 8 weeks; Ter. 12 weeks). (C1, C2) Temporal periphery (550 µm from the ora 
serrata) in a 14 week-old dog (Z272; Group #3; Inj. 7 & 10 weeks; Ter. 14 weeks). 
(D1, D2) Superior periphery (680 µm from the ora serrata) in a 15.6 week-old dog 
(Z288; Group #4; Inj. 12 weeks; Ter. 15.6 weeks). Note the prominent increase in 
ONL thickness in dogs from Groups #1-3 (A2, B2, C2), and the misplacement of rod-
like nuclei in the  INL (A2, B2; arrows). No significant difference in ONL is seen in 
Group #4 (D1, D2). A loss of the photoreceptor (PRL) layer is seen in Groups #1-3, 
which causes the external limiting membrane to be in direct contact with the retinal 
pigment epithelium (A2, B2, C2; asterisks). In Group #4, short inner segments persist 
in the PRL (D2, arrows). Cryosections; H&E stain; scale bars: 100 µm.
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Table 5.3 Increase in ONL thickness and loss of IS and OS in the XLPRA2 peripheral 
retina after CNTF treatment. 
SUP: superior meridian; INF: Inferior meridian; NAS: Nasal meridian; TEMP: 
Temporal meridian; ONL: outer nuclear layer; IS: inner segment; OS: outer segment. 
L: length of retina (measured in µm from the ora serrata) over which there is an 
increase in ONL thickness in the CNTF-treated eye in comparison to the PBS-treated 
eye. 
D: distance from the ora serrata (measured in µm) of the site of highest ONL thickness 
in the peripheral retina of the CNTF-treated eye. 
R: ratio of ONL thickness in the CNTF-treated eye over the ONL thickness in the 
PBS-treated eye at distance D from the ora serrata. 
l:Length of retina (measured in µm from the ora serrata) over which there is a loss of 
IS and OS in the CNTF-treated eye in comparison to the PBS-treated eye. 
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 Group 1 (Inj 4; Ter 8)  Group 2 (Inj 4&8; Ter 12)  Group 3 (Inj 7&10; Ter 14)  Group 4 (Inj 12; Ter 15.6)   
         
  
ID Z262
 
  Z263
 
Z264
 
Z258
 
  Z259
 
Z260
 
Z272
 
  Z273
 
Z274
 
Z286
 
  Z287
 
Z288
    
L                
                
          
              
  
                
                
          
               
               
            
              
             
            
                
                
                
           
             
3,200 4,700 1,300 5,200 5,800 4,500 2,650 2,200 2,700 0 0 0
D 2,350 3,400 1,000 3,550 3,900 3,800 1,500 2,000 2,150 None None None
R 1.48
(68/46) 
1.67 
(87/52 
1.85 
(72/39) 
 
1.59
(62/39) 
1.87 
(71/38) 
1.85 
(63/34) 
2.03
(67/33) 
1.22 
(44/36) 
2.77 
(72/26) 
None None NoneSUP 
l 2,300
 
3,300
 
700
 
3,800
 
3,900
 
3,800
 
1,900
 
2,200
 
2,700
 
0
 
0
 
0
    
L 2,000 1,800 1,000 3,000 3,200 1,400 1,900 1,400 1,500 0 0 0
D 1,250 1,000 400 2,000 1,350 550 650 1,100 1,350 None None None
R 2.05
(80/39) 
1.83 
(75/41) 
1.69 
(44/26) 
1.61
(61/38) 
2.40 
(72/30) 
2.27 
(68/30) 
2.35
(61/26) 
1.41 
(41/29) 
2.26 
(43/19) 
None None NoneINF 
l 1,350 1,200 300 2,100
 
1,350 600 400
 
1,400 1,200 0 0 0
L / / / / / /  1,300
 
 1,200 1,150
 
 / / 0
D / / / / / / 700 1,100 900 / / None
R / / / / / /  2.77
(61/22) 
 
1.53 
(46/30) 
 
2.24 
(56/25 
 
/ / NoneNAS 
l / / / / / / 800
 
1,200 950 / / 0
L 800 500 / 750 900 850 1,000 1,400 900 0 0 0
D 600 450 / 500 650 600 550 1,100 600 None None None
R 1.53
(52/34) 
1.44 
(46/32) 
/ 1.24
(36/29) 
 
2.28 
(57/25) 
3 
(69/23) 
2.5
(60/24) 
 
1.46 
(38/26) 
2.17 
(39/18) 
None None NoneTEMP 
 
l 650 300 / 600 500 550 700 700 600 0 0 0
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When combining results from all 4 meridians of treatment Groups #1, #2, and 
#3, the mean distance from the ora serrata over which an increase in ONL thickness 
could be observed in the CNTF-treated eye was 2,075 µm (min: 500 µm; max: 5,800 
µm). The longest expanse of altered ONL was seen in the superior meridian, and then 
in the inferior meridian. The peripheral ONL remodeling was most extensive in 
animals from treatment Group #2. The increase in ONL thickness was associated with 
an increase in spacing between nuclei, such that the density of photoreceptors 
appeared to be reduced following CNTF injection. Because of this, and due to the 
misalignment of layers of photoreceptor nuclei, the thickness of the ONL was 
measured in micrometers rather than in number of rows of nuclei. This was done at the 
site of highest ONL thickness. If, an equal increase in ONL thickness was observed 
throughout an extended length of ONL, the area that was selected for analysis was the 
one located the furthest distance from the ora serrata. At that site, there was a 1.94 
fold average increase (min: 1.22; max: 3) in ONL thickness in comparison to the 
corresponding region of the PBS-treated eye (Figure 5.7 and Table 5.3). 
Finally, misplacement of rod-like nuclei in the outer plexiform layer (OPL) 
and INL caused a disorganization of the typical layering of the retina. A wavy aspect 
of the vitreal edge of the ONL was responsible for the frequent loss of a clear 
delimitation by the OPL of both nuclear layers (Figure 5.7 A2, B2). 
To determine the nature of the cell population(s) responsible for this apparent 
increase in cell number in the ONL, immunohistochemical studies were performed 
using several cell-specific markers on XLPRA2 retinas from all 4 treatment groups. 
The results confirm that the overwhelming majority of cells present in the peripheral 
ONL, and migrating to the INL of CNTF-treated eyes (Groups #1-3), are rod opsin-
positive (Figure 5.8 A2). Although we have previously reported in XLPRA2 a 
mislocalization of rod opsin to the soma and axons of rods,14 (see Figure 5.8 A1) this 
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was more pronounced in retinas examined 4 to 8 weeks after CNTF treatment. In 
addition, in contrast to what is seen in the untreated XLPRA2 retina,14 there was 
absence of rod opsin labeling in rod OS and IS in the periphery, thus, further 
confirming the loss of these structures following CNTF treatment (Figure 5.8 A2). The 
use of a cone arrestin antibody also confirmed the presence of heterotopic cone somas 
in the middle and inner portions of the ONL. These cells had neither an axon nor an IS 
(Figure 5.8 A2). One week following the injection of CNTF in a 4 week-old XLPRA2 
retina, the migration of cone somas down their axon was seen in the periphery (Figure 
5.8 B3). 
Rod opsin and cone arrestin immunoreactivities were also examined in 
XLPRA2 retinas 1 and 7 days following an injection of CNTF, and a significant 
decrease in intensity of labeling was seen in comparison to the PBS-injected eye. 
(Figure 5.8 B1, B2). This decrease in rod opsin and cone arrestin expression which 
was more pronounced 1 week post-CNTF injection was seen throughout the entire 
length of the retinal sections, but was most prominent in the periphery. This reduction 
in immunoreactivity was not present 4 weeks after the injection. 
Peripheral remodeling of the retina also involved cells of the INL. The use of 
cell markers for bipolar cells showed significant dendritic sprouting into the peripheral 
ONL, as well as heterotopia of PKCα-positive cells (a marker for rod bipolar cells) 
(Figure 5.8 C1, C2). Similarly, radial extension into the ONL of processes originating 
from calretinin-immunoreactive horizontal cells was observed in the peripheral retina 
(Figure 5.8 D1, D2). CNTF treatment also caused misplacement in the ONL of the 
somas of some CRALBP-positive Müller cells (Figure 5.8 E1, E2). Glial Fibrillary 
acid protein (GFAP) immunoreactivity was also examined and showed a similar 
labeling of the entire cell body of Müller cells (data not shown) in both CNTF- and 
PBS-treated 
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Figure 5.8 Immunohistochemical characterization of CNTF-mediated remodeling of 
the peripheral retina of XLPRA2. (A1, A2, B1, B2) Double immunofluorescence 
labeling of rods and cones with, respectively, anti-rod opsin (green) and anti-cone 
arrestin (red), in a 12 week-old dog, 8 weeks after the first CNTF injection (Group # 
2; A1, A2), and in a 5 week-old animal one week post-CNTF injection (B1, B2). No 
labeling is seen at the level of the PRL due to the loss of inner and outer segments (A2; 
asterisks).The majority of the cells found in the ONL are rod opsin-positive due to the 
increased mislocalization caused by CNTF (A2). Rod opsin immunoreactive cells are 
seen displaced in the INL (arrows), and cone arrestin-labeled somas are present within 
the thickened ONL (arrowheads). One week following CNTF injection, there is a 
significant decrease in rod opsin and cone arrestin expression (compare B2 with B1 
which were taken at the same exposure settings). Digitally increasing the red 
fluorescent signal in an area of (B2) shows the displacement of cone somas 
(arrowheads) down their respective axons (arrows; B3). (C1, C2) Double 
immunofluorescence labeling of ON bipolar cells with anti-Goα (red), and rod bipolar 
cells with anti-PKCα (green) in a 12 week-old dog 8 weeks after the first CNTF 
injection (Group # 2). DAPI (blue) was used as a nuclear counterstain. Rod bipolar 
cells are co-labeled with both antibodies and appeared yellow-orange, whereas ON 
cone bipolar cells were only labeled with anti-Goα and appeared red. Note the neuritic 
sprouting extending into the ONL (arrows), and the presence of Goα- and PKCα-
positive somas in the ONL (arrowheads) of the CNTF-treated eye. (D1, D2) 
Immunofluorecence labeling of horizontal and amacrine cells with anti-calretinin in a 
12 week-old dog (Group #2) 8 weeks after the first CNTF injection. There are radial 
extensions into the ONL of neurite sprouts origination from the horizontal cells 
(arrows) in the CNTF-treated eye. (E1, E2) Immunofluorescence labeling of Müller 
cells with anti-CRALBP in a 12 week-old dog (Group #2) 8 weeks after the first 
CNTF injection. Müller cell somas are seen displaced into the ONL (arrowheads) in 
the CNTF-treated eye. Note the intense normal CRALBP labeling in the RPE. Scale 
bars: 20 µm. 
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eyes. This is not surprising since increase in GFAP expression in Müller cells is 
known to occur at the ages examined.14 
 
CNTF causes an increase in cell number in the peripheral XLPRA2 retina. 
To determine whether the thickening of the ONL was caused solely by an increased 
internuclear spacing, or by a higher number of ONL cells, plastic embedded retinal 
sections of two XLPRA2 dogs were examined; each dog was treated using the same 
protocols as for Group #1 (Inj. 4 wk; Ter. 8 wk), and Group #2 (Inj. 4 & 8 wk; Ter. 12 
wk), respectively. These 1-µm thick sections permitted individual cell counts (Figure 
5.9) which could not be done on the thicker (7 or 10 µm) cryosections where 
substantial overlap of nuclei occurred. Examination of the peripheral retina of the 
CNTF-treated eyes confirmed that there was more space between the photoreceptor 
nuclei, although it could not be determined whether this resulted from intra- or 
extracellular swelling. Elevation of the external limiting membrane, suggesting 
cytoplasmic swelling of photoreceptors or Müller cell processes, has been reported in 
both rcd1 and non-mutant dogs implanted with a long-term CNTF release device.22 
This was not observed in the current study.  In addition to heterotopic rod nuclei in the 
INL (Figure 5.9 C2; arrows), there were cells with larger nuclei within the thickness of 
the ONL (arrowheads). These nuclei contained fewer chromatin clumps than rods, and 
resembled that of cones. Nuclear count in both CNTF- and PBS-injected eyes was 
done at the site of highest ONL thickness as described above. Although statistical 
analysis could not be done due to the limited number of observations, we observed a 
consistently higher number of cells in the CNTF-treated peripheral retina (Table 5.4). 
To determine how early following an injection of CNTF an increase in ONL 
thickness is observed in the peripheral XLPRA2 retina, and to determine if this is  
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Figure 5.9 Changes in the ONL of the inferior periphery in an 8 week-old XLPRA2 
dog following intravitreal injection of CNTF (PBS in the contralateral eye) at 4 weeks 
of age. Note the increase in ONL thickness (Compare A and B). The 1 µm-thin epoxy 
resin sections enabled counts of individual cells in the ONL (C1, C2). Rod-like nuclei 
were seen in the INL (arrows), and larger euchromatic nuclei with a cone-type 
morphology were found in deeper layers of the ONL (arrowheads). Azure II-
methylene blue stain with PPDA counterstain; scale bars: (A, B) 100 µm; (C1, C2) 20 
µm. 
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Table 5.4  ONL nuclear count (mean [min; max]) in a 40X microscope field (290 µm in length) of the peripheral XLPRA2 retina 
treated with CNTF or PBS. (Note: rod-like nuclei present in the INL were also included in this count) 
 
 
Dog: 
meridian 
 
PBS-injected   CNTF-injected % increase
Z265: (Inj. 4 wk; Ter. 8 wk) (Inj. 4 wk; Ter. 8 wk)  
Superior 483 [469 ; 498] 552 [546 ; 556] 14 
Inferior 362 [360 ; 366] 544 [533 ; 553] 50 
Temporal 398 [391 ; 406] 530 [520 ; 548] 33 
    
Z261: (Inj. 4 & 8 wk; Ter. 12 wk) (Inj. 4 & 8 wk; Ter. 12 wk)  
Superior 363 [341 ; 384] 424 [411 ; 431] 17 
Inferior 298 [280 ; 318] 421 [400 ; 445] 41 
Temporal 
 
321 [313 ; 331] 393 [376 ; 416] 22 
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Figure 5.10 Evidence for cell proliferative events in the peripheral ONL of XLPRA2 
following intravitreal injection of CNTF. (A-D) One week after CNTF injection there 
was increased ONL thickness in a 5 week-old dog. Note also the extended loss of the 
PRL (B, and C2, asterisks). (D1-D3) Fluorescence immunohistochemical labeling for 
BrdU (green) shows incorporation in the ciliary epithelium of the pars plana (D1, D2, 
arrowheads), and in cells located at the retinal margin (D1, D2, arrows) in both the 
CNTF- and PBS-injected eye. (D3) BrdU incorporation was detected in cells located in 
the INL (arrowhead), GCL and NFL in both eyes, but few BrdU-positive cells were 
seen only in the ONL of the CNTF-treated eye (arrow). 
(E1, E2) Fluorescence immunohistochemical labeling for the nuclear cell marker of 
proliferation Ki67 (red). (E2) Ki67-positive cells were seen exclusively in the ONL of 
the CNTF-treated eye (arrows), but Ki67 positive cells were found in other retinal 
layers in both PBS-and CNTF-injected eyes. Scale bars: (A, B) 100 µm; (C1-E2) 20 
µm. 
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caused by cell proliferation, BrdU pulse labeling and Ki67 immunohistochemical 
studies were performed in two dogs. No major differences in ONL thickness, BrdU 
incorporation, or Ki67 immunolabeling were observed 24 hours following CNTF 
injection (data not shown). Yet, a major increase in ONL thickness was observed in 
the dog whose retina was collected one week post-CNTF administration (Figure 5.10 
A, B). Although BrdU incorporation was seen in cells located at the peripheral retinal 
margin (Figure 5.10 D1, D2), and in the NFL, GCL, and INL throughout the entire 
length of the retina of both CNTF- and vehicle-treated eyes, there was a higher 
number of BrdU-positive nuclei with CNTF (Table 5.5). Indeed, combining results 
from three meridians, a mean of 47 and 135 cells per 10,000 µm of retina length, was 
found in the PBS- and CNTF-injected eyes, respectively. In addition, rare BrdU-
positive cells were found exclusively in the ONL of the CNTF-treated retina (Figure 
5.10 D3). A similar finding was observed with Ki67 (Figure 5.10 E2). 
 
 
 
Table 5.5 Number of BrdU-positive cells per unit length of retina (10,000 µm) 
following CNTF or PBS injection in a 5 week-old XLPRA2 dog. Mean [minimum; 
maximum] values were obtained from at least three sections for each of the meridians. 
 
 
 
 
Meridian 
 
PBS-injected 
 
CNTF-injected 
 
 
Superior 
 
43 [39; 47] 
 
138 [122; 161] 
 
Inferior 
 
54 [41; 65] 
 
101 [  97; 104] 
 
Temporal 
 
 
45 [34; 55] 
 
165 [140; 187] 
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DISCUSSION 
XLPRA2 is an early onset model of retinitis pigmentosa characterized by an early burst 
of photoreceptor cell death that begins at 4 weeks of age and reaches a peak at 7 
weeks. This event is followed by a more gradual loss of rods and later of cones that 
persists for over 9 months.14 An attempt to rescue photoreceptors from this initial 
phase of cell death with intravitreal injections of CNTF failed to promote in XLPRA2 a 
similar neuroprotective effect as seen in the rcd1 dog.10 A peculiar set of findings that 
were exclusively observed in XLPRA2 consisted of remodeling of the retinal periphery 
and an increase in cell number in the ONL. In addition, ocular toxic effects that 
involved the cornea, lens, and uveal tract were seen in both mutants and normal dogs. 
 Intravitreal injection of survival factors in animal models of RP has been used 
routinely to establish proof of principle of their photoreceptor rescue properties.5 Yet, 
a recognized limitation to this route of administration for the treatment of retinal 
degenerations is the short half-life of these agents, and their associated ocular side-
effects.23-26 In this study, corneal epitheliopathy, cataracts, and clinical signs of uveitis 
were observed within a few days following a single intravitreal injection of 12 µg of 
CNTF. Similar clinical findings were found in the rcd1 dog (Pearce-Kelling, 
unpublished) and Rdy cat27 treated with Axokine® (Regeneron, Tarrytown, NY), a 
recombinant mutein of human CNTF. These side-effects appear to be dose-related 
because they are not observed in rcd1 dogs that are intravitreally implanted with a 
long-term delivery device that releases a daily dose approximately 1000 fold lower.10 
  Several hypotheses may explain the absence of a positive rescue effect in 
photoreceptors of the XLPRA2 dog: 1) A lack of activation of intracellular signaling 
pathways may be responsible for the absence of a survival response. This study 
showed that the α subunit of the CNTF receptor (CNTFRα) was expressed throughout 
the course of retinal degeneration in rcd1 and XLPRA2, but we did not investigate 
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whether CNTF triggered any cell signaling pathways. Therefore, it is not known 
whether the binding of CNTF to CNTFRα activates the same molecular signaling 
cascades in both diseases. 2) The activation of anti-apoptotic molecules may not 
interfere with the molecular mechanisms of cell death that are involved in XLPRA2. 
Identifying the key molecular events that occur in different models of photoreceptor 
degeneration may reveal a spectrum of cell death pathways that respond differentially 
to survival factors. This may be the basis for the difference in response between rcd1 
and XLPRA2, and could explain CNTF’s positive rescue effect in the rd/rd, nr/nr and 
Q344 ter mice, and its absence in the rds/rds, pcd/pcd, P23H and VPP mice.28 3) In 
the mutant, there may be activation of a stimulus so detrimental to the cell’s 
homeostasis that its effects can not be countered by the survival factor. We 
intentionally chose to target the initial burst of photoreceptor cell death that occurs 
between 4 and 7 weeks of age in XLPRA214 as an approach to inhibit as early as 
possible the onset of the disease, and rescue the highest number of cells. However, this 
may not have been the optimal time-window for therapy, if the putative toxic gain of 
function caused by the RPGR frameshift mutation is at its highest level during this 
period. 4) A rapid elimination of CNTF from the eye may prevent prolonged 
activation of a rescue response. Despite the absence of any published pharmacokinetic 
study on the rate of clearance of intravitreally-injected CNTF, it is assumed that it is 
eliminated from the eye in less than 24 hours, as shown for pigment epithelium-
derived factor (PEDF).7 If achieving photoreceptor rescue in XLPRA2 requires the 
continuous activation of pro-survival signaling pathways, then sustained 
bioavailability of CNTF through the use of a long-term delivery device may be 
necessary in this disease. 
Quantitative methods were not used to measure the levels of expression of rod 
opsin and cone arrestin, yet immunohistochemical results suggested that CNTF caused 
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a rapid but transient decrease in the expression of these two proteins. This was seen as 
early as 24 hours following the injection, and was more pronounced 7 days later. This 
negative regulation in the expression of phototransduction proteins by CNTF has been 
also reported in the  normal rat,29 the rd mouse,30 and in the rcd1 dog.22 Such an effect 
may be responsible for the electroretinographic alterations reported in rat and mouse 
models of retinal degeneration, as well as in the normal albino rabbit following 
intraocular delivery of CNTF. 31-34 
A striking finding was the prominent remodeling that occurred in the 
peripheral retina of XLPRA2 dogs following intravitreal injection of CNTF. These 
retinal alterations consisted of loss of IS and OS, neuronal neuritic sprouting, 
heterotopia of retinal cells, and increase in the number of rods that contributed to the 
thickening of the ONL. The changes were disease- and age-specific. Indeed, they were 
only observed in XLPRA2 dogs, and only if the first intravitreal injection of CNTF was 
done no later than at 7 weeks, an age at which the normal canine retina is reaching full 
maturation.35 
The disorganization in the normal retinal layering was associated with the loss 
of inner and outer segments, which has been also observed by others.29,33 Although IS 
are beginning to bud in the 4 week-old canine peripheral retina, IS and OS are fully 
formed when the retina has reached maturity at 7-8 weeks of age. CNTF, therefore, 
may have prevented the formation of IS and OS when injected at 4 weeks of age 
(treatment Groups #1 and #2), and caused their loss when injected later in 7 week-old 
dogs (treatment Group #3). Numerous reports have shown that CNTF causes a 
transient arrest in rod differentiation in the developing retina.30,36,37 Our findings 
suggest that CNTF may not only arrest photoreceptor maturation in the XLPRA2 dog, 
but also cause them to dedifferentiate. This is not unexpected since CNTF has recently 
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been shown to induce the dedifferentiation of adult human myoblasts into multipotent 
progenitor cells.38  
CNTF is known to elicit the formation of new neuritic processes in rodent 
motor neurons.39,40 More recently, it was reported that gene delivery of CNTF in a 
feline model causes neurite extension from rods, bipolar, and horizontal cells.41 We 
observed in this study a similar effect in the XLPRA2 dog. This may be caused by an 
alteration in neurotransmission at the synaptic terminal between rods, horizontal, and 
bipolar cells, as a result of a negative regulation on the phototransduction pathway. 
Another feature of the retinal remodeling that took place in the periphery was 
heterotopia of some rod, cone, bipolar, and Müller cell somas. Although we could not 
determine whether these rods and bipolar cells had migrated to an ectopic location, or 
whether these were newly generated neurons, we do provide evidence that displaced 
cones represented somas that had moved down the cone axon.  
The most prominent feature of the peripheral remodeling was the abnormal 
increase in ONL thickness that has also been reported in normal rabbits implanted 
with ECT devices secreting a high dose (22ng/day) of CNTF.11 In the present study, 
the thickened ONL could be seen extending several millimeters away from the ora 
serrata, and was detected as early as one week following CNTF administration. 
Although this was undoubtedly associated with some degree of intra- and/or 
extracellular swelling, an increase in the number of rod opsin-positive cells was the 
major contributing factor. The extent of the increase in cell number could not be 
explained only by a rescue effect. The use of cell proliferation markers confirmed that 
CNTF caused a higher number of cells to enter the cell cycle. Yet, the number of 
BrdU- or Ki67-positive cells that were found in the ONL was limited, and could not 
account completely for the supernumerary nuclei seen in this layer. The most plausible 
explanation for this discrepancy has to do with the period of cell proliferation, and the 
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time-points at which tissues were collected. It is indeed possible that, despite doing 
repeated injections of BrdU, a high enough concentration may not have been attained 
at the optimal time for its incorporation. Similarly, one week following CNTF 
injection, the great majority of these cells may have exited the cell cycle and were no 
longer be Ki67-positive. Addressing this issue would require determining the precise 
time of onset of the cell proliferation, and performing additional BrdU pulse-labeling 
experiments. This will be the subject of future studies. 
The increased number of cells in the ONL raises the question of their origin. 
Although there is recent evidence for the presence of retinal progenitor cells at the 
retinal margin of ptc+/- mice,42 monkeys, and humans,43 it is unlikely that neurogenesis 
in this zone may account for all the additional cells that are seen over distances as far 
as 5,000 µm from the ora serrata. Recently, a pool of mitotic retinal progenitor cells 
was found distributed in the central retina of the adult Chx10-/- mouse.44 Therefore, it 
may be possible that in XLPRA2, CNTF induces proliferation of such precursor cells.45 
Finally, another possibility is that CNTF causes rods to dedifferentiate and 
subsequently re-enter the cell cycle. The elimination of CNTF from the eye would 
cause the cells to stop proliferating, and assume a differentiated phenotype. 
In summary, this study shows that intravitreal injection of CNTF does not 
prevent the early phase of cell death that occurs in a canine model of X-linked retinitis 
pigmentosa caused by a frameshift mutation in RPGR exon ORF15. Whether CNTF 
can rescue photoreceptors from the later phase of degeneration now needs to be 
addressed. This should provide further evidence as to whether human patients with 
similar mutations in RPGR would be expected to respond to this specific 
neuroprotective agent. CNTF also caused substantial remodeling in the peripheral 
retina of XLPRA2 dogs. These peripheral alterations are most likely dose- and disease-
specific. In addition, they were only observed when CNTF was injected before the 
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canine retina had reached full maturation. Therefore, although this may not be an issue 
for adult human patients treated with sustained release of CNTF,12 peripheral retinal 
changes observed in normal adult rabbits,11 and the suggestion that endogenous 
secretion of CNTF may be the cause of cell proliferation in humans with mutations in 
the  NR2E3 gene46 warrants further investigation.
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CHAPTER SIX 
 
CONCLUSION 
 
Among the various therapeutic strategies aimed at maintaining vision in human 
patients affected with retinitis pigmentosa, the intravitreal long-term delivery of ciliary 
neurotrophic factor appears as one of the most promising approaches to rescue 
photoreceptors prior to cell death. Over the past recent years, proof of principle of 
CNTF’s neuroprotective effect on photoreceptors and the results of preclinical safety 
studies in large animal models using the ECT-CNTF device have led to the testing of 
this therapeutic approach in 10 human patients with RP in a Phase I clinical trial. With 
Phase II clinical trial now being planned in humans with ARMD and RP, there is an 
increasing need for a better understanding of the mechanism of action by which CNTF 
promotes a survival response in photoreceptor cells. 
The work presented in this thesis began to address this issue by characterizing 
the site of expression of the receptor for CNTF (CNTFRα) in the mammalian retina. 
This hopefully has contributed at resolving what used to be a matter of debate in the 
field of retinal cell biology. Our results (Chapter 2) show that CNTFRα is expressed 
by both rods and cones in the normal adult canine retina, thus implying that the 
photoreceptor survival effect observed in rcd1 dogs treated with CNTF may be 
occurring through a direct mechanism of action. We also demonstrate that this finding 
is not specific to the dog but is also seen in the following non-rodent species: cat, 
sheep, pig, horse, monkey, and in human (Chapter 3). In the rat and mouse, 
immunolocalization of CNTFRα is not found in photoreceptor cells. These results 
imply therefore that the canine retina may be a more relevant model system than the 
rodent retina to characterize CNTF-mediated signaling pathways in photoreceptors.  
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A common assumption in using neuroprotective survival factors as a potential 
treatment for RP is that these agents should be capable of rescuing photoreceptors and 
curing all forms of RP regardless of the genetic cause of the disease. To begin 
addressing this issue we evaluated whether CNTF could rescue photoreceptors in 
XLPRA2, an early and rapidly progressive canine model for X-linked retinitis 
pigmentosa that was recently identified. We selected this model because the severity 
of disease is comparable to that of rcd1, yet the causative mutations are different. For 
this purpose, we first characterized the morphologic retinal changes that occur during 
the course of the disease and determined the kinetics of photoreceptor cell death 
(Chapter 4). Our results show a burst of photoreceptor cell death at an early stage of 
the disease which is responsible for a significant loss of photoreceptor cells. These 
findings suggest that this period of increased risk of cell death might be an optimal 
therapeutic time-window to test the neuroprotective effects of CNTF in this model. 
Intravitreal injections of CNTF during this acute and initial phase of cell death failed 
to protect photoreceptors in XLPRA2. In addition, significant remodeling is observed 
in the peripheral retina of the XLPRA2 dogs treated with CNTF, while no such 
abnormality is observed in non-mutant and rcd1 retinas. 
In summary, several elements are strongly in favor of pursuing the 
development of this therapeutic strategy. These include the proof of principle of 
CNTF’s photoreceptor rescue effect in small and large animal models of RP caused by 
mutations in different genes, the existence of an encapsulated cell therapy device that 
allows the prolonged intravitreal release of small and therapeutically active doses of 
CNTF, and the very encouraging results of a Phase I clinical trial in humans using this 
technology. Yet, some recent observations following the intraocular delivery of CNTF 
in animal models of RP ought to draw our attention. We and others have found that 
CNTF can down-regulate the expression of phototransduction proteins, which may 
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explain a reduction in retinal function as assessed by electroretinography. The absence 
of any rescue effect in some rodent models of retinal degeneration, as well as in the 
XLPRA2 dog following intravitreal injections of CNTF, suggests that some forms of 
RP will most likely not be responsive to this survival factor either. A possibility is that 
only a limited number of forms of RP that share a common pathogenic mechanism 
and/or signaling pathway of cell death will be responsive to a particular survival 
factor. If this is proven to be correct, the ultimate strategy for treating RP may consist 
in matching a neuroprotective agent or a combination of these factors with a particular 
form of RP. Finally, our findings and those from other groups suggest that CNTF has 
the potential for causing cell dedifferentiation and proliferation. While this may be 
explained by a dose effect or by the age at which the intravitreal injections were done 
in the case of the XLPRA2 dog, it is critical to assess that prolonged intravitreal 
delivery of CNTF does not cause a similar effect in the human eye. 
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